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I N T R O D U C T I O N 
Living organism and modern techniques make use of regulation 
mechanisms (WIENER 1950, WAGNER 1954). As evolution proceeds the 
number and complexity of regulation mechanisms in organisms increases. 
In the various regulation mechanisms, messages are carried along circuits 
in a humoral or neural way. Both in humoral and in neural transmission 
of messages chemical substances (e.g. transmitters) are involved. It is 
possible to influence transmission and thereby regulation mechanisms 
by compounds resembling to some extent the transmitting substance 
and which therefore interfere with the action of the transmitters. Such 
compounds have been derived from hormones, neurohormones, vitamins 
etc. It has also been found that naturally-occuring substances of plant 
origin, such as atropine and muscarine, do in fact resemble transmitting 
substances. 
Substances either of natural or synthetic origin have been found 
accidentally which do not chemically resemble any biologically active 
substance, but which nevertheless have a specific effect upon biological 
specimens, e.g. digitoxin and barbiturates. Substances which exert a 
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FIG. 1 
Strongly simplified block scheme for the regulation of autonomic and motor actions. 
In the heavy blocks acetylcholine is involved as a transmitting substance. These are 
the myoneural junction (m.m.j.), the sympathetic and parasympathetic ganglia (s.g. and 
p.s.g.) and the parasympathetic end-synapse (p.s.e.s.). In the sympathetic end-synapse 
(s.e.s.) arterenol acts as a transmitter. 
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specific effect upon an organism are called drugs, irrespective of whether 
or not they are of therapeutic use. 
The study of structure-action relationships and of the mechanism of 
action of drugs is only possible if theory and experiment go hand in 
hand. Theories concerning drug actions, as well as extensions thereof, 
are given first. 
On the basis of the theories of drug actions, the pharmacodynamics 
of cholinomimetic and cholinolytic drugs is studied. Since both cholino-
mimetics and cholinolytics resemble acetylcholine to some extent, they 
may interfere in those stages of biological regulation mechanism where 
acetylcholine operates under physiological conditions. 
As may be seen from figure i, acetylcholine is the transmitter 
substance in various parts of the peripheral nervous system. For this 
reason the following distinctions are made. 
a) Pharmacodynamics of cholinomimetic and cholinolytic drugs at 
the level of receptors in the myoneural junction, and in general drugs 
affecting skeletal muscle. 
b) Pharmacodynamics of cholinomimetic and cholinolytic drugs at 
the level of receptors in the parasympathetic nervous system, especially 
drugs affecting intestinal smooth muscle. 
c) Pharmacodynamics of cholinomimetic and cholinolytic drugs at 
the level of receptors, concerned with heart action and blood pressure. 
This includes the ACh receptors in the sympathetic and parasym-
pathetic ganglia and in the parasympathetic end-synapse. 
The drugs used as cholinomimetics and cholinolytics at the different 
ACh-receptors are quaternary ammonium salts. 
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CHAPTER I 
THEORIES ON DRUG ACTIONS 
INTRODUCTION 
The study of concentration-response curves and time-response curves 
forms the foundation of a proper understanding of drug actions. The 
concentration-response curves express the relationship between the con­
centration of the drug applied and the effect obtained w ith the biological 
object. Generally this relationship underlies a chain of individual steps 
or reactions, which is schematically represented in figure i. 
W0 r (dose applied) 1 
Mi , 
(biophase) 2 
„ s t i m u l u s " 
3 
d r u g - spec i f ic 
t r a n s f e r e n c e r e c e p t o r s 
F I G . I 
Block scheme by which the sequence of events leading to the effect of a single drug, 
may be described. Block ι represents the relationship between the dose applied and 
the drug concentration in the biophase. The influences of transport, breakdown etc. are 
collected in this block. The reaction of drug molecules with the specific receptors is 
presented by block 2 A stimulus which is linearly proportional to the quantity of receptors 
occupied leaves block 2 and enters block 3. The relationship between the stimulus and 
the final effect is given by block 3. 
It is generally assumed that in order to produce an effect, drug mole­
cules have to interact with specific receptor molecules in the biological 
object. Receptor-occupancy is however, not necessarily the first step 
in the chain leading to the effect. In addition to the interaction of the 
drug molecules with their specific receptors, absorption, transport, 
breakdown ect. are of importance. The influence of these factors is 
collected in the first block of the scheme and designated as " drug-
transference " . Generally the drug concentration [A], in the immediate 
vicinity of the receptors (i.e. in the biophase) is a function of the dose 
13 
applied (i.e. the concentration [A]
 0 in the bath fluid for isolated organs). 
The use of simple isolated organs as a biological object for the experi-
ments may reduce the influence of absorption, transport, biotransfor-
mation etc. to a large extent. Then the drug concentration in the bio-
phase often is a linear function of the concentration in the bath fluid. 
For instance there is a partition equilibrium according to Henry's law. 
Thus : 
[A],· = KA . . [A]. (i) 
Here KA p is the partition equilibrium constant of drug A. Since the 
experiments are chiefly undertaken with isolated organs, in this thesis 
it is assumed that the concentration of the drug in the biophase is 
directly proportional to the dose of the drug applied. Hence attention 
is mainly called to the receptor-occupancy (block 2) and to the effect 
which is the result of it (block 3). 
In biochemistry, the mass law as introduced by MICHAELIS and 
MENTEN (1913) has been found useful. The introduction of the same 
principles for the drug receptor interaction proved to be of value for 
many pharmacological actions (See for instance CLARK 1937). It must 
be borne in mind that, although in some cases the receptors are enzymes, 
in fact they are often not known in any detail. The assumption of their 
existence is, however, essential for the molecular approach to drug 
actions. The application of the mass law to the drug receptor reaction 
signifies that the affinity of the drug is inversely proportional to the 
dissociation constant of the drug-receptor complex. 
It was stated by ARIËNS (1950) that after reaction with receptors, 
various drugs may differ quantitatively in their efficiency in producing 
an effect. The magnitude which represents the ability of the drug-
receptor complex to contribute to the effect was called " Intrinsic acti-
vity " . A large intrinsic activity means that the drug is effective after 
occupation of the receptors. A very low intrinsic activity means that, 
although combining with the receptors, the drug is unable to produce 
an effect. The introduction of intrinsic activity made it possible to explain 
paradoxical effects of various drugs (ARIËNS 1950). STEPHENSON (1953) 
introduced the same principle in discussing the ability of the drug-
receptor complex to produce an effect, which he later called efficacy 
(STEPHENSON 1956). 
As long as the effect is directly proportional to the number of receptors 
occupied the biological activity of a drug is determined by the affinity 
and intrinsic activity. As a matter of fact this is not always the case. 
It is however always possible to indicate a magnitude which is linearly 
H 
proportional to the number of receptors occupied. As such a magnitude 
may be mentioned the " stimulus " (STEPHENSON 1956) and the trigger 
magnitude (ARIËNS and VAN ROSSUM 1956c). This magnitude enters 
block 3 and gives rise to the effect. The relationship between the dose 
applied and the effect is still more complicated if there is a feedback 
of the effect to one of the blocks of figure 1. 
The interaction of one drug with a single receptor system will be 
considered first. Interactions in which more receptor systems and several 
drugs are involved will be considered later. 
RECEPTOR-OCCUPANCY 
Unless otherwise indicated, the interaction of drug and receptor 
molecules is supposed to be reversible. As a matter of fact irreversible 
interactions are also possible, but there is good evidence that many 
drug actions are based on reversible processes. If [R] is the concentration 
of free receptors, [A] the concentration of free drug and [RA] the 
concentration of drug-receptor complex, the interaction may be repre-
sented by : 
[R] + [A] ^ [RA] (2) 
The reversibility of the processes implies that there are only small 
changes in free energy. In other words, generally only intermolecular 
forces, e.g. van der Waals forces, are involved in receptor occupation 
(ING 1944)· This is further indicated by the fact that often the steric 
configuration of the drug has a great influence on the affinity for the 
receptors (CROXATTO and HIUDOBRO 1956). Naturally the number of 
receptors of a specific type in a biological object is limited. Hence when 
the concentration of the drug is increased a saturation of the receptors 
by the drug molecules will result. The fraction of the total number, 
[r], of receptors occupied by a drug A may be represented by the mass 
law or Michaëlis-Menten equation (*) : 
[Al/K. 1 [RA]/[r] = L J A = (3) 1 J / L J
 i + [A]/KA i + KA/[A] V J ' 
in which KA is the dissociation constant of the drug-receptor complex. 
The concentration of the drug is supposed to be large with respect 
to the concentration of free receptors. From equation (3) it may be 
(') Derivations of most of the formulae used will be found elsewhere ( A R I Ë N S , VAN 
ROSSUM and S I M O N I S 1956 а, Ь, с and 1957). 
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seen that when the value of [A] is increased, [RA] increases and asympto-
tically approaches [r]. Of course the relationship between the drug 
concentration and the fraction of receptors occupied may be represented 
by other functions. A good deal of the reasoning given below holds as 
long as these functions represent a saturation of the receptor system 
for high drug concentrations. Exponential functions may be useful 
(NORDGREN and ÖBRINK 1956). The fraction of receptors occupied by 
drug A may be represented for the exponential function by : 
[RA]/[r] = 1 — e-[A]/KA (4) 
In theory a criterion for a certain type of function may be obtained 
by plotting such magnitudes that straight lines are obtained, when a 
certain function is correct. 
This has been done for certain enzyme-substrate interactions (L INE-
WEAVER and BURK 1934, HALDANE 1930, HOFSTEE 1955 and others). 
In most pharmacological experiments, however, the biological and ex-
perimental variances are so large that a differentiation between the 
various functions is often impossible. In some cases, it has been proved 
within the limits of experimental error that the Michaëlis-Menten 
function holds (MATSUMOTO et al. 1954, CLARK and RAVENTOS 1937). 
For reasons of simplicity we shall in this chapter take the Michaelis-
Menten function as our basis for the relationship between drug con-
centration and receptor-occupancy. 
It is of advantage to plot the fraction of receptors occupied against 
the logarithm of the drug concentration, since then the curves become 
linear over a rather large concentration range. Independently of the 
value of the dissociation constant KA curves with a similar S-shape 
are obtained. This may be seen by the differentiation of equation (3). 
Thus d[RA]jd log [A] is constant for equal values of [RA]/[r]. Another 
advantage of a log concentration scale is that larger concentration ranges 
can be plotted in one graph. 
From equation (3) it follows that [A] = KA when [RA]/[r] equals £. 
In this simplest case the affinity is equal to the reciprocal of the disso-
ciation constant. If the concentration of the drug in the bath fluid is 
not equal to that in the biophase the fraction of receptors occupied as 
a function of the concentration of the drug in the bath fluid becomes : 
^
№ Ι
 - -ттда—
 (5) 
The shape of the curves obtained by plotting [RA]/[r] versus log [A], 
does not change with KA j ). Now the affinity is equal to the reciprocal 
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of К Д / К А , . Both the dissociation constant of the drug-receptor complex 
and the partition equilibrium constant may change with the molecular 
properties of the drug. In considering the relationship between the 
chemical structure and the biological activity, this has to be taken into 
account. If [A], is a non-linear function of [A]
 0, the affinity is no longer 
a drug constant with relation to the receptor system concerned. As a 
matter of fact, for intact animals or large animal preparations the 
relationship between the quantity of drug applied and the concentration 
in the biophase will be more complicated than that given by the simple 
equations (3, 5) and will vary with the mode of application. 
When structure-action relationships are studied on such complicated 
objects, it is quite possible that this relation is mainly determined by 
absorption, transport, breakdown, etc. and only to a lesser degree by 
the final interaction of the drug with its specific receptors (BRODIE and 
HOGBEN 1957). The concentration-response curves represent the recep­
tor-occupancy as function of the drug concentration if the effect is a 
linear function of the number of receptors occupied. In that case the 
concentration-response curves are represented by equation (3) or (5), 
if the receptor occupation is based on a Langmuir isotherm or bimole-
cular reaction (CLARK 1937). 
In the case of discrepancies between experimental log concentration-
response curves and curves obtained from equation (3) or (5), a correction 
of the theory may possibly be obtained from the introduction of a special 
relationship between the drug concentration in the bath fluid and in 
the biophase (FURCHGOTT 1955, MARSHALL 1955). The assumption of 
a higher-order reaction between drug and receptors, e.g. a trimolecular 
reaction, has been used as a correction in order to explain the fact that 
experimental curves were found to be steeper than those obtained from 
equation (3) (CLARK 1937, CAVANAUGH and HEARON 1954). This as­
sumption can hardly serve as a useful correction, since the higher-order 
reactions are very improbable. Also steep log concentration-response 
curves are obtained if instead of higher-order reactions, a sequence 
of bimolecular reactions is involved in the receptor-occupancy (see 
also DRUCKEY 1957). Another explanation for a difference in the slope 
of the theoretical and experimental curves is found in the relationship 
between the fraction of receptors occupied and the effect. Consideration 
of this relationship is the next step in the study of concentration-response 
curves. 
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RELATIONSHIP BETWEEN NUMBER OF RECEPTORS OCCUPIED AND EFFECT 
In the most simple case the effect, EA, of a drug A is linearly pro-
portional to the number of receptors occupied. Then the effect of A 
expressed as fraction of Em, the maximally possible effect with the 
biological object concerned, is given by : 
EA /Em = « [RA]/[r] = e / ( i + KA/[A]) (6) 
where a. is the proportionality constant or the contribution to the effect 
per unit of drug-receptor complex (ARIËNS 1954). 
When the effect is not linearly related to the number of receptors 
occupied, it is always possible to indicate a stimulus which is a linear 
function of the numbers of receptors occupied. It goes without saying 
that also when EA and [RA] are linearly related it is possible to indicate 
a stimulus which is always a step previous to the final effect. The sti-
mulus, S, as introduced by STEPHENSON (1956) has no dimensions. Here, 
therefore, the stimulus produced after occupation of the specific re-
ceptors by drug A, is a magnitude with dimensions and designated as 
SA· SA m is the maximal stimulus when the total number of receptors 
is occupied by A, while S m is the maximally possible stimulus with the 
biological object concerned. The value of the stimulus expressed as 
fraction of S m is defined as the number S. Thus : 
S = SA/Sm = « [RA]/[r] = «/(i + KA/[A]) (7) 
where α is the intrinsic activity or the contribution to the stimulus 
per unit of drug-receptor complex. If the stimulus SA is measured it 
is to be considered as an effect so that equation (6) and (7) are strongly 
analogous. The stimulus enters block 3 of figure ι and leaves it as the 
effect according to some transfer function. Thus : 
E A / E m = / ( S A / S m ) = / ( 5 ) (8) 
It is useful to examine the possibilities for the function which represents 
the relationship between the stimulus and the effect. 
a) Linear function. 
b) Discontinuous function. Increasing the number of receptors oc­
cupied a response and then a full response is obtained at a distinct 
value of [RA] (all or none response). 
c) Non-linear continuous monotonie increasing function (e.g. ex­
ponential and hyperbolic functions). 
18 
As a general principle the simplest is always preferable to the more 
complicated explanation. 
a) The linear function. 
The effect is directly proportional to the number of 
receptors occupied. It is therefore not necessary to consider ^R 
the stimulus separately. The effect of a drug A in case of a R 
linear function is given by equation (6). The intrinsic Î 
activity is proportional to EA m , the maximal effect possible \ 
with A, but independent of the function that represents the 
relationship between the concentration of the drug and the number 
of receptors occupied. The intrinsic activity is defined as α = EA„,/En„ 
which implies that the intrinsic activity may vary from zero to unity. 
What is generally called the " biological activity " of a drug is deter­
mined by both the affinity and the intrinsic activity. Variation in the 
value of the intrinsic activity results in the following possibilities : 
i) Drugs with a high intrinsic activity (a = i) are able to produce 
an effect and are therefore called agonists. 
2) Drugs with a low intrinsic activity (at = o) are ineffective as such, 
but behave as competitive antagonists to drugs with an intrinsic activity 
larger than zero. 
3) Drugs with intermediate values for the intrinsic activity (o < 
at < 1) are in fact agonists. The maximal effect obtainable is however 
smaller than for the drugs mentioned under 1). In combination with 
drugs with a large intrinsic activity they may behave as competitive 
antagonists. There is a competitive dualism in action (ARIËNS 1950, 
1954, 1956α). The same type of drug was called by STEPHENSON (1956) 
partial agonist. 
Theoretical log concentration-response curves calculated from equa­
tion (6) are represented in figure 2. From this figure it may be seen 
that the variation of KA results in a shift of the curves without changing 
their shape. A variation of the intrinsic activity results in a decline of 
the slope of the curves and a decrease of the maximal height. In the 
case of the linear function the activity of the drug is determined by 
the affinity, i/KA and the intrinsic activity a. For drugs with equal 
values for the intrinsic activity, equiactive concentrations are a measure 
for the biological activity. A more useful magnitude is the negative 
logarithm of the equiactive concentration or pD
x
 value. For drugs with 
different intrinsic activities the />D
 x
 value is the negative logarithm of 
that drug concentration, which produces an effect, E A m / E A , equal to x. 
*9 
(APIËNS and VAN ROSSUM 1957c). The pO2 value is equal to the logarithm 
of the affinity. 
1er1 1 10 [A] 1 10 [A] 
FIG. га, b 
Log concentration-response curves for agonists A with various values for the intrinsic 
activity, a, and the affinity. In figure га the effect is assumed to be a linear function of 
the quantity of receptors occupied KA = ι except for where KA = 0.25 and 
where K A = 4. 
In figure 26 the effect is assumed to be based upon an all-or-none response, the response 
value, τ, of which is distributed according to a normal frequency distribution (f = 0.5 
and a = 0.1). KA = 1 except for where KA = 16. 
b) The all-or-none response. 
As mentioned before, the effector unit in this case gives ^R 
a response, and then a full response, if a certain fraction ^ 
of the receptors is occupied by A. The concentration at t 
which this takes place may be called the response concen- I 
tration [A]
r
. 
The concentration-response curve for the all-or-none response there­
fore shows a very sharp discontinuity. The increase in the fraction of 
the receptors occupied is linearly coupled with the increase of the 
stimulus S A . In a previous paper (ARIËNS and VAN ROSSUM 1956c) for 
the stimulus, SA, the term " trigger magnitude ", TA , was used. It is 
however more convenient to adopt the term stimulus of STEPHENSON 
(1956). 
A full response is obtained with the effector unit as soon as SA/Sm 
reaches the response value r. 
The twitch of the so-called quick muscle fibre may serve as an example 
of the all-or-none response. The end-plate potential (e.p.p.) is a con-
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tinuous function of the drug concentration. The contration of the 
fibre takes place if the e.p.p. or the change in the e.p.p. reaches a certain 
value. 
Independently of the function on which the receptor-occupancy is 
based, it holds for the all-or-none response that the effect is zero, if 
S A /S m < τ and that the maximal response from the effector unit is 
obtained if S A /S m > т. Since S A /S m can at its maximum reach the 
value a (equation (7), only drugs for which the intrinsic activity is 
greater than or equal to τ are able to produce an effect. 
The study of single effector units require very special experimental 
conditions. Since the biological object is practically always composed 
of a great number of effector units discontinuous concentration-response 
curves are seldom found. The response values, r, for these units will 
generally exhibit a biological variance which can be given by a sym­
metrical (e.g. GAUSS) or skew (e.g. POISSON) frequency distribution. 
The fact that experimentally graded curves are found does not exclude 
an all-or-none response (CLARK 1937, GADDUM 1937). In the comparison 
of various drugs which interact by identical reaction mechanisms with 
the same biological object, the shape and the slope of the log concen­
tration-response curves depend mainly on the intrinsic activity. The 
mean response value f and the standard deviation σ will generally be 
constant if the same type of drug acts upon a certain tissue. The con­
centration range for which the relationship (f — 3 σ) < S A /S m < (f + 
3 σ) holds covers an effect from 0.1 to 99.9 % of E
m
. This implies that 
for drugs with an intrinsic activity α > (f -f- 3 σ) only a fraction of 
the receptors has to be occupied in order to obtain a practically maximal 
effect. There is a reserve of receptors which increases with the value 
(a — f — 3 σ). An effect E A essentially equal to E m is obtained if the 
total number of receptors is occupied by a drug with an intrinsic activity 
equal to unity, since SA/S„, approaches asymptotically to the value unity. 
Figure zb represents theoretical log concentration-response curves 
for the case that the response value, τ, is distributed according to a 
normal frequency distribution and that the receptor occupation is descri-
bable by equation (3). From this figure it may be seen that a change 
in the dissociation constant of the drug-receptor complex only results 
in a parallel shift of the curves along the log concentration-axis. Variation 
in the intrinsic activity results in a shift along the log concentration 
axis as well as in a change of the slope of the curves and for certain 
values a change in the maximal height. In the case of the all-or-none 
response also both the affinity and the intrinsic activity, as well as the 
type of frequency distribution is important with respect to the analysis 
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of the drug action. A variation in the intrinsic activity leads to three 
different possibilities. 
i) Drugs for which α > (f + 3 σ) produce, if added in sufficiently 
high concentration, a (practically) maximal effect, E„„ even before the 
total number of receptors is occupied. There is a receptor reserve. 
2) Drugs for which α < (f — 3 a) are ineffective as such. Even in 
high concentrations less than 0.1 % of the effector units will respond. 
These drugs may behave as competitive antagonists of those for which 
the intrinsic activity is greater than (f — 3 σ). 
3) Drugs for which (f — 3 σ) < α < (f + 3 σ) are effective as such. 
The maximal effect E A m that they produce, however, is smaller than 
the maximal effect obtainable with the biological object E
m
. In com­
bination with drugs of higher intrinsic activity these drugs may act as 
competitive antagonists. There is a competitive dualism in action. 
The frequency distribution is also of great influence upon the slope 
of the log concentration-response curves. If experimental log concen­
tration-response curves are found to be steeper than those expected 
in case of the linear function and if the receptor-occupancy is describable 
by equation (3), it is possible that the all-or-none response is concerned. 
Experimentally, the receptor reserve or the maximal height of the curves 
is a measure of the intrinsic activity. As will be discussed later, the 
affinity can be determined quantitatively after elucidation of the amount 
of spare receptors with an irreversible competitive antagonist. 
c) Non-linear continuous monotonie increasing function. 
As mentioned before non-linear continuous monotonie / 
increasing functions may also represent the relationship J* 
between the number of receptors occupied and the effect. I 
STEPHENSON (1956) deduced from his experiments a hyper- A 
bolic function for the relationship between effect and the fraction of 
receptors occupied. 
STEPHENSON could do this as he assumes that for some of his drugs 
the fraction of receptors occupied is linearly proportional to the dose 
applied, i.e. that a large receptor reserve exists. 
Between the occupation of the specific receptors or stimulus and the 
final step, the production of the effect by the effector system, several 
intermediate steps are often encountered. In the different steps, different 
stimuli may be postulated. The function representing the relationship 
between the fraction of receptors occupied and the effect is the resultant 
of the functions for the stimuli in the intermediate steps. The numerical 
value of the first stimulus, which is directly proportional to the fraction 
2 2 
of receptors occupied, is designated now as S
v
 In the following step 
a stimulus of the value S2 is produced by 5 t and this in turn induces 
a stimulus of the value S3 in the third step. If π intermediate steps are 
involved, the reasonings can be represented by the following equation : 
E A / E m = ƒ„ (Sn) S ( p + U = /¿S,) S2 = MS,) (9) 
Each stimulus value S(p h a) is some function of the proceeding one, 
Sv. It is supposed that 5, v ¡.
 υ
 approaches asymptotically to a saturation 
value with increasing S„ values. As a consequence of such a " saturation " 
function, for larger values for S„ the stimulus value S(v + 1 } hardly 
increases further. If it is assumed that each intermediate stimulus can 
Curves representing the relationship between the stimulus S A and the effect in the 
case of a non-linear continuous monotonie increasing function which is assumed to be 
the resultant of various intermediate stimuli. For each intermediate stimulus it holds 
that S „ -4 ι = Lp (i — e-S„/K„) in which the constants L„ and K p which are to a 
certain degree analogous to the intrinsic activity and affinity and have been taken 
as unity. In the curves nos. ο, ι, 2 and 3 we find zero, one, two or three intermediate 
steps respectively The Si values in the curves for which the effect has reached 98 % 
of E
m
 are marked h„, hi etc Note that the curves are steeper according as more inter­
mediate steps are involved 
become large enough to produce the saturation value for the following 
one, the curve representing the effect as function of 5 X is steeper when 
more intermediate steps are involved (See F I G . 3). Whatever the relation­
ship between 5X and the effect may be, the S1 value for which, for 
instance, the effect approaches 99 % of E
 m
 is of practical value. This 
Sl value is called h. For 5 X values larger than h, the effect hardly in­
creases with increasing drug concentrations. It follows from equation 
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(7) that for drugs with an intrinsic activity α > A, the stimulus value 
5 X already reaches A when only a fraction of the receptors is occupied. 
There is a receptor reserve which is determined by the value of (a — A). 
However the total number has to be occupied or S
x
 has to be equal 
to unity, in order to obtain an effect E A actually equal to E m . Thus a 
receptor reserve means that as soon as a certain fraction of the receptors 
is occupied, such that 5
Χ
 has reached the value h, the effect hardly 
increases but in fact asymptotically approaches E A m with a further 
increase of the number of receptors occupied. 
From a variation in the intrinsic activities the following possibilities 
result : 
i) Drugs for which α > A are able to produce an effect E A larger 
than 99 % of E
m
. There exists a receptor reserve. 
2) Drugs for which α = о are ineffective as such. In combination 
with drugs for which α > о, they act as competitive antagonists. 
3) Drugs for which ο < α < A are effective as such. The maximal 
effect that they can produce, however, never reaches 99 % of E
m
. In 
combination with other drugs interacting with the same receptor system 
they may act as agonists or as competitive antagonists, dependent on 
the effect already produced by the other drug. There is a competitive 
dualism in action. For these drugs STEPHENSON (1956) uses the term 
partial agonists. 
In the case of the non-linear continuous monotonie increasing function, 
the shape of the log concentration-response curves depends on the type 
of function representing the relationship between SA and the effect, 
the intrinsic activity and the affinity. A variation of the affinity results 
in a parallel shift of the curves along the log [A]-axis, if the receptor-
occupancy is based upon the mass law. A decrease in the intrinsic 
activity results in a non-parallel shift of the curves, which is coupled 
with a decline in the slope. As soon as α < A, there is also a decline 
in the maximum height. The function representing the relationship 
between SA and E A has an influence upon the slope of the log concen­
tration-response curves. As in the case of the all-or-none response, here 
also the curves may be steeper than those for the linear function. 
Since the receptor reserve depends on the value of (a — A), the amount 
of spare receptors gives a measure of the intrinsic activity. For drugs 
with a < A, the maximal height of the curves ( E A m / E m ) may serve as 
a measure of the intrinsic activity. As will be discussed later, the receptor 
reserve can be estimated with the aid of irreversible competitive anta­
gonists. The estimation of both the affinity and the intrinsic activity 
will be discussed in detail under " irreversible competitive interaction " . 
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With respect to the shape of the concentration-effect curves, in 
summary the following remarks may be made for a drug with a constant 
intrinsic activity. In the case of a linear function the concentration-
effect curve represents the relationship between concentrations of the 
drug and the fraction of receptors occupied (the mass law, Langmuirs 
adsorption isotherm). In the case of an all-or-none response the con­
centration effect curve represents the result of the biological variance 
for the effector units and the relationship between drug concentration 
and receptors occupied. 
In the case of non-linear continuous monotonie increasing function 
the concentration-response curve is the resultant of the functions re­
presenting the relationship between the quantity of receptor complex 
and the effect and those representing the drug-receptor interaction. In 
the case of a large receptor reserve, the fraction of receptors occupied 
is linearly proportional to the drug concentration and the concentration-
effect curve represents the effect as a function of the fraction of receptors 
occupied. Independently of the functions that are involved (linear, all-
or-none or otherwise) a decrease in the intrinsic activity in a series of 
drugs always results in a change from agonistic into competitive anta­
gonistic actions. The biological activity depends on affinity and intrinsic 
activity and in a number of cases also on the function representing the 
relationship between the fraction of receptors occupied and the effect. 
INTERACTION OF A SINGLE DRUG WITH SEVERAL RECEPTOR SYSTEMS 
In this paragraph the action of a single drug with combinations of 
receptor systems will be treated. Unless otherwise stated, it is assumed 
that the effect is a linear function of the quantity of receptors occupied. 
If the effect of a single drug is the result of its interaction with various 
receptor systems, various drug-receptor complexes, affinities and intrin­
sic activities have to be reckoned with. Such an interaction may be 
called auto-interaction (ARIENS et al. 1955, 1956o, с). Attention will 
be called here only to the non-competitive and functional auto-inter­
action. 
In the case of the non-competitive auto-interaction, the occupation 
of the receptors R of the interdependent receptor system R ^ R ' with 
drug molecules results in an effect. This effect is changed as a result 
of the interaction of molecules of the same drug with the second inter­
dependent receptor system R'. This change in the effect may be due 
to a change in the affinity of the drug for the receptors and to a change 
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of the function representing the relationship between the fraction of 
receptors occupied and the effect. 
In the case of the functional auto-interaction, the drug interacts with 
the receptor system Ri as well as with the independent receptor system 
R
n
. The occupation by drug molecules of Ri and RM may result in 
an effect by means of a common effector system, EH. 
a) Non-competitive auto-interaction resulting in a change in the affinity 
In this case of non-competitive auto-interaction there is 
a mutual influence of the drug-receptor complexes with R 
respect to the affinities of molecules of the same drug A for w 
the receptors R and R' of the interdependent receptor ^ S 
system R c R ' · 
This type of interaction may be represented by the following equation 
(ARIENS et al. 1956o) : 
a. 
E..'IE
m
 = — (io) 
i + KA/A A '/[A] * 
The factor / A A ) represents the mutual influence and varies inter alia, 
with the concentration of the drug. Therefore /A A ' may have a great 
influence upon the shape of the concentration-response curves for the 
drug. There is a mutual furtherance of the receptor occupation if /ду 
is less than unity. If /AA' is greater than unity there is a hindrance with 
respect to the occupation of both receptors. The mutual hindrance may 
be so large that a simultaneous occupation of the receptors R and R' 
of the receptor system R c R ' is excluded. Now R and R' are strongly 
interdependent. R c R ' are therefore called double receptors. In concrete 
this type of interaction can be a two-way fit of the drug on the double 
receptor R c R ' . An effective on R and an ineffective on R'. In this case 
equation (10) is reduced to : 
V ,F I / ( I + K A / K ' A ) / ^ 
Е . . ' / Е
я
 = a ( i l ) 
ι + KA/(i + K A /K' A ) [A] 
Depending on the value of KA/KA the following possibilities result : 
1) KA/KA < δ, (δ = o.oi), the drug A combines with the part R 
of the double receptor R c R ' and therefore is an agonist if the intrinsic 
activity is large enough. 
2) KA/KA > ι/δ, the drug A combines only with the part R' of the 
double receptor R c R ' and therefore is ineffective if applied singly. 
In combination with an agonist as mentioned under 1) this drug behaves 
as a " competitive antagonist " . 
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3) δ < К
А
/ К
А
 < ι/δ, the drug A combines with both R or R' 
of the double receptor R c R ' . A simultaneous occupation of R and R' 
is, however, excluded. The drug may produce an effect if applied 
singly. In combination with an agonist as mentioned under i) it shows 
" competitive " antagonistic properties. Therefore, drugs with an inter­
mediate value for KA/KÁ behave as " competitive dualists ". 
If the reaction velocity constant of the interaction of a drug A with 
R is greater than that for R', while the affinity for R' is greater than 
for R, the addition of the drug A results in an effect that is transient 
and followed by a block of the receptors. Certain forms of tachyphylaxis 
can be explained on this basis (ARIËNS et al. 1956o). If in a homologous 
series of drugs KA/KA' increases, there is a gradual change from agonists 
to " competitive antagonists " via drugs with a competitive dualism in 
action. 
Hence a gradual change from agonist to competitive antagonist may 
have its cause in a gradual decrease in the intrinsic activity or in a 
gradual increase of KA/KA in this type of non-competitive auto-inhibi-
tion. The change in KA/KA becomes manifest as a change in the in-
trinsic activity. Experimentally it is impossible to differentiate between 
the two forms of interaction on the basis of equilibrium studies. It is 
therefore discussable whether the term " non-competitive auto-inhibition 
resulting in a change in the affinity " has a say in the matter, if/ΛΑ' = °°. 
b) Non-competitive auto-interaction with a change in the intrinsic 
activity. 
The occupation of the receptor R of the interdependent 
receptor system R c R ' by drug A molecules results in an | R 
effect. The intrinsic activity or the relationship between ~ 
the fraction of receptors occupied and the effect are "* S 
changed as a result of the simultaneous occupation of 
receptors R'. This change is expressed by (1 -+- a'), where a' is the 
intrinsic activity with respect to this change. The occupation of receptors 
R' as such does not result in an effect. The effect of this type of auto-
interaction is represented by (ARIËNS et al. 19566) : 
E /E = - " [ А І / К А + α ( ΐ + - ) [ А ] 2 1 Ъ К ^ 
κκΊ m
 r + [ Â ] / K A + " [ A ] / K ' A + [A]VKAK'; 
where KA and KA are the dissociation constants of the drug-receptor 
complexes RA and R'A. The value of a.' determines the result of this 
type of non-competitive auto-interaction. If a' > о there is an auto-
sensitization and if a' < о there is an auto-inhibition. In the case that 
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a' = — ι there is a complete non-competitive auto-inhibition and bell-
shaped log concentration-response curves are obtained. 
If the effect is based upon an all-or-none response, the equation for 
the stimulus is obtained by replacing EAA'/ETO by SA A '/Sm. In figure 4 
log concentration-response curves are given for the auto-interaction on 
the basis of an all-or-none response, while the values for KA/KA and 
for a. and a' are varied. 
JJJJJ 
FIG. 4 
Auto-interaction. Log concentration-response curves for agonists exhibiting an auto-
interaction for various values of the intrinsic activities and affinities. In the curves nos. ι, 
2 etc. the dissociation constants are KA = i, 2, 4, 10 and 8 and K'A = 400, 50, i6, 40 
and 2000 while the intrinsic activities are a. = i, 1, 1, 1, and 0.6 and a.' = — 1, — 1, 
— °-5> — 1 and — 1 respectively. The effect is assumed to be based on an all-or-none 
response under conditions as given in figure гЬ. 
Curves with similar characteristics are obtained if the effect is a linear or non-linear 
continuous monotonie increasing function of the quantity of receptors occupied. 
If a' = — 1, equation (12) is reduced to the well-known equation 
of non-competitive substrate-inhibition (HALDANE 1930, HOFSTEE 1955). 
'/E„ = (-
-) (13) 1 + KA/[A] * 1 + [A]/K'A 
The log concentration-response curves calculated from this equation 
show a maximum, which is found after differentiation for dE^/dA = о. 
On doing this, it is found that [A]
m
 = -\/К
А
.К
А
, in which [A]„, 
is the concentration of A for which the maximum is reached. The 
maximum effect becomes : 
n
/E 7 = «/(i + VKA"/K'A)» (14) 
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The activity of a drug exhibiting an auto-inhibition depends on two 
affinities and two intrinsic activities. The procedure of choice in evalu-
ating KA, KÁ, and a depends on the KA/KA ratio. 
i) If KA/KA < δ, (δ = o.oi), the log concentration-response curve 
has a flat top. Thus KA is equal to the concentration of A for which 
Ед /Ε,η = h f ° r t n e ascending part of the curve, while KA is equal 
to the value of [A] for which EAV/E^, = £ for the descending part 
of the curve (ARIENS et al. 1957α). 
ζ) If KA/KÁ > ι/δ, the drug has only affinity for R' and therefore 
produces no effect if applied singly. In combination with drugs as men­
tioned under 1) it acts as a non-competitive antagonist, so that KA 
can be determined. 
3) If δ < KA/KA < ι/δ, it is not possible to determine KA and 
KÁ from the concentration-response curve. For enzyme action, HOFSTEE 
(1955), has given a useful procedure. For pharmacological interactions 
ARIËNS and VAN ROSSUM (1957a) have presented a suitable procedure. 
c) Functional auto-interaction. 
Evidence is presented by ARIËNS et al. (1956c) that on ER 
the rectus abdominis muscle of the frog nicotine can pro- / \ 
duce an effect by means of two independent receptor Ri R n 
systems. In others words, with the nicotine action a fune- ^ / 
tional auto-interaction is involved. The occupation of both A 
independent receptor systems Ri and R n by drug molecules leads to 
a final effect by means of a common effector system. There will be a 
mutual interference of the interactions upon the effector system. There-
fore the resultant effect is smaller than the total sum of the effects 
obtained from each of the receptor systems alone, since the effects 
obtained by means of the individual receptor systems overlap to a certain 
degree. According to ARIËNS et al (1956c) the following equation may 
be used for the functional auto-interaction : 
ЕІЛИА/ЕТО = E I A / E m + E I I A / E m E I A . E I I A / E m (15) 
where E I A and Е І Г А are the effects of drug A on a single receptor system 
and E
m
 is the maximal effect obtainable with the effector system. If an 
all-or-none response or a non-linear function underlies the effect the 
stimulus SIÄIIA expressed as a fraction of S m becomes : 
Si = S I A I I A /S m = S I A /Sm -\- SM A /Sm SIA.SIIA/S2OT (16) 
Whatever the function representing the relationship between fraction 
of receptors occupied and drug concentrations and the relationship 
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between effect and fraction of receptors occupied may be, equation (16) 
may still be useful. When the intrinsic activities are varied the following 
possibilities occur : 
a) Both the intrinsic activities αϊ and a M are large : then the occu­
pation of both receptor systems causes an effect. Since the effector 
system is limited, the effect cannot be larger than E
m
. The affinity ratio 
determines on which of the receptor systems an effect is caused first. 
If, for instance, the affinity for R t is much larger than for R „ , the effect 
on R i r is fully masked by the effect on R,. With the aid of antagonists 
for the effect on Ri the effect on R
n
 can be unmasked (ARIËNS et al. 
b) Both the intrinsic activities are low : then the drug behaves as a 
competitive antagonist of drugs interacting with Rt as well as of drugs 
interacting with Rn. 
c) One intrinsic activity, at, is large, the other, <хц, is low, then the 
drug produces an effect on one of the receptor systems, R b while on 
the other system, RXI, it behaves as a competitive antagonist of agonistic 
compounds with affinity to R
n
. 
Evidence has been obtained for these types of interaction (BROWN 
and WERNER 1949, ARIËNS et al. 1956c and this thesis chapter 3). 
The intrinsic activities and affinities of drugs exhibiting functional 
interaction can be calculated from the log concentration-response curves 
with the aid of other agonists or antagonists, using procedures as given 
before. 
Up to now the interaction of a single drug with one or more receptor 
systems was considered. The next step is the competitive interaction 
of more drugs with one receptor system. In the case of competitive 
interaction the reactions take place in block 2 of figure 1 while the 
events in block 3 are not affected. 
COMPETITIVE INTERACTION 
The combined effect of two drugs A and В having an ^R 
affinity for the same receptor system depends on the R 
fractions of receptors occupied by each of these drugs У N^ 
and on their intrinsic activities, α and ß. A B 
EA B /Em = « [RA]/[r] + β [RB]/[r] (17) 
where a and β are the intrinsic activities of A and Β. According to the 
values of the intrinsic activities, various types of competitive interactions 
are possible. 
ЗО 
a) Competitive antagonism. One of the intrinsic activities is high, 
the other very low (e.g. a = ι, β = о). 
b) Competitive dualism. One of the intrinsic activities is high, the 
other has an intermediate value (e.g. a = τ, о < β < ι). 
c) Competitive synergism. Both intrinsic activities are high (e.g. a. = 
β = i). 
On the assumption that the fraction of receptors occupied as function 
of the drug concentration obeys the Michaëlis-Menten or Clark equation, 
equation (17) is changed to : 
_
 tt[A]/KA + flB]/KB 
b A B / E m - -- + [ A ] / K A + [BJ/K; ( l8 ) 
where KA and KB are the dissociation constants of the drug-receptor 
complexes (ARIËNS et al. 1954, 1956α). There is a mutual interference 
of drug A and В molecules with respect to the occupation of the receptors, 
which can be seen better if equation (18) is written in a modified form : 
Елв/Е*. = r+7TT[B]/K¡}K^]+ 7T(ÏTTAÎ/KA)KB7[BÎ ( I 9 ) 
From this equation it may be seen that the drug which is present in 
excess finally determines the effect independently of the effect already 
induced by one of the drugs. It seems as if by the interaction of В the 
dissociation constant KA is increased while by the interaction of A, K B 
is increased. 
a) Competitive antagonism. 
Competitive antagonism is a special form of competitive interaction. 
The combined effect of the agonist A (a > o) and the competitive 
antagonist Β (β = о) is given by the classical equation for competitive 
inhibition (CLARK 1937, SCHILD 1947, ARIËNS et al. 1954, 1956α). 
E /E = (20Ì 
1 + (1 + [B]/KB)KA/[A] 
From this equation it may be seen that addition of a certain concen-
tration of the competitive antagonist results in a parallel shift of the 
log concentration-response curve for the agonist to higher values. See 
figure 5. The amount of shifting, (log [A]B — log [A]0), depends on 
the concentration and the affinity of B, according to 
[A]B/[A]0 = [B]/KB + 1 (21) 
where [A]B is the concentration of A in the presence and [A]0 the 
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concentration of A in the absence of a certain concentration of B. The 
concentrations [A]B and [A]0 produce equal effects. In the experiments 
to be described later on the " dissociation constants " have been calcu-
lated from the log concentration-response curves using equation (21). 
A measure for the affinity of a competitive antagonist is the concentration, 
which produces a certain shift of the curves for the agonist (CLARK 
and RAVENTÓS 1937). Also the dose ratios [A]B/[A]0 caused by a certain 
concentration of various antagonists are used as a measure for their 
affinity (GADDUM et al. 1955). On the basis of Clark's method, SCHILD 
(1947) introduced the " pAx " value. The pAx value is defined as the 
negative logarithm of the molar concentration of a competitive anta-
gonist which reduces the effect of an дс-fold concentration of an agonist 
to that of the single one. In our terms this means that : 
pK
x
 = -log K B — log(jc-i) (22) 
where * is the concentration ratio [A]B/[A]0. See equation (21). The 
pA2 value equals the log of the affinity of the competitive antagonist B. 
The />A2 and the pAin value are often used by various authors (SCHILD 
1947, 1949, MARSHALL 1955, etc.). In fact thepA^ value is a standardized 
concentration-ratio or dose-ratio. Generally the mass law holds for 
the reaction of the competitive antagonist with the receptors. It is there-
F"/r F . y E 
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FIG. sa, b 
Competitive antagonism. Log concentration-response curves for the agonist A (a = 
1, KA = 1) in the presence of constant concentrations of a competitive antagonist В 
(β = о, К
в
 = ι) . In figure 5α the effect is assumed to be a linear function of the quantity 
of receptors occupied. In figure 5b the effect is assumed to be based on an all-or-none 
response, under conditions as given in figure 26. Also in the case of a non-linear con­
tinuous monotonie increasing function the same characteristics are found. 
•л α 
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fore justifiable to calculate the pAx value from the concentration-ratio 
using equation (21). 
Another useful measure for the affinity of a competitive antagonist 
is the ratio [A]B/[B] for equal effects. This ratio is called inhibition 
index (ARIËNS et al. 19546) or the drug-ratio (GADDUM et al. 1955). 
The inhibition index is constant if [A]B > [A]0. 
If an all-or-none response with a biological variance underlies the 
effect, the stimulus induced by the combined action of an agonist A 
(™ > (f — 3 σ) and a competitive antagonist Β (β = о) becomes : 
SAB/Sm = OL [RA]/[r] = — - (23) 
A B L J L
 1 + (1 + [B]/KB)KA/[A] V 3 ; 
The response concentration for the effector units is increased as a result 
of the interaction of drug B. The effect as function of S A B/S,„ is given 
by the symmetrical or skew frequency distribution underlying the bio­
logical variance of the effector units. The shape of the log concentration-
response curve is therefore not changed by the action of a competitive 
antagonist. Since S A B /S m decreases with a certain concentration of В 
in the same way as Е
А
в / Е
т
 f ° r the linear function, the competitive 
antagonist causes a parallel shift of the log concentration-response curves 
for the agonist A. The amount of shifting (log [A]B — log [A]0) is 
determined by equation (21). Hence the affinity of a competitive anta­
gonist can be determined from the amount of shifting also in case of 
the all-or-none response. 
If the effect is a non-linear continuous monotonie increasing function 
of the stimulus the competitive antagonist В causes again a parallel 
shift of the log concentration-response curves according to equation (21). 
Since В only interferes with the occupation of the receptors with 
drug A molecules, the principles of competitive antagonism hold what­
ever the function ƒ may be. Compare equation (24) with equation (8). 
With the aid of a competitive antagonist it is therefore impossible to 
manifest a reserve of receptors for the agonist. 
In the most general case the combined effect of an agonist A and a 
competitive antagonist Β (β = о) may be represented by : 
E A B / E m = /(S A B /S m ) = f(S) (24) 
Experimentally, addition of an antagonist often results in a parallel 
shift of the log concentration-response curves for the agonist according 
to equation (21). Such a shift is a criterion for competitive antagonism 
and indicates that the fraction of receptors occupied is a Michaelis and 
Menten or similar function of the concentration of the drug. 
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b) Competitive dualism. 
The combined action of an agonist A with a large intrinsic activity 
(a > β) and a competitive drug В with an intermediate intrinsic activity 
(o < β < α) results in a competitive dualism. The addition of В to 
the biological object that is already in contact with the agonist may 
result in a competitive synergism or antagonism, according to the 
fraction of receptors originally occupied by A. This is clearly demon­
strated by the theoretical log concentration-response curves for the 
dualist В as calculated from equation (19) and presented in figure 6. 
A variation of the concentration of the agonist results in the following 
possibilities (ARIËNS 1954). 
1) If [A] = KA./?/(a — β), addition of В does not result in a change 
of the effect, E A / E m = E A B / E m = β. 
2) If [A] < KA.j9/(oi — β), addition of В always results in an increase 
of the effect to the value β (synergism), E A / E m < E A D / E m . 
3) If [A] > KA.j9/(<x — β), addition of В always results in a decrease 
of the effect to the value β (antagonism), E A / E m > E A B / E m . 
Independently of the initial effect obtained with A with increasing 
concentrations of the competitive dualist В the same final effect (EA B/E,„ 
= /J) is always obtained. 
E W E m , 
I r f Τ • • • d 
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FIG. 6 
Competitive dualism. Log concentration-response curves for the competitive dualist В 
(/? = 0.4, К
в
 = ι) in the presence of constant concentrations of the agonist A (a = 1, 
KA = 1). The effect is assumed to be a linear function of the quantity of receptors occu­
pied. For the points marked with open circles it holds that (E B — EA)/(EB „ — E A ) = 0.5. 
Note that В is agonistic, inactive or competitive antagonistic according to the effect 
already produced by A. 
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Log concentration-response curves for the agonist A in the presence 
of constant concentrations of the dualist В as calculated from equation 
(19) are presented in figure ηα. From this figure it may be seen that 
previous addition of a certain concentration of the dualist В causes a 
shift of the curves for the agonist. At the point of intersection of these 
curves the effect is independent of the concentration В and therefore 
at that point the concentration of the agonist equals the value KA.ß! 
The affinities of the agonist A and the competitive dualist В can be 
determined from their log concentration-response curves when they are 
applied singly. The pD
 x
 value for A can be estimated from the curve 
for [B] = о in figure ηα and the pO
 x
 value for В can be estimated from 
the curve for [A] = о in figure 6 (ARIËNS and VAN ROSSUM 19570). 
The affinity of the dualist В can also be determined from the log con­
centration-response curves for A as given in figure ηα. A certain con­
centration of В causes a shift of the log concentration-response curve 
for A, but since [B] itself induced the effect E B , the curve for A is now 
extended over the range ( E A m — E B ) . In this case also equation (21) 
holds if [A]o and [A]B are chosen such that E A / E A m = ( E A B — EB)/ 
( E A m — E B ) . Since in the case of pure competitive antagonism E B = o, 
[A]o and [A]B then have to be choosen such that they produce equal 
effects ( E A / E m = E A B / E m ) . In figure ηα the points for which E A / E m = 
(EA — E B )/(E A B — E m ) = \ are indicated with circles. The affinity 
of the agonist A can also be determined from the log concentration-
response curves for the dualist В as given in figure 6. A certain con­
centration of A causes a shift of the log concentration-response curve 
for B, but since [A] already produced the effect EA the curve for A 
now is extended over the range ( E B m — E A ) . The following equation 
also now holds : 
[B]A/[B]0 = [A]/KA + 1 (25) 
where [B] 0 and [B]A are the concentrations of the dualist in the absence 
and the presence of a certain concentration of the agonist for which 
E B / E B m = ( E A B — E A )/(E B m — E A ). The points for which E B / E B m = 
( E A B — E A ) / ( E B m — EA) = \ are indicated with circles in figure 6. 
The circles are the points of inflection of the various log concen­
tration-response curves both in figure 6 and ηα. 
The pA
x
 values are equal to the negative logarithm of the molar 
concentration of the drugs which causes the shift, so that the ratio 
[A]B/[A]o in equation (21) or [B]A/[B]0 in equation (25) equals x. From 
a drug В with a competitive dualism in action the pO2 value may 
be expected to be equal to the pA2 value. 
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If an all-or-none response with a biological variance underlies the 
effect, the stimulus, S A B /S m , induced by the combined action of an 
agonist A (a > β) and a competitive dualist B, (f — 3 o) < β < (f + 
3 σ), becomes : 
S A B /S m = « [RA]/[r] + β [RB]/[r] 
+ 
ß (26) 
ι + (ι + [B]/KB)KA/[A] ' 1 + (1 + [A]/KA)KB/[B] 
The stimulus, S A B /S m , of this equation is identical with the effect, 
E A B / E m , of equation (19). With respect to S A B /S m ) the concentration 
of the agonist A determines whether addition of В will result in an 
increase or a decrease of the stimulus. For large values of [B] the stimulus 
10 102 [в] ι io io' [A] 1 
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a) Competitive dualism. Log concentration-response curves for the agonist (α = ι, 
K A = 1) in the presence of constant concentrations of the competitive dualist Β (β = 
°·4. К
в
 =
 О· The effect is assumed to be a linear function of the fraction of receptors 
occupied. In the point of intersection of the curves, the effect is independent of B. 
b) Log concentration-response curves for the competitive dualist Β (β = 0.5, К
в
 = ι) 
in the presence of constant concentrations of the agonist A (ex = i, K A = i) . The effect 
is assumed to be based on an all-or-none response under conditions as given in figure 26. 
According to the effect already obtained with A, a synergism or antagonism occurs. 
With subactive concentrations a kind of potentiation takes place. 
always becomes equal to β, independent of the original effect produced 
by the agonist. The effect as function of S A B /S m is given by the frequency 
distribution which underlies the biological variance of the response 
value, τ, of the effector units. Hence the set of log concentration-response 
curves obtained in this case is similar to that in the case where the 
effect is a linear function of the fraction of receptors occupied. Compare 
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F I G . 6 and F I G . ηЬ. As long as the frequency distribution is unknown 
it is only possible to determine the order of the intrinsic activity and 
the order of the affinity of the dualistic drugs under study. 
If the effect is a non-linear continuous monotonie increasing function 
of the fraction of receptors occupied, the combination of an agonist A 
(a > β) and a competitive dualist Β (ο < β < a.) results in a set of 
concentration-response curves similar to those presented in figure 6 
and ηα. 
Hence from the foregoing it may be concluded that it is always true 
that a change from agonistic to competitive antagonistic drugs, via drugs 
with a competitive dualism in action, has its cause in a gradual decrease 
of the intrinsic activity. This holds irrespective of what function re­
presents the relationship between effect and fraction of receptors oc­
cupied. 
c) Competitive synergism. 
The combination of the agonists A and В which have affinity to the 
same receptor system and equal intrinsic activities, results in a compe­
titive synergism. Addition of one of the agonists to a biological object 
which has already produced an effect, caused by the action of the other 
agonist, always results in an increase of the effect (EA < E A B ; E B < 
EAB)· The combined effect of the agonists is given by equation (19). 
The log concentration-response curves for A in the presence of constant 
concentrations of the agonist В remain symmetrically S-shaped. 
The traject, ( E A m — E B ), over which the effect of A is extended 
decreases with increase of concentrations of B. 
The pO
 x
 value for the agonist A is equal to the negative logarithm 
of the molar concentration of A producing an effect such that (EA m — 
E B )/(E A B — EB) equals x, where E B is the effect already obtained with 
the agonist previously added. Although the combination of agonists 
with intrinsic activity is not very useful in evaluating affinities, it is 
sometimes inevitable. The combination of competing agonists in the 
case that the effect is a linear function of the fraction of receptors occu­
pied always results in an addition and never in a potentiation (ARIËNS 
et al. 19566). 
If an all-or-none response with a biological variance underlies the 
effect, the stimulus SAB,'Sm induced by the combined action of the 
agonist A (a > f — 3 σ) and the agonist Β (α = β) is given by equation 
(26). With respect to S A B /S m in this case, addition of the one agonist 
to a biological object already in contact with the other always results 
in an increase of the stimulus. There is an addition with respect to 
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SAB/S
 m
 while as a result of the biological variance there may be a poten­
tiation in the effect. (See F I G . 8). 
If the effect is a non-linear continuous monotonie increasing function 
of the fraction of receptors occupied or SA/Sm, the same reasonings 
hold as in the case of an all-or-none response. The combination of the 
agonist A (a > o) and the agonist Β (β = α) now also results in a compe­
titive synergism. 
[A] 
F I G . 8 and 9 
Competitive synergism. Log concentration-response curves for the agonist Α (α = ι 
K A = 1) in the presence of constant concentrations of the competitive agonist Β (β = ι, 
г ц = ι ) . T h e effect is assumed to be based on an all-or-none response under conditions 
as given in figure zb Note a potentiation. 
Competitive antagonism and auto-interaction. Log concentration-response curves for 
the agonist A (a = 1, a' = — 1 , K A = 1, K ' A = 16) exhibiting an auto-inhibition in the 
presence of constant concentrations of a competitive antagonist Β (β = о, К
в
 = ι) . 
The effect is based on an all-or-none response under conditions as given in figure 26. 
Since there is competition only on R there is only a shift of the ascending part of the 
bell shaped curves 
COMPETITIVE INTERACTION AND AUTO-INTERACTION 
Experimental pharmacology has furnished evidence that 
many drugs interact with an interdependent receptor 
system R c R ' . In other words they exhibit an " auto-
interaction " (AUGUSTINSSON 1949, ARIENS et al. 1956ο). 
As a matter of fact, with these drugs also a second drug may compete 
for one of the receptor systems R or R'. 
As an example we shall consider here the combined action of an 
I " 
R C R ' 
/ \ J/ 
В A 
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agonist A exhibiting an auto-inhibition (a > o, a' = — i ) and a drug В 
(β < a) competing with A on the receptor system R. The combined 
action of A and В may be represented by : 
« [A]/KA + β [B]/K„ ι 
A B A V
 " " " i + [A]/K"A + [B]/K. ' ι + A/K'A l * 7 ) 
Comparison of this equation with equation (13) shows that the first 
term of the latter is replaced by the term for the competitive interaction 
of A and В on R as given by equation (18). If the drug В is a competitive 
antagonist (β = о) addition of В results in a shift of the ascending part 
of the bell-shaped log concentration-response curve for A, while the 
descending part is not shifted. From equation (27) it is derived for 
the case that β = о that : 
Елл '/Е
А В А
' = ι + [B]/KB(i + [A]/KA) (28) 
in which ЕДА' is the effect of a certain concentration of A in the absence 
of В and ЕДВА' is the effect of the same concentration of A in the presence 
of B. When EAA'/EADA' is plotted against [B] straight lines are obtained 
(AUGUSTINSSON and NACHMANSOHN 1949), the slope of which varies 
with the concentration of the agonist. The dissociation constant of the 
competitive antagonist can be calculated from the slope of this lines. 
The [A]-dependence or independence is not a criterion for competitive 
or non-competitive inhibition as was tacidly believed by AUGUSTINSSON 
et al. 1949). 
If an all-or-none response with a biological variance underlies the 
effect, the stimulus SABA'/S™ induced by the combined action of an 
agonist A exhibiting an auto-inhibition (a > f — 3 σ; a' = —1) and 
a drug Β (β < a) competing with A on R may be represented by equation 
(27) in which EABA'/Em is replaced by S A B A 7S W . Log concentration-
response curves for an agonist A (a. = 1 ; a' = —1) and a competitive 
antagonist Β (β = о) for this case are represented in figure 9. From 
this figure it may be seen that the competitive antagonist causes a shift 
of the ascending part of the log concentration-response curve, while 
the descending part is unaffected. 
If the effect is a non-linear continuous monotonie increasing function 
of the fraction of receptors occupied, similar log concentration-response 
curves may be obtained. In the case of a competitive interaction similar 
series of log concentration-response curves are obtained irrespective of 
whatever the relationship between the effect and the quantity of receptors 
occupied may be. Only in the case of an all-or-none response may a 
potentiation take place. 
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IRREVERSIBLE COMPETITIVE INTERACTION 
Up to now the drug receptor interactions have been *•„ 
assumed to be reversible and therefore the formulae as R 
given above were based upon equilibrium states. In this f * \ 
paragraph drugs will be considered which combine with A B 
the receptors in a non-equilibrium (NICKERSON 1957) or an " irrever­
sible " way. 
Once occupied by such drug molecules the receptors are excluded 
from reaction with other molecules. The irreversible reaction of mole­
cules of a drug В with the receptors is represented by : 
[R] + [B] — ^ - * [RB] (29) 
The quantity of drug-receptor complex formed per unit of time is 
given by : 
¿[RB] 
at 
= kB(b- [RB])([r] - [RB]) (30) 
where b is the initial concentration of drug В and kB is the reaction 
velocity constant. The fraction of receptors occupied by В when В 
has been in contact with the receptors during the time t is found after 
integrating equation (30) : 
1 — e-<b-[r])k
a
t 
[RB]/[r] = - - — - — _ (31) 
1 — lr].e-(.b~[r])kBt 
b 
It is assumed that the concentration of drug applied or the bath fluid 
concentration, is equal to the concentration in the biophase. If the 
concentration in the biophase is a time-dependent function of the con­
centration of drug applied, complicated correction terms have to be 
introduced in equation (31). 
If the drug concentration is large with respect to the concentration 
of receptors, equation (31) is reduced to : 
[RB]/[r] = 1 — <KB]V (32) 
If the irreversibly-acting drug В has been in contact with the biological 
object during the time t, after which В is thoroughly washed out, the 
fraction, И 7 И , of receptors still available for the interaction with 
drugs is given by : 
И 7 И = «-[в]** (зз) 
4o 
E A B / E « = e-[B]kBt (34) 
The effect of a drug Α (α > o) interacting in a reversible way with the 
receptors still available is represented by : 
[RA] [r]'
 =
 1 _ 
И ' " ' [Л " 1 + KA/[A] 
The irreversibly-acting drug В causes a decrease in the amount of re­
ceptors for the agonist and therefore a decrease in the maximal effect 
obtainable with drug A. With high concentrations of the antagonist, 
И 7 И approaches zero, which implies that there are no receptors left 
for the agonist. 
From equation (34) it follows that as a result of the previous contact 
with drug B, the log concentration-response curves for A show a decline 
in the slope and a decrease of the maximal height as if a non-competitive 
E A ^ E r 
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Irreversible competitive antagonism. Log concentration-response curves for the agonist 
Α ( α = ι , Κ
Α
 = ι) reacting in a reversible way with a receptor system that has been 
for a time t in contact with an irreversible competitive antagonist В (kB 1 = 1 ) . 
In figure 100 the effect is assumed to be a linear function of the fraction of receptors 
occupied. 
In figure iofc the effect is assumed to be based on an all-or-none response under con­
ditions as given in figure 2b. Since there is receptor reserve for A, the decline in the 
curves is preceded by a shift. 
interaction was involved (See F I G . IO«) . The reaction velocity constant 
of В can be calculated from the decrease of the maximum height of 
the curves, using equation (34). 
If an all-or-none response with a biological variance underlies the 
effect, the stimulus S A B/S O T induced by the reversible interaction of an 
agonist A with receptors of a biological object that was previously in 
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contact with the irreversibly-acting drug Β (β = о) may be represented 
b y : 
[RA] Μ' ι 
S A B / S m = a - . _ Ì i — = a . <r[B]V (35) 
И ' И i + KA/[A] V 3 5 ; 
For large concentrations of the agonist A this equation becomes : 
S A m B / S m = « И 7 И = «e-[B]*.t (36) 
As mentioned before spare receptors for the agonist may exist if the 
intrinsic activity a is larger than (f -+- 3 σ). In the presence of В there 
are still spare receptors if SA m B/ST O is larger than (f + 3 σ). The amount 
of spare receptors is given by (1 — M 7 M ) f° r t r i e case that S A 7 n B /S m 
equals (f + 3 σ). The irreversibly-acting drug В causes a decrease in 
the amount of spare receptors and therefore a shift of the log concen­
tration-response curve for A. If for larger concentrations of В, ас-[ в ]*
в
' 
< (f -+- 3 σ) the reserve of receptors is exhausted, and as a consequence 
only a decline in the curves takes place with a further increase of [B] 
(See F I G . IOÒ). 
As pointed out before the intrinsic activity and affinity of an agonist 
which produces an effect on the basis of an all-or-none response with 
a biological variance cannot be obtained from the log concentration-
response curve as such. 
With the aid of an irreversible competitive antagonist B, however, 
relative values for the intrinsic activity can be obtained. In evaluating 
the intrinsic activities of the agonists A1; A2 etc., concentration-response 
curves are produced after previous contact during the time t with such 
concentrations [B]x; [B]2 etc. of an irreversible antagonist В that for 
equation (36) it holds that S A l B l B / S m = SA 2 m B/S,„ = = f. This 
implies that the maximal effects of the agonists in this case are equal 
to 50 % of E
m
. Since the intrinsic activities 0 ,^ a2 etc. of the agonists 
may vary, such concentrations [B]1, [B]2 etc. of В have to be used that 
the following equation holds : 
« i W i / И = ««MVM = = constant (37) 
in which [í"]í/[r], [r]2/[r] etc. are the fractions of receptors still available 
for the agonist Alt A2 etc. Then it follows from equation (36) that the 
relative intrinsic activities of the various agonists are given by : 
<х
г
 : <x2 = e[B], : e[B]2 (38) 
Under these conditions the stimulus is independent of the intrinsic 
activity and is represented by : 
1 
S»n/SOT = constant. (-iq) A B
 1 + KA/[A] U y ' 
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in which the constant is given by equation (37). Hence the relative 
dissociation constants for the various agonists are represented by : 
KA1 : KA2 : KA , = [A,] : [AJ : [AJ .... (40) 
where [AJ, [A2] etc. are the concentrations of the various agonists 
which produce equal effects in the concentration-response curves of 
these agonists obtained with a biological object which had previously 
been in contact with such concentrations [B] l t [B]¡¡ etc. of an irreversible 
antagonist В during the time t that E A m B / E m equals \. 
If the effect is a non-linear continuous monotonie increasing function 
of the fraction of receptors occupied, there exists a reserve of receptors 
for an agonist A if a. > h. A previous contact with a certain concentration 
of В during a certain time t results in a decrease of the amount of spare 
receptors. Hence the log concentration-response curves are shifted as 
a result of the action of increasing concentrations of В until the receptor 
reserve is exhausted, then a decline in the curves becomes manifest. 
The receptor reserve is exhausted by concentrations of В such that 
the maximal value S A m B / S m for the stimulus becomes smaller than h. 
In evaluating relative intrinsic activities and affinities, concentration-
response curves are produced for the various agonists, A l t A2 etc. after 
previous contact during a time t with such concentrations [B] lF [B]2 
etc. of an irreversible antagonist В that the maximal effect E A m B ob­
tainable with the agonist is equal to 5 0 % of E
m
. Then S A m B / S m of 
the various agonists are equal so that equation (39) holds. Under these 
conditions the relative intrinsic activities are given by equation (38) 
while the relative affinities are given by equation (40). 
Whatever the relationship between the fraction of receptors occupied 
and the effect may be, it is a consequence of the theory that different 
irreversible competitive antagonists manifest essentially the same re­
ceptor reserve. 
NON-COMPETITIVE INTERACTION 
Non-competitive interaction is defined as the interaction of an agonist 
A reacting with the receptor system R and a drug В reacting with the 
receptor system R' which differs from R. The drug В produces no 
visible effect if applied singly, but the effect of the agonist A is changed 
as a result of the occupation of R' by B. The influence of В on the 
effect of A may result in a change in the affinity of the agonist for the 
receptors R, i.e. a change in the fraction of receptors occupied as function 
of the concentration of drug applied. The function representing the 
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relationship between the effect and the fraction of receptors occupied 
may also be changed. 
The following possibilities may be concerned. 
i) A change in affinity. 
2) A change in the intrinsic activity, which implies a change in 
E A / E m for the linear function and an analogous change in SA/Sm for 
the all-or-none response and the non-linear continuous monotonie in­
creasing function. 
3) A change in the function representing the relationship between 
the stimulus and the effect. 
It is useful to consider separately the case in which the ability of 
the effector system to respond is changed. 
The various types of non-competitive interaction will be considered 
in more detail in the next paragraphs. 
a) Non-competitive interaction with a change in affinity. 
The reversible reaction of the non-competitive drug В ^н 
with the receptor system R', resulting in a change of the R С R' 
affinity of the agonist A for R, implies that there is a mutual Τ i 
influence upon the affinities. The receptor systems R and A В 
R' are called interdependent. It is conceivable that these receptor 
systems are located close to each other. 
The combined effect of the agonist A and the non-competitive drug В 
may be represented by (ARIENS et al. 19566) : 
ι 
Ε Α Β ' / Έ « = « — ---------------- (4i) 
1
 + KA/AB'/[A] 
in which /AB' represents the mutual influence of RA and R'B upon 
the affinities of В for R' and A for R respectively. Dependent on the 
value of /AB', the log concentration-response curve for A is shifted 
parallel to higher or lower values along the log[A]-axis (See F I G . 11). 
There exists a mutual furtherance if / A B ' < 1 (synergism) and a mutual 
hindrance if /
А
в' > ι (antagonism). The mutual hindrance may be so 
great that a simultaneous occupation of the R and R' parts of the 
" double " receptor R c R ' is excluded. Since only the occupation of 
R leads to an effect, the interaction of drug В with R' then results in 
a type of " competitive antagonism " . In this case equation (41) becomes 
identical with equation (20) for the competitive inhibition. It is therefore 
possible that the phenomenon of competitive inhibition may become 
apparent although agonist and antagonist interact with different but 
strongly interdependent receptors. 
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If an all-or-none response with a biological variance underlies the 
effect, for the stimulus, SA B '/Sm, the same holds as for EA B-/Em in case 
of a linear function. Thus in this case also addition of the non-compe­
titive drug В results in a parallel shift of the log concentration-response 
curves for the agonist to higher or lower concentrations. Analogous 
reasoning holds if the effect is a non-linear continuous monotonie in­
creasing function of the fraction of receptors occupied. 
ю* [A] 
FIG. I I 
Non-competitive interaction inducing a change in affinity. Log concentration-response 
curves for the agonist A (at = i, KA = i) in the presence of constant concentrations of 
a non-competitive antagonist В (K B = i , / A B ' > i). The effect is assumed to be a linear 
function of the fraction of receptors occupied. Here there is a real change in the affinity 
while in the case of a competitive antagonism there is a virtual change in the affinity. 
b) Non-competitive interaction with a change in intrinsic activity. 
The reaction of the non-competitive drug В with the E R 
receptor system R' results in a change in the intrinsic R с R' 
activity of the agonist A interacting with R. The receptor î Î 
systems R and R' are also called interdependent but they А В 
are not necessarily located close to each other. 
It is assumed that the change in the intrinsic activity of the agonist 
is proportional to the fraction of receptors R' occupied by B. The 
proportionality constant β' is called the intrinsic activity of В in this 
respect. The fraction of receptors occupied by В is assumed to be a 
Michaëlis-Menten function of the concentration of В applied. Other 
functions may also be introduced. The combined effect of an agonist A 
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(α > ο) and a non-competitive drug В (—ι < β') of the type just 
mentioned is given by (ASIENS et al. 1955 and 19566) : 
Е л в / Ь т
 ι + Κ
Α
/[Α] · i + [B]/K'B ( 4 2 ) 
From this equation it may be seen that : 
1) If β' > о the non-competitive drug causes an increase of the effect 
of the agonist. There is a non-competitive synergism or sensitization. 
2) Η β' = о, the drug В exerts no influence at all, but В would behave 
as a competitive antagonist of a drug С (γ' φ о) also interacting with R'. 
3) If —1 < β' < о, the drug В causes a decrease of the effect of 
the agonist. There is a complete non-competitive antagonism if /3' = 
—1 and an incomplete non-competitive antagonism if — 1 < β < о. 
The result of the interaction of a non-competitive drug В is a change 
in the effect of the agonist by a factor which depends not only on β', 
but also on the affinity of B. Log concentration-response curves for 
non-competitive antagonism (β' = — ι ) and for incomplete non-compe­
titive antagonism (β' = — 0.5) are given in figure 12. From these 
curves it may be seen that a non-competitive antagonist causes a decline 
in the slope and a decrease of the maximal height of the log concentration-
response curves of the agonist. From the decrease in the maximal height 
the affinity ( i/K B ) of В for R' can be estimated. If the intrinsic activity 
β' = — ι , equation (42) may be reduced to : 
E A / E A B ' = [B]/K'B + 1 (43) 
From this equation it follows that the concentration of a non-compe­
titive antagonist that produces a standard decline of the maximal height 
is a measure of the affinity. The negative logarithms of the concen­
trations of various non-competitive antagonists which produce the same 
decline are called ρΌ'
χ
 values (ARIËNS and VAN ROSSUM 1957a). The 
pO'x value is defined as the negative logarithm of the molar concentration 
of a non-competitive antagonist which gives a reduction of the effect 
of a certain concentration of an agonist such that EA/EAB' equals x. 
The pD' 2 value is equal to the logarithm of the affinity of the non-
competitive drug. The />D'X value is independently derived by SCHILD 
(1957) and designated the pAh value. Since the pD'x value is analogous 
to the pOx value we continue to use pO'x. 
If β' > — ι the pT>'2 value is defined as the negative logarithm of 
the molar concentration of the non-competitive antagonist В that gives 
a change in the effect of the agonist equal to 50 % of the maximal change 
obtainable with B. 
46 
If an all-or-none response with a biological variance underlies the 
effect of an agonist for SAB'/S^, equations analogous to those for 
ΕΑΒ'/Ε„, in case of a linear function hold. Then according to the value 
of β' there is also a non-competitive synergism or antagonism. As so 
far mentioned there may exist a reserve of receptors for the agonist 
if a. is larger than (f + 3 σ). If a certain concentration of a non-compe­
titive antagonist Β (β' — — ι ) is brought into contact with a biological 
Ю"
1
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Non-competitive interaction with a change in intrinsic activity, bog concentration-
response curves for the agonist A (a = i, K A = i) in the presence of constant con­
centrations of a complete (β' = — ι Fie. 12a) or an incomplete {β' — о.s F I G . 126) 
non-competitive antagonist ( К '
в
 = ι) . The effect is assumed to be a linear function of 
the quantity of receptors occupied. Note a decline in the slope and a decrease of the 
maximal height of the curves. 
object, a certain fraction of R' is occupied by B. This implies that only 
the R receptors of R c R ' in which R' is free can still contribute to the 
effect after occupation by drug A molecules. In other words, as a result 
of the interaction of В with R' the receptor reserve in R (if any) is 
decreased. Therefore addition of a non-competitive antagonist which 
causes a change in intrinsic activity results, in the case of an all-or-none 
response, when spare receptors exist for the agonist, in a shift of the 
log concentration-response curves for A to higher log [A] values. 
As soon as, with larger concentrations of B, SAmB/S,n becomes smaller 
than (f + 3 σ) the receptor reserve is exhausted and a decline in the 
curves becomes manifest (See F I G . 13). 
In the case of a non-competitive synergism the non-competitive 
drug Β (β' > о) may cause an increase or even an induction of the 
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receptor reserve for the agonist with the consequence that the maximal 
height of the log concentration-response curve for A is increased and 
the curves are shifted to lower log [A] values. The maximal height of 
the curves, however, never exceeds E
m
. 
If the effect is a non-linear continuous monotonie increasing function 
of the fraction of receptors occupied, the same reasoning holds as for 
the all-or-none response. If there exists a receptor reserve for the agonist 
A, if α > A, here also addition of a non-competitive antagonist B, 
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Non-competitive interaction with a change in intrinsic activity Log concentration-
response curves for the agonist A (a = 1, K A = 1) m the presence of constant concen­
trations of the non-competitive antagonist Β (β' — — ι, К '
в
 = — ι) . The effect is assumed 
to be based on an all-or-none response under the conditions of figure zb 
Since there is a receptor reserve for the agonist the decline in the curves is preceded 
by a shift. 
which changes the intrinsic activity for the agonist, results in a shift 
of the log concentration-response curves as long as SA „,Β'/S ,„ > h and 
in a decline in the curves when for larger values of В the receptor reserve 
is exhausted. As mentioned before, it is impossible to estimate for a 
drug with a receptor reserve the intrinsic activity and the affinity from 
the concentration-response curves as such. With the aid of a non­
competitive antagonist resulting in a change in intrinsic activity this is, 
however, possible as may be seen from the following procedure. 
Log concentration-response curves are plotted for the various agonists, 
Aj, A2 etc. in the presence of such concentrations [B]lt [B]2 etc. of 
the same non-competitive antagonist Β (β' = — ι ) that the maximal 
height of the curves is equal to 50 % of E
m
. For SAB'/S,„ in the case 
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of an all-or-none response as well as in the case of a non-linear continuous 
monotonie increasing function, the following now holds : 
SAWS
~
 =
 TTïbxr · ι + m/κΤ (44) 
so that with analogous reasoning to that given for the irreversible 
competitive inhibition the relative intrinsic activities of the agonists 
Aj, A2 etc. are given by : 
-i : <4 = (K' B + [B]0 : (K' B + [B],) (45) 
while the relative affinities are given by : 
K A 1 : K A 2 ... = [AJ : [AJ (46) 
in which [AJ, [AJ etc. are equi-active concentrations on the concen­
tration-response curves for the agonists Alt A2 etc. obtained in the 
presence of such concentrations [B]lt [B]2 etc. of the same non-competi­
tive antagonist В that Е
А п 1 в '/Е т = i· 
с) Non-competitive interaction exerted directly on the effector system. 
It is conceivable that the non-competitive drug В reacts ER с R' 
with receptors R' located directly on the effector system, | Τ 
resulting in a change in ability of the effector system to R B 
respond. This implies that as a result of the occupation J 
of the receptor system R by drug В molecules the maxi- A 
mum effect, E
m
, obtainable with the biological object is changed accor­
ding to the following equation : 
E
m B = E m ( i + /3'[R'B]/[r']) (47) 
where β' is the intrinsic activity of В with respect to this change in 
E
m
. According to the value of β' there is a sensitization if /J' > о and 
an inhibition if — 1 < β' < о. The combined effect of the agonist A 
and this type of non-competitive drug В is represented by : 
EAB' E A [R'B] 
E
m
 E
m
 [/] 
in which EA is the effect of A in the absence and EAB' the effect in the 
presence of the non-competitive drug B. This equation holds irrespective 
of whether the effect is a linear or non-linear function of the fraction 
of receptors occupied. Hence with this type of non-competitive anta­
gonist it is not possible to demonstrate a reserve of receptors R (if any) 
for the agonist. As a result of the addition of a non-competitive anta-
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gonist В reacting with receptors on the effector system, the slope and 
the maximal height of the log concentration-response curves are changed, 
while a shift of the curves never takes place. In contrast to the case 
of the preceding paragraph, addition of a non-competitive synergist В 
(β > о) may now result in the maximal effect of the agonist exceeding E
m
. 
If the effect of the agonist is a linear function of the fraction of re­
ceptors R occupied, equation (48) becomes identical with equation (42). 
Therefore in the case of a linear function it is not possible to distinguish 
whether the receptor system for the non-competitive drugs is located 
near the receptor system for the agonist or directly on the effector 
system. 
d) Non-competitive interaction resulting in a change of the relationship 
between the effect and the stimulus. 
It is conceivable that a non-competitive drug В reacting E R 
with the receptor system R' in between the receptor system I ~ R' 
for the agonist and the effector system, may result in a » Τ 
change of the function representing the relationship be- j, в 
tween the effect and the stimulus. A 
In the case of the linear functions this is a change in the intrinsic 
activity. 
In the case of an all-or-none response with a biological variance the 
effect as function of the stimulus is given by some frequency distribution 
characterized mainly by the value of f and σ. Both these magnitudes 
may change as a result of the occupation of R' by drug B, which implies 
a change in the shape of the log concentration-response curves. 
As pointed out before, in the case of a non-linear continuous monotonie 
increasing function the relationship between effect and the first stimulus 
may be the resultant of a number of " saturation " functions. The 
occupation of R' by В may result in an interference at a step SP any­
where in the chain of steps leading from S
x
 to the effect. Each step 
may contribute to possible receptor reserve, so that the interference at 
one of the intermediate steps may result in a manifestation of spare 
receptors. While with the aid of irreversible competitive antagonists 
it is possible to find the total amount of spare receptors, in this case 
often only a fraction can be made manifest. The amount of spare re­
ceptors that becomes manifest depends on the point of attack of the 
non-competitive drug B. If R' is located near the step where 5 X is 
produced a large amount of spare receptors may be found, while, if 
R' is located nearer to the effector system fewer spare receptors are 
made manifest. 
5° 
When there exists a receptor reserve for the agonist, addition of non­
competitive antagonists may bring to light various amounts (from total 
to zero) of spare receptors. The total receptor reserve may be found 
with non-competitive antagonists reacting with receptors related directly 
to the receptor system for the agonist. As pointed out before the amount 
of spare receptors can be exactly determined with irreversible competitive 
antagonists. 
NON-COMPETITIVE INTERACTION AND NON-COMPETITIVE 
AUTO-INTERACTION 
In the foregoing paragraphs the non-competitive inter- ^н 
action has been considered as the combined interaction R с R' 
of a non-competitive drug В interacting with R' and an * \ У * \ 
agonist A interacting with the receptor system R. In A B 
some cases the agonist A also shows affinity to the receptor system R' 
(auto-interaction). In the case of interdependent receptor systems R 
and R' the combined effect of a non-competitive drug В iß' > — ι ) 
reacting with R' and a drug A (a > ο, a' > — i ) exhibiting a non­
competitive auto-interaction may be represented by (ARIËNS et al. 
19566): 
F „, ι І + ( І + « ' ) [ А ] / К '
Д
 + ( І + Л [ В ] / К ' . 
Е , . /Ь„, — a. . - - - (40) 
А А в
 ' '" ι + К
А
/[А] ι + [А]/К'
А
 4 [В]/К'
в
 ™' 
From this equation it may bc seen that there is a competitive interaction 
of A and В on the receptor system R'. It can be derived by differentiation 
of equation (49) that [A]„,, the concentration of the agonist A for which 
a maximal effect is obtained is shifted to higher values as a result of 
the addition of B, according to the following formula : 
[A]
m D = [A]„, V 1 + [B]/KB (50) 
Concentration-response curves as calculated from equation (49), as well 
as experimental evidence for this type of interaction, are given by 
ARIËNS et al. (1956ο). If the receptor system R' is located directly on 
the effector system, essentially the same equations are obtained. Then 
also there is competition between A and В on R', so that the maximum 
in the concentration-response curve for A is shifted to higher values, 
according to equation (50). 
The non-competitive drug В and the drug A exhibiting an auto-
51 
interaction may, however, react with different R' receptors. EH с R* 
For instance the drug A (a > o, a' = — i ) reacts with * \ 
the R and R' parts of the interdependent receptor system ^ B 
R c R ' , while the non-competitive drug В reacts with R" * ^ 
receptors directly on the effector system. The combined д* 
effect of these drugs A and В may be represented by : 
α ΐ ι 
E . . '
n
» / E
m
 = . . (51) 
A A B
 '
 
 1 + KA/[A] 1 + [A]/K'A 1 + [B]/K"B 
From this equation it can be derived by differentiation that [A]
m B = 
[A]
m
. Thus the maximum in the curve for A does not shift as a result 
of the addition of B. 
This is conceivable since now there is no competition between A 
and В on any receptor system. Analogous reasoning holds if the effect 
is a discontinuous or a non-linear continuous monotonie increasing 
function of the stimulus. 
NON-COMPETITIVE INTERACTION AND FUNCTIONAL AUTO-INTERACTION 
In this case the agonist shows affinity to both ER 
the independent receptor systems Rj and R I t j while / ^ . 
a non-competitive drug В changes the effect of A. R i R n ~ R i i 
This may be the result of the occupation of a receptor \ / \ 
system which is interdependent with Ri or Rn. An- B 
other possibility is that the non-competitive drug В may react with 
receptors directly on the effector system. The combined effect of an 
agonist A (oti > о, ац > o) reacting with Ri and R
n
 and a non-com­
petitive drug В (ß'n > — ι) which in reacting with Rn changes the 
intrinsic activity of A (ац) on Rn may be represented by (ARIËNS et al. 
1956c) : 
ΕΙΑΠΑΒ'/ЕЖ = E I A / E m + E I I A B ' / E m — E I A . E I I A B ' / E
2
m
 (52) 
As pointed out before, the effect of A on Ri may be masked by the 
effect of A on RM if the affinity of A is greater for R i r than for R|. 
Addition of a non-competitive antagonist Β (β' = — ι), which reacts 
with Rn eliminates the effect of A on Rn with the consequence that 
the effect of A on Ri may become visible. 
In the case in which the non-competitive antagonist В reacts with 
receptors on the effector system, the effect of the combination of A 
and В is given by : 
Е
І А
„ л в ' / Е
т
 = E I A I I A ( i + /?'[R'A]/[r'])/Ero ( 5 3 ) 
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in which EIA ид is the effect of a drug A with a functional auto-interaction 
(see equation 15). Thus the antagonist В interferes equally with the 
effects of A on Ri and on R
n
. 
DUALISM IN ANTAGONISM 
One of the more often encountered forms of dualism in *•„ 
antagonism is the case that a drug В which is inactive if R с R' 
applied singly shows competitive as well as non-competi- ¿? N^ у 
tive antagonistic properties. The combined effect of an A B 
agonist A (a > o) and a dualistic antagonist Β (β = ο, β' = — ι) may 
be represented by the following equation (ARIËNS et al. 1956ο) : 
α ι 
ΕΑΒΒ'/Ε*. = - - + ( ι + [ Β ] / Κ Β ) Κ Α / [ Α ] · ! + [Β]/Κ'Β ( 5 4 ) 
This equation holds independently of whether В interacts with the 
interdependent receptor system R' or with a receptor system R' directly 
on the effector system. From the log concentration-response curves as 
calculated from this equation and presented in figure 14a it may be 
seen that as a result of the addition of the dualistic antagonist В the 
curves for A are shifted to higher values, while for larger values of В 
a decline in the slope of the curves and the maximal height becomes 
manifest. The shift is due to the competitive and the decline to the 
non-competitive action of B. The concentration range over which the 
shift in the curves for A is extended before a decline takes place is 
dependent on the ratio K D /K B . When the value of KB/KB' is varied 
the following possibilities are found : 
1) If KB/KA < δ, (δ = o.oi) the drugs В are practically competitive 
antagonists. The affinity for the receptor system R can be determined 
with procedures as given for the competitive antagonism. Here also 
the affinity can be expressed in terms of pA
x
 values. With very high 
concentrations of В a decline in the maximal height of the concentration-
response curve for A takes place, so that the affinity of В for R' can 
be estimated using the following equation : 
E A m / E A m B B < = 1 + [B]/K'B (55) 
in which E A m is the maximal effect of A in the absence and Е А т В в ' 
in the presence of a certain concentration of B. 
2) If K B /K B > ι/ίο δ the drugs В behave as practically pure non­
competitive antagonists. In estimating the affinity of В for R' or the 
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ρΌ'
χ
 value the same procedure can be followed as given for non-competi­
tive inhibition. In this case it is not possible to estimate the affinity 
of В for R since the curves for A are reduced to zero before a shift can 
be observed. If the non-competitive inhibition is incomplete, (— ι < 
β' < о), however, the curves for A are reduced only to a certain value. 
The remaining curve for A then is shifted by higher values of B. The 
amount of shifting can be used in estimating the affinity of A for R. 
3) If δ < K B / K B < 1/10 δ the drugs В show competitive and non-
competi ive antagonistic properties within a narrow concentration range. 
The pD'
x
 value or the affinity of В to R' can be determined using equation 
IO IO7 [XI I IO IO5 [A] 
F I G . 14a, 6 
Dualism in antagonism. Log concentration-response curves for the agonist A (a = 1, 
K A = 1) in the presence of constant concentrations of the drug Β (β = ο, β' = — ι, 
Κ
Β
 = ι, Κ '
Β
 = 4ο) exhibiting a dualism in antagonism. In figure 14a the effect is assumed 
to be a linear function of the fraction of receptors occupied. The shift in the curves is 
accounted for by the competitive actions while the decline in the slope and decrease 
of the maximal height is due to the non-competitive actions of В 
In figure 146 the effect is assumed to be based on an all-or-none response under the 
conditions of figure 26 Since there is a receptor reserve for the agonist the shift in the 
curves is the resultant of the competitive and non-competitive action of B. The decline 
in the slope of the curves and the decrease of the maximal height is due to the non­
competitive action of В 
(55)· The pk
x
 value or the affinity of В to R can be found from equation 
(21), where [A]0 is the concentration of agonist A producing the effect 
E A in the absence and [A]B that producing the effect Е*Вв' equal to 
Е
А
. Е
А т
в в 7 Е
А т
 in the presence of [B] (ARIENS and VAN ROSSUM 1957a). 
If an all-or-none response with a biological variance underlies the 
effect, the stimulus induced by the combined action of an agonist A 
(a > o) and a dualistic antagonist Β (β = ο, β' = — ι) is given by 
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equation (54) in which SABB'/S,,, is substituted for Е
А
вв'/Е
т
. From the 
log concentration-response curves for this case, as given in figure 14a, 
it may be seen that here also there is a shift in the curves for A as a 
result of the addition of B, while subsequently a decline at higher 
values of В takes place. If there are spare receptors for the agonist 
(« > f + 3 σ) the shift has to be attributed partly to the competitive 
and partly to the non-competitive action of B. The decline in the slopes 
of the curves and in the maximal height is due only to the non-competi­
tive action of B. That part of the shift which is actually due to the 
competitive inhibition of В can be found if agonists are used for which 
there does not exist any receptor reserve. Thus with agonists for which 
EA,„ < E„, (i.e. a < (f + 3 σ)). 
If the non-competitive inhibitory action of В results from a reaction 
of В with a receptor system R' directly on the effector system, the shift 
in the curves for A is caused only by the competitive inhibitory action 
of B, since in this case receptor reserve, if any, has no influence. 
If the effect is a non-linear continuous monotonie increasing function 
of the fraction of receptors occupied, a reasoning analogous to that 
given for the all-or-none response holds. 
FUNCTIONAL INTERACTION 
A functional interaction is involved if the drugs A and 
В produce identical effects, by means of a common effector 
system, as a result of their reactions with the independent 
receptor systems Ri and R l r respectively. Assuming a 
simple mutual overlapping on the effector system, the 
combined effect of A (a^ > o) and В (ßu > о) may be represented 
by the following equation (ARIËNS et al. 1956c) : 
^ідмв/^и = Е
І А
/Ь„, + Ь
І І В
/ Ь
т
 Ь
І А
. Ь
І І В
/ Ь
т
 (50) 
With respect to the intrinsic activity of A and В there are various 
possibilities. 
1) If «i = ßu = 1, both drugs may produce an effect equal to Е
и 
if applied singly. The combination of the agonists A and В always 
results in a synergism which is similar, but not equal to the competitive 
synergism. 
2) If »i > o, ßu = o, the drug A produces an effect. The drug B, 
which is inactive if applied singly, does not interfere with the action of A. 
3) If л 1 = 1 and о < ßu < ι, the combination of the agonist A 
R. R, 
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with the partial agonist В always results in a synergism, as may be seen 
from figure 15a. This is in marked contrast with the case in which 
A and В interact with the same receptor system. If A and В are competing 
drugs, the drug В may act as a synergist or as an antagonist, depending 
on the effect already produced with the agonist A. Compare figure 15a 
with figure 6. 
FIG. 15a, b 
Functional interaction. Log concentration-response curves for the agonist Β (β = 0.5, 
K I B = ι) in the presence of constant concentrations of the agonist A (<xIT = 1, K I I A = 1 ) . 
A and В react with independent receptor systems. 
In figure 15a the effect is assumed to be a linear function of the fraction of receptors 
occupied. 
In figure 156 the effect is assumed to be based on an all-or-none response under the 
conditions of figure xb. In the case of a functional interaction the combination of a drug В 
with intermediate intrinsic activity and an agonist always results in a synergism, while 
in the case of a competitive interaction a dualism in action (synergism and antagonism) 
takes place. Compare figure 15a, b, with figure 6 and ηb. 
If the all-or-none response with a biological variance underlies the 
effect, an analogous reasoning holds. The stimulus for the combination 
of an agonist Α (αϊ > о) and a partial agonist В (о < ßn < ι), interacting 
with Ri and Rn respectively may be represented by : 
°ІАІІв/°т = S I A /S r a + S I I B / S m S I AS,iB/S„, (57) 
Here also there is always a synergism. See figure 15O and compare with 
figure jb for competitive interaction. If the effect is a non-linear con­
tinuous monotonie increasing function, an analogous reasoning again 
holds. 
The prediction of a dualism in action for the combined action of an 
agonist (high i.a.) and a partial agonist (intermediate i.a.) competing 
56 
on the same receptor system, and of a definite synergism if these drugs 
make use of different, independent receptor systems, has been confirmed 
by experimental evidence (chapter 3 and ARIËNS et al. 1956α, с). 
DISCUSSION 
The effect induced by addition of a drug to a biological object is 
practically always based upon an interaction between drug molecules 
and specific molecules, molecule complexes or parts of molecules in 
the biological object. The latter are called receptors. One receptor can 
be occupied by only one drug molecule. In analysing the effect of a 
drug the first step is given by the relationship between the dose of drug 
applied to a biological object or the concentration in the bath fluid and 
the drug concentration in the immediate surroundings of the receptors 
or biophase. See figure 1. The second step gives the relationship between 
the drug concentration in the biophase and the fraction of receptors 
occupied. The third step represents the effect as function of [RA]/[r]. 
As a fourth step may be considered separately the ability of the effector 
system to respond. 
With respect to the first step, very complicated relationships may be 
found especially in the intact animal. By using simple isolated organs, 
while studying the effect in the steady state, this step may often be 
eliminated. Chemical interactions, which may result in a change of the 
effective concentration of a drug in the biophase or in the effectivity 
of a drug as such, come under the " drug transference " as given in 
block 1 of figure 1. 
The second step, which depends on the affinity of a drug for the 
receptors, is of great importance for the study of structure-action re­
lationships. The competitive interaction is usualy limited to the second 
step. 
The function represented by the third step may be : ' 
a) a linear function, 
b) a frequency distribution, if the effect is based upon an all-or-none 
response with a biological variance and 
c) a non-linear continuous monotonie increasing function. 
The third step is much more characteristic of the specific biological 
object and independent of the molecular properties of the drug under 
study. Non-competitive drugs may interfere in this step. 
Drug action can be studied in a satisfactory way with the aid of 
concentration-response curves. In this thesis use is made chiefly of 
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concentration-response curves in which the concentration-metameter 
(GADDUM 1953) is the logarithm and the effect-metameter the percentage 
of the maximal effect obtainable with the biological object. Other meta-
meters can be used, as for instance for the effect, probits, logits, etc. 
With the use of other metameters under given conditions the same 
conclusions can be drawn as from log concentration-response curves in 
which the response is expressed in percent of Е
ш
. 
As may be seen from the foregoing paragraph, the log concentration-
response curves for a drug can be influenced in various ways as a result 
of the action of other drugs. Recently CHIHARA (1955) has found that 
as a result of the action of certain drugs the concentration-response 
curves for various agonists are shifted to higher or lower values and 
the slope and the maximal height are decreased or increased. Chihara's 
findings can be explained on the basis of the theories mentioned. 
The analysis of the mechanism of action of drugs and the study of 
structure-action relationships necessitate theories concerning drug ac­
tions. For the estimation of the activities of drugs for which the mecha­
nism of action is known in practice it is possible to use various proce­
dures. Bioassays on a mathematical background have been critically 
reviewed by GADDUM (1953). 
The affinities of agonists, competitive antagonists and non-competitive 
antagonists can very suitable be expressed in terms of pD
 x
, pA
x
 and 
pD'
x
 values respectively. As remarked by SCHILD (1957) for the pA
x 
and pD'
x
 (his pAh) value these three magnitudes are empirical measures 
of the activity of drugs. In some special cases they have theoretical 
significance since they may correspond to the mass equation constants 
of agonists, competitive antagonists and non-competitive antagonists. 
The theories on drug actions thus far given are the basis of the study 
of the structure-action relationships as presented on the following 
chapters. The term " structure " has to be considered in the broadest 
sense. The physical and chemical properties which underly the molecular 
configuration of drugs have to be concerned with it. The term " action " 
includes here the mode of action as well as the activity. If one studies 
the relationship between molecular properties and the affinity of drugs 
with an identical mode of action (e.g. atropine substituents) it is better 
to speak of structure-activity relationships. It may be seen from the 
following chapters that molecular properties can be connected with 
intrinsic activities and affinities. Consequently that gradual changes in 
the molecular configuration are coupled with gradual changes in the 
intrinsic activities and or affinities. 
S« 
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CHAPTER II 
PHARMACODYNAMICS OF D R U G S AFFECTING 
SKELETAL MUSCLE О 
Structure-action relationships in homologous series of 
quaternary ammonium salts 
INTRODUCTION 
There is a diversity in skeletal muscle. A distinction is made into 
twitching muscles and muscles which produce a contracture. There are 
also intermediate types. The differences are partly due to the mode 
of innervation of the muscle fibres (KATZ 1956). 
In twitching muscle fibres the nerve connections are restricted to 
one or a few circumscript loci or myoneural end-plates. It has been 
found that even at rest subluminal quanta of acetylcholine ( i o 3 molecules) 
are released at random moments in the end-plate which results in minia­
ture changes in the end-plate potentials (KATZ 1956). The submicros-
copic vesicles which are produced from the motor nerve endings (PALADE 
1954) may be the containers of the ACh-quanta (KATZ 1956). If more 
impulses come down along the nerve, the number of quanta of acetyl­
choline (ACh) released increases. The receptors for ACh are located 
at the exterior side of the muscle cell membrane (KATZ 1956). With 
the occupation of the receptors a decrease in the end-plate potential 
takes place, which possibly serves as a stimulus. If the decrease in end-
plate potential reaches a critical value an action potential is set up, 
which is propagated along the muscle fibre. Subsequently the fibre 
responds in an all-or-none fashion. Independently of whether or not 
the receptors for ACh still remain occupied, the contraction is followed 
by a relaxation. The phenomena can be repeated if the transmitter 
(') A small part has been presented in a preliminary paper (VAN ROSSUM and A B I Ë N S 
1956). 
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substance is removed, which is accounted for by the hydrolysis of ACh 
by ACh-esterase. Persistent high concentrations of ACh cause neuro-
muscular block. Although presumably the depolarization is not persistent 
(THESLEFF 1955, 1956) the block has been said to be of the depolarizing 
type (BURNS and PATON 1951). 
In the muscle fibres, which produce a contracture the nerve connec-
tions are more diffusely placed along the fibre. A local decrease of the 
membrane potential is not followed by a propagated action potential 
but a local persisting contracture is induced (KATZ 1956). These muscle 
fibres produce a graded response. 
Since there is a sequence of events leading from the occupation of 
the specific receptors to the final effect, it is possible to interfere with 
the muscular activity at different points and therefore by the use of 
drugs with a different mode of action. 
1) Drugs reacting with the specific ACh-receptors. If the intrinsic 
activity of these drugs is high they are called cholinomimetics or de-
polarizing drugs. If the intrinsic activity is low they behave as competitive 
antagonists of the mimetics and are designated cholinolytics. The bio-
logical activity is determined by both the affinity and the intrinsic activity 
(ARIËNS 1954α). Large numbers of drugs have been subjected to in­
vestigation about structure-action relationships (CRAIG 1947, BARLOW 
and I N G 1948, PATON and ZAIMIS 1949, BOVET et al. 1951, TAYLOR 1951, 
CHEYMOL 1954α, BRÜCKE 1956). It is, however, not yet possible to draw 
firm conclusions concerning physical and chemical properties essential 
for an optimal affinity of cholinomimetics or cholinolytics towards the 
receptors in skeletal muscle. As a rule bis-onium compounds have a 
better affinity than mono-onium compounds. 
There is no optimal distance for the two onium groups (LoEWE et al. 
1954) as has been tacitly assumed (BARLOW and I N G 1948, PATON and 
ZAIMIS 1949). The cholinolytics generally are larger molecules than the 
cholinomimetics. Consequently the receptors for the former may be 
more extended than those for the latter. It is even possible that both 
types of drugs may behave as competitive antagonists, although they 
react with different but strongly interdependent receptors (this thesis 
chapter I). In this case it is conceivable that the molecular properties 
required for good affinity may differ for the cholinomimetics and cholino-
lytics. T h e steric configuration is also of importance (WASER 1957). 
In a physico-chemical sense the reaction between drug and receptor 
molecules implies an interaction between the electrical fields inherent 
to their charge distributions. The affinity is related to the interaction 
between these fields in the most general sense. The intrinsic activity 
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often will be connected with a special part of the field interaction (VAN 
ROSSUM and ARIËNS 1957). In the case of cholinomimetics the intrinsic 
activity is connected with the depolarizing action, which is evidently 
associated with the positive charge of the onium group. The onium 
group, which generally is ammonium, may also be phosphonium or 
arsonium (HOLMES et al. 1949). It has been found that introduction of 
large substituents on the quaternary nitrogen atom of depolarizing drugs 
results in a decrease of the intrinsic activity (ARIËNS et al. 1954e, 19560, 
BRÜCKE 1956). It is suggested that the intrinsic activity is directly con-
cerned with the effectiveness of the positively charged onium group in 
interfering with the electrical field of the receptor. The reduction of 
the intrinsic activity by heavier substituents on the onium group may 
be caused by an increase of the distance between the onium group and 
the receptor and possibly by a masking or reduction of its positive 
charge. 
2) Drugs reacting with receptors different from the specific ACh-
receptors and being inactive as such. These drugs are non-competitive 
with respect to cholinomimetics or cholinolytics. The effect of a non-
competitive drug is a change in activity of the agonist or antagonist, 
which is accounted for in the following ways : 
a) A change in the relationship between concentration of the drug 
and the ACh-receptors occupied, thus a change in the affinity. 
b) A change in the relationship between the fraction of ACh-receptors 
occupied and the effect, thus a change in intrinsic activity (thesis chapter 
I, ARIËNS et al. 1955, 1956o). 
The physical and chemical properties required for intrinsic activity 
and affinity of non-competitive drugs will differ from those of the 
cholinomimetics and cholinolytics. It has been found that quaternary 
ammonium salts which exert a strong surface activity often behave as 
non-competitive antagonists of the type b) (ARIËNS et al. 19566). The 
antagonistic action of edrophonium or neostigmine with respect to 
cholinolytics (D-tubocurarine) and their sensitizing action with respect 
to cholinomimetics (suxamethonium) may be partly accounted for by 
a non-competitive interaction of the type a). It is also in part due to 
the inhibition of ACh-esterase. 
3) Drugs which produce an effect by reacting with others than ACh-
receptors. There is a functional interaction of these drugs and cholino-
mimetics. 
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METHODS AND MATERIALS 
The experiments were chiefly performed with the isolated rectus 
abdominis muscle of the frog (Rana esculenta). The muscles were 
suspended in a bath containing ι о ml of a Ringer solution of the following 
composition: per one litre distilled water: 6.5 g NaCl, 0.15 g KCl, 
0.15 g NaHCOg, 0.2 g CaCl2 and 1 g glucose. The contracture induced 
by the drug was recorded isotonically on a sooted drum and in some 
cases isometrically by measurements of capacity differences (Fielden 
Proximity meter). 
Cumulative concentration-response curves were obtained by adding 
doses of a drug in the following sequence : a; a; 2.a; 40; etc. Each 
dose was left in contact with the muscle for 15 minutes. This was enough 
to reach equilibrium. Then the concentration was doubled by adding 
F I G . I 
Cumulative dose-response curves as obtained with the frog rectus. The dose (m.mols) 
of the drug is doubled every 15 minutes. The experiments with muscle No. 9 demonstrate 
the competitive inhibition of С^СЬМез as a parallel shift of the curve for BuNMe 3 . 
The experiments with muscle 13 and 14 demonstrate the difference in intrinsic activity 
of C 1 0 M e 3 and С 4 СЬМе 3 as a difference in the slope and the maximal height of the curves 
(1/3 of full size). 
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5 
the subsequent dose (See F I G . I ) . After each curve washing was carried 
out for 30-90 minutes, the time necessary for complete relaxation. 
(Compare ASIENS et al. 1954A). With one muscle many cumulative 
concentration-response curves can be obtained. Because of the time 
limit, usually three curves were registered with one muscle in the 
following sequence : St; X; St or X; St; X. Here St is the standard 
(mostly BuNMe
s
) and X the drug under study or the combination 
of a constant concentration of an antagonist and the standard (See 
F I G . I ) . The log concentration-response curves were calculated by ex­
pressing the effect of each concentration of the drug in percent of the 
maximal effect possible with the standard. The shape and the piace 
(pD 2 value) of the curves on the concentration-axis of duplicate curves 
with the same muscle were in good agreement (The sensitivity of 
different muscles varied to a large extent). Curves obtained with different 
muscles were " parallel " within close limits, but their pO2 values varied 
to a large extent. The average slope and ρΏ2 value of a number of curves 
for BuNMe
a
 and C 8CarbChMe 3 are given in table I. It is obviously 
TABLB I 
BuNMe
a 
C C a r b C h M e , 
intr. 
act. 
1 
1 
log affinity 
p D , , P.5 
5-32 
6-55 
5.16 — 5.48 
6.48 — 6.62 
log E/(E
m
—E) 
versus log cone. 
slope 
2.03 
2-53 
P., 
1.64 — 2.41 
2.4O 2.66 
number of 
estimations 
and 
muscles 
8 and 5 
15 and 8 
incorrect to construct log concentration-response curves by calculating 
the mean of the response produced by a given concentration (PERRY 
1950, GADDUM 1953). The slope oí the average curve calculated in such 
way is flatter than that obtained with the correct procedure (i.e. to 
calculate the mean concentration for a given effect). In the study of 
drug interactions one often encounters a difference between the slope 
of experimental and theoretical concentration-response curves. Usually 
the experimental curves are steeper (CAVANAUGH and HEARON 1954)-
Since VAN MAANEN (1950) used an incorrect procedure to calculate 
the average log concentration-response curve for ACh, the agreement 
of the slope of his experimental curve with the theory is only apparent. 
In our experiments the affinity is expressed as the negative logarithm 
of the molar concentration of a drug which produces a standard effect. 
Thus for the agonists the pO2 value, for the competitive antagonists 
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the рА
г
 value and for the non-competitive antagonists the />D¿ value 
were used (SCHILD 1949, ARIËNS and VAN ROSSUM 1957a). 
The intrinsic activity was taken to be directly proportional to the 
maximal effect possible with the drug under study (i.a. of B u N M e 3 = 1 ) . 
This was admissible since the existence of possible spare receptors could 
not be manifested, irreversible competitive antagonists not being available 
(ARIENS et al. 1957b, thesis chapter I). 
In addition to the in-vitro experiments with the frog rectus muscle, 
in-vivo experiments with nerve muscle preparations were performed. 
The peroneus — tibialis anterior preparation of the cat was used as a 
twitching muscle and the sciatic — gastrocnemius of the chicken (PELI-
KAN et al. 1954) as a twitching and contracturing muscle. The latter 
preparation is especially suitable for classifying the neuromuscular re-
laxants. 
Various homologous series of drugs were studied. For the greater 
part they were synthesized in our laboratory (thesis chapter V). Some 
others were obtained from various sources (See acknowledgments). 
EXPERIMENTS WITH THE FROG'S RECTUS ABDOMINIS MUSCLE 
a. Decamethylenebis(dimethylalkylammonium salts). 
MejRN+—(CH t)I0—N+RMe, Code: C1(lMe,R 
Successive replacement of methyl groups by ethyl groups in deca-
methonium (C1 0Me3) results in a gradual decrease of the intrinsic activity. 
Both on the frog rectus muscle (ARIËNS et al. 19546) and on the chick 
muscle (THESLEFF and U N N A 1954) the cholinomimetic actions of C 1 0 Me s 
change into the cholinolytic actions of C1 0MeEt2 via the competitive 
dualistic actions of C1 0Me2Et. 
On introduction of homologous alkyl groups there is a reduction of 
the effectiveness by which the positively charged onium group can 
interfere with the electrical field of the receptor. This reduction is due 
to a spatial effect, to a reduction of the positive charge and presumably 
to a masking of the onium group by electro-repulsive alkyl groups. 
Therefore it may be expected that in the C1 0MeaR series the intrinsic 
activity will gradually decrease with increasing length of the alkyl chain. 
Consequently in this series cholinomimetic actions may be expected 
to change into cholinolytic (competitive antagonistic) actions via drugs 
with dualistic actions. 
With larger alkyl groups a surface activity is also introduced. Hence 
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the higher C 1 0 Me 2 R members will probably show non-competitive anta­
gonistic properties also. These expectations are fully confirmed by ex­
periments and illustrated by figure 2. 
Fie. га, b, c, d 
a) Cumulative log concentration-response curves for the C1 0Me2R series. Note that 
with elongation of the alkyl chain R there is a progressive decrease of the intrinsic activity 
shown as a decline in the slope and a decrease of maximal height Consequently there 
is a gradual change from agonist (C l 0Me 3) to competitive antagonist (C10Me2Pr). 
b), c), d) Cumulative log concentration-response curves for BuNMe,. With elongation 
of the alkyl chain R in the C,„MejR series there is a progressive decrease of the competi-
tive/non-competitive affinity ratio Thus the higher homologue C„Me4Hept is practically 
a pure non-competitive antagonist. 
Thus C 1 0 Me 3 is a cholinomimetic with a rather high intrinsic activity. 
C 1 0 Me 2 Et and C 1 0Me 2iPr are drugs with a competitive dualism in action 
(intermediate i.a.). They can behave as cholinomimetics or cholinolytics 
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according to the effect already produced by an agonist. C10Me2Pr, which 
is devoid of intrinsic activity, causes a shift of the log concentration-
response curves for an agonist such as e.g. BuNMe3 (F IG. 26). For 
this reason C10Me2Pr is a cholinolytic or competitive antagonist of 
cholinomimetics. In higher concentration C10Me2Pr causes a decline in 
the slope as well as a decrease of the maximal height of the curves. 
This implies that besides a competitive antagonism the drug has non-
competitive antagonistic properties too. For this reason C10Me2Pr is 
called a drug with dualism in antagonism. Drugs with a dualism in 
antagonism react with two different receptor systems, one for the com-
petitive and one for the non-competitive action (this thesis chapter I). 
The ratio of the affinities for the competitive and non-competitive 
receptor systems determines whether competitive action precedes the 
non-competitive action (positive log affinity ratio) or the reverse (negative 
log affinity ratio). With increasing length of the alkyl chain in C10Me2R 
the ratio of the affinities for the competitive and non-competitive re-
ceptors decreases. Thus C10Me2Pent causes a non-competitive inhibition 
at lower concentrations than C10Me2Pr (See FIG. zc). In C10Me2Hept 
the non-competitive antagonistic action is still more pronounced (See 
FIG. 2d). From this figure it can be seen that the decline in the curves 
is not preceded by a shift. C10Me2Hept is therefore a non-competitive 
antagonist. Data on the complete C10Me2R series are included in table II. 
From this table it is evident that at increasing length of R a gradual 
change takes place from cholinomimetic actions (high i.a.) via competitive 
dualistic actions (intermediate i.a.) to competitive antagonistic actions 
(low i.a.). The competitive antagonistic action changes gradually via 
drugs with a dualism in antagonism into non-competitive antagonists. 
The compound C10Me2iPr is of special interest. Although still a 
cholinomimetic (i.a. > o) it shows non-competitive antagonistic pro-
perties in higher concentrations. C10Me2iPr exhibits therefore auto-
inhibition (Compare this thesis chapter I). If, in the C10Me2R series, 
other than alkyl groups are substituted for R analogous changes take 
place. For instance, C10Me2Benz, and C10Me2pNO2Benz are drugs with 
a dualism in antagonism with a relative high affinity ratio. The complete 
data are collected in table II. 
In the investigation of the antagonistic properties of Ci0Me2Pr and 
its higher homologues by using an agonist with lower intrinsic activity 
(e.g. C10Me3), the same results were obtained. Since for C10Me3 no 
spare receptors exist, this definitely implies the presence of a competitive 
and a non-competitive component in the action of drugs with a dualism 
in antagonism. This conclusion is once more underlined by the fact 
69 
TABLE II 
Decamethylene derivatives tested on the frog rectus 
Drug 
C1 0Me3 
C1 0Me2Et 
C10Me2iPr 
C,„Me2Pr 
C1 0Me2Bu 
C10Me2Pent 
C1 0Me2Hex 
C1 0Me2Hept 
C 1 0Me 2Dec 
C10Me2Benz 
C1 0Me2pNO2Benz 
C10PyrroldMe 
C10PipMe 
C,0MorphMe 
C10Et3 
C10Pr3 
C10Bu3 
ACh-receptors 
i.a. 
0.75 
0.35 
0.10 
0 
0 
0 
0 
— 
— 
0 
0 
°·5 
0.0s 
0.05 
0 
— 
— 
- log aff>) 
5-9 
5-2 
4.8 
5° 
S-9 
6.2 
5-9 
— 
— 
S-9 
6.2 
5·ΐ 
4-9 
4-9 
5-S 
— 
— 
non-comp. receptors 
i.a. 
— 
— 
— 1 
— 1 
I 
I 
I 
I 
— I 
— 1 
I 
— 1 
_
 I 
J 
log äff.») 
— 
4-1 
5-7 
6.0 
S-9 
6.2 
6.4# 
S-o 
S-i 
4.0 
4-ϊ 
4-1 
5-2 
6-3 
7.0* 
log 
(aff. ratio) 
> o 
> 0 
> 0 
0.9 
0 . 2 
0 . 2 
0 
< 0 
< 0 
> 0.9 
I . I 
I . I 
0.8 
0.8 
0.3 
< 0 
< 0 
») pD 2 or pA2 values 
") pD' 2 values 
The upper and lower limits of the 95% confidence range for the logarithm of the 
affinity are from 0.1-0.2 below to 0.1-0.2 above the number given in the table. For the 
numbers marked with · the limits are wider since less than 5 estimations were made. 
that the various drugs with a dualism in antagonism produced a different 
amount of shifting when the same agonist was used. See figure 2 (Com­
pare thesis chapter I). The assertion of FURCHGOTT (1955) that there 
exists no experimental evidence for the reversible non-competitive 
inhibition definitely has to be rejected on the basis of the experiments 
presented here. 
The fact that experiments and theory are in good agreement up to 
now encourages us to carry out further experiments and more thorough 
tests of the theory. 
b. Decamethylenebis(N-methylcyclinium iodides). 
X = N + — ( C H 2 ) 1 0 — N + = X Code: C10CyclMe 
С С 
Investigations concerning the neuromuscular blocking effects of bis-
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heterocyclic quaternary ammonium salts suggest a dualistic behaviour 
of decapyrrolidinium (C10PyrroldMe) (MASON and WIEN 1955). 
Experiments on the frog rectus substantiates these suggestions. 
C10PyrroIdMe brings about cholinomimetic and cholinolytic (competitive 
antagonistic) effects by its intermediate intrinsic activity. See figure 3a. 
The curves in this figure show that in higher concentrations C10PyrroldMe 
manifests non-competitive antagonistic properties likewise. As was to 
be expected, a bell-shaped log concentration-response curve appears if 
Cumulative log concentration-response curves for BuNMe s in the presence of constant 
concentrations of CioPyrroldMe and C10PipMe. Both compounds have intermediate 
intrinsic activity. Note agonistic, competitive antagonistic and non-competitive anta-
gonistic properties. 
this drug is investigated singly. C10PyrroldMe is thus a drug with 
intermediate intrinsic activity and exhibits auto-inhibition (Compare with 
C10Me2iPr). In comparison with C10Me2Et (i.a. = 0.35) and C10MeEt2 
(i.a. — o) the intrinsic activity of C10PyrroldMe is rather high. This 
may be accounted for by the fact that the reduction of the effectiveness 
of the positive charge is larger when —NMe2 in decamethonium is 
replaced by —NEt2 than by a pyrrolidine group. Two ethyl groups 
produce more spatial interference and are more electro repulsive than 
a pyrrolidine group. 
The higher homologues decapiperidinium (C10PipMe) and decamor-
pholinium (C10MorphMe) are likely to have lower intrinsic activity 
because in these drugs the substituents on the quaternary nitrogen atom 
are still heavier. Experiments have confirmed this. Thus C10PipMe and 
C10MorphMe have low intrinsic activity and are drugs with a dualism 
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in antagonism (See F I G . 36 and TABLE II). In the experiments with 
the frog rectus C1 0PyrroldMe was found to be the most potent drug 
of the C1 0CyclMe series, which substantiates the in-vivo experiments 
of MASON et al. (1955). 
c. Decamethylenebis(trialkylammonium salts). 
R3N+—(СН
г
)ю—+NR 3 Code: C 1 0 R a 
Complete ethylation of decamethonium results in a loss of the intrinsic 
activity. Thus C 1 0 Et 3 is a competitive antagonist of cholinomimetics. 
In higher concentration C 1 0 Et 3 also shows non-competitive antagonistic 
properties. It may be expected that the non-competitive affinity will 
increase with increasing chain length of the alkyl substituents in C 1 0R 3 . 
This was confirmed by experiments (See TABLE II) ; the ratio of the 
affinities for the competitive and non-competitive receptors decreases 
gradually from C 1 0 Et 3 via C 1 0Pr 3 to C1 0Bu3, so that the latter drug 
behaves practically as a pure non-competitive antagonist. The 
in-vivo experiments (THESLEFF and UNNA 1954) revealed that C 1 0 Bu 3 
is a neuromuscular blocking agent, which is not of the cholinomimetic 
or depolarizing type. Neither is C 1 0Bu 3 a cholinolytic, since the paralyses 
induced in mice could not be antagonized by neostigmine. The con­
clusion can be drawn, therefore, that C 1 0Bu 3 is a non-competitive neuro­
muscular relaxant. Elongation of the alkyl chain in C 1 0 Et 2 R also results 
in an increase of non-competitive antagonistic properties. Thus C 1 0Et 2Bu 
is a practically pure non-competitive antagonist. 
d. Polymethylenebis(choline salts). 
M e 3 N + — ( С Н г ) г — О — ( C H 2 ) „ — О — < С Н г ) , — + N M e s Code : CnChMe, 
It has been found for the decamethonium homologues that a reduction 
of the number of methylene groups separating the onium groups causes 
a decrease of the intrinsic activity (ARIENS et al. 1956c). The mutual 
interference of the two onium groups leads to a decrease of the effective­
ness wherewith these groups can interfere with the receptor field. 
Analogous changes were found in the CnChMe 3 series (See F I G . 4 and 
TABLE III). 
Although the lengths of the chains separating the onium groups are 
practically equal in C 1 0 Me 3 and C 4ChMe 3, the latter has a lower intrinsic 
activity. This means that both the length and the nature of the chain 
are of importance. Possibly the mutual interference of the onium groups 
in the CnChMe 3 series is larger than in the CnMe 3 series. The lower 
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homologues C 2 ChMe 3 and CjChMej have low intrinsic activity, by 
virtue of which they behave as competitive antagonists of cholinomime­
tics ( F I G . \b). In-vivo experiments with avian muscle revealed similar 
phenomena (THESLEFF and UNNA 1954). 
FIG 4a, 6 
a) Cumulative log concentration-response curves for the CnChMe3 series. Note the 
gradual decrease of the intrinsic activity with shortening of the chain separating the 
omum groups CjChMe3 has an intrinsic activity equal to zero 
b) Cumulative log concentration-response curves for BuNMe3 in the presence of 
constant concentrations of C^hMe,. Note the competitive antagonistic action of the 
last homologue of the CnChMe3 series. 
e. Polymethylenebis(earbamylcholine) derivatives. 
R3N+—<CH,) 2 —O—C—NH—(CH 2 )„—NH—С—O—(CH 2 ) t —+NR 3 
II II 
о о 
Code : CnCarbChR, 
The polymethylenebis(carbamylcholines) are powerful neuromus­
cular blocking agents of the cholinomimetic or depolarizing type 
( K L U P P et al. 1953, CHEYMOL et al. 1954e). Introduction of heavier 
substituents on the onium group in this series or shortening of the 
chain separating them results in a decrease of the intrinsic activity, as 
was to be expected (See F I G . 5 and TABLE III). 
The intrinsic activity of the compounds of the CnCarbChMe 3 series 
is rather high owing to the electro-repulsive groups in the chain separa­
ting the onium groups ( F I G . 5a). The intrinsic activity of the lower 
member C 2CarbChMe 3 is somewhat lower. If one methyl group on the 
onium groups is replaced by an ethyl group, a moderate decrease of 
the intrinsic activity takes place (See C 8CarbChMe 2Et). On complete 
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ethylation the intrinsic activity becomes zero. Hence C
e
CarbChEt 3 be­
haves as a competitive antagonist ( F I G . 56). The affinity in the CnCarb-
ChR 3 series increases on increase of length of the chain separating the 
onium groups. Ethylation also causes a reduction of the affinity (See 
TABLE III). 
^contracture 
100 η 
foconi ractur· 
100 
BO 
60-
•40 
2 0 -
CjCarbCh 
mmol/1 ΐσ 4 mmol/1 10"^ Carb Chrlc, 
FIG. sa, 6 
a) Cumulative log concentration-response curves for the CnCarbChR3 series. Substi­
tution of ethyl groups for methyl groups results in a gradual decrease of the intrinsic 
activity. C
e
CarbChEt3 has an intrinsic activity of zero. 
b) Cumulative log concentration-response curves for C
e
CarbChMe3 (" Imbretil ") in 
the presence of constant concentrations of C
e
CarbChEt
a
. Note the competitive antagonism. 
f. Bisquaternary ammonium salts of diearboxamides. 
R
a
N+—(CH 2 ) t —NHC—(СН 2 ) Я 
II 
о 
-С—NH(CH
a
) 2 —N+R 3 
II 
о 
Code: DnAR3 
These drugs have been shown to be weak neuromuscular blocking 
agents (PHILLIPS 1955). It is of interest to investigate whether they 
belong to the cholinomimetics (high i.a.) or to the cholinolytics (low 
i.a.). Our experiments revealed a low affinity for the compounds of 
the DnAMe 3 series. It is striking that even the trimethyl derivatives 
have rather low intrinsic activity ( F I G . 6a). 
The lower intrinsic activity of D 2 AMe 3 in comparison with suxa­
methonium (SuCh) (identical chain length) might be explained as follows. 
The electro-negative ester groups in SuCh may intensify the positive 
charge on the onium groups and the effectiveness wherewith these 
positive charges can interfere with the receptor field. The hydrogen 
atom of an amide can dissociate, which implies that the amide N-atom 
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TABLE III 
Bis choline derivatives and quaternary amides tested on the frog rectus 
Drug 
CiChMe3 
C2ChMe3 
C4ChMe3 
C2CarbChMea 
C,CarbChMe
a 
CCarbChEtj 
C
e
CarbChMe3 
C
e
CarbChMe
a
Et 
CioCarbChMe3 
D„AMe3 
D„AMe2Et 
DjAMej 
D2AMe,Et 
D2AMe2Pr 
D2AMe2Pent 
DjAMej 
D4AMe2Et 
D,AMe, 
ACh-receptors 
i.a. 
о 
0.05 
o-S 
0.9 
1 
0 
I 
0.8 
I 
O.I 
0 
o-S 
0 
0 
0 
0.3 
0 
0 . 2 
log aff. (>) 
4-3 
4-4 
4.8 
4-5 
5-9 
S-o 
6.4 
6.1 
6.7 
2.8 
3-1 
3-2 
4.0 
4-1 
4-3 
3-3 
4-1 
З.6 
non-comp. receptors 
i.a. 
— 
— 
— 
— 
— 
— 
— 
— 
— 
-
— 
— 
— 
— 
— ' 
— 
— 
log aff. (») 
— 
— 
— 
— 
— 
— 
— 
-
— 
— 
— 
З І 
— 
— 
— 
log 
(aff. ratio) 
> 0 
» 
в 
> o 
» 
I) 
» 
» 
» 
> О 
в 
в 
в 
в 
1.2 
> О 
В 
в 
(l) pD 2 or pAj values 
(') pD' 2 values. 
The 95% confidance range is the same as that in table II. 
is to a certain degree positively charged. In the succinamide derivative 
D 2 AMe 3 there may be a mutual interference of the positive charges of 
the quaternary onium and the amide nitrogen atoms. Consequently a 
reduction in the capacity of the onium group to interfere with the 
receptor field takes place. 
In consequence D 2 AMe, has a rather low intrinsic activity. In this 
respect it is interesting that decamethonium, which has neither an 
electro-negative nor an electro-positive group between its onium groups, 
has an intrinsic activity intermediate between those of SuCh and 
DjAMe,. 
In analogy to the CnMe 3 and CnChMe 3 series, shortening of the 
chain which separates the onium groups is followed by a decrease of 
the intrinsic activity. This was to be expected, and it is now evident 
that DoAMe 3 (low i.a.) behaves as a competitive antagonist of cholino­
mimetics ( F I G . 6ό). Replacement of methyl groups by alkyl groups on 
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the onium groups of DnAMe 3 compounds always means a further 
decrease of the intrinsic activity. In consequence D 2AMe 2Et, D 2AMe 2Pr 
and D 4AMe 2Et are competitive antagonists. Data on the complete series 
are included in table III . 
%contracture 
100-ι 
°/o contracture 
lOO-i 
mmol/1 ΐ σ 1 ЮГ2 mmol/1 K>"'BuN+Me
s 
FIG. 6α, Ь 
a) Cumulative log concentration-response curves for the DnAMEj series. Note the 
low affinity and the rather low intrinsic activity, especially of DoAME3. 
b) Cumulative log concentration-response curves for BuNMe3 in the presence of 
constant concentrations of DoAMe,. Note the competitive antagonism. 
g. Alkyltriethylammonium salts. 
R'—N+(C 2HS), Code: R'NEt, 
The higher alkyltrimethylammonium salts produce a neuromuscular 
block which differs from the cholinomimetic (depolarizing) and cholino-
lytic (competitive) type. (DALLAMAGNE and PHILLIPOT 1951). Experi­
ments with R'NMe 3 on the frog rectus demonstrated that increase of 
the length of the alkyl chain in R'NMe 3 brings about a gradual change 
from cholinomimetics to non-competitive antagonists (ARIÈNS et al. 
1955, 1956ο). In this connection the R'NEt 3 series was investigated. 
Triethylammonium derivatives are generally competitive antagonists of 
cholinomimetics. Therefore it may be expected that in the R'NEt 3 
series an increasing length of the alkyl chain will be accompanied by 
a gradual change from competitive to non-competitive antagonists. This 
was confirmed by the experiments (See TABLE IV). 
From this table it is seen that in the alkyltriethylammonium series a 
positive correlation exists between the non-competitive affinity and the 
surface activity. On elongation of the alkyl chain other physical pro-
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TABUE IV 
Affinities and intrinsic activities of the R'NEt^ series tested on the frog rectus 
D r u g 
M e N E t j 
E t N E t , 
PrNEta 
B u N E t s 
PentNEta 
H e x N E t 3 
H e p t N E t , 
O c t N E t 3 
D e c N E t j 
1 
ACh-receptors 
— 
1
 i.a. | log aff. H 
I 
| 0.2 
1 
— 
4.0 
2.7 
— 
— 
' 1 
1 
1 
— 1 — | — — 
non-comp. 
receptors 
i.a. log aff. ( a ) 
— 1 1.4 
- 1 2.3 
— 1 3 1 
— 1 3-3 
— 1 3-8 
— ι 4 2 
— 1 4-8 
— 1 5-4 
— 1 6.8 
log 
(aff. ratio) 
2.6 
0.4 
< 0 
< 0 
< 0 
< 0 
< 0 
< 0 
< 0 
surface b ) 
activity 
< 0 
< 0 
< 0 
0 3 
0.8 
1.2 
1.6 
2.1 
2.9 
Rr-value <•) 
1 
46 
5° 
56 
62 
69 
74 
76 
78 
80 
(·) pD 2 values. 
(') pD' 2 values. 
The 95oо confidence range is the same as that in table II. 
b ) The negative logarithm of the molar concentration which induces a lowering of the 
surface tension from 72 to 60 as measured with the ring method. 
c) Eluent : Butanol : ethanol : Η,Ο = 5 : 3 : 1 . 
perties are also changed regularly (e.g. fat-solubility). Since both the 
surface activity and the fat-solubility correlate with the length of R it 
is not possible to decide whether the surface activity or the fat-solubility 
is responsible for the non-competitive affinity. It is interesting that the 
lower member MeNEt 3 shows agonistic properties (high i.a.). This may 
be accounted for by the fact that because of the smaller methyl group 
the onium group can approach the receptor close enough to induce the 
necessary change in the receptor field. 
The high intrinsic activity of MeNEt 3 is not so remarkable since the 
higher homologue BuNMeEt 2, a member of the homologous R'NMeEt 2 
series also produces agonistic actions (ARIENS et al. 1957). 
h. Quaternary dioxolanes. 
O—CH¡ 
/ \ HC с н 
/ \ / \ 
R' О CH,—N+Me 3 Code: R'FMe, 
The lower member of this series, H F M e 3 (2249 F), brings about 
ACh-like actions (FOURNEAU et al. 1944)· The expectation arises that 
in analogy with the R'NMe 3 series a gradual change from cholinomimetic 
to non-competitive antagonistic actions will be occasioned by lengthening 
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of the alkyl chain. Experiments performed with the frog rectus ab­
dominis muscle have confirmed this, as illustrated by figure 7. 
^ c o n t r a c t u r e 
ιο·= 10 τητηοΙ/1 IO"' 
FIG. 7 
Cumulative log concentration-response curves for the R'FMe, series. Note the pro­
gressive increase of the non-competitive affinity with elongation of the alkyl chain. 
Consequently there is a gradual change from agonists (e.g. HFMe3) via drugs with a 
non-competitive auto-inhibition (e.g. PrFMe3) into non-competitive antagonists 
(HexFMe,). 
Conclusion : HFMe 3 , MeFMe 3 and E t F M e 3 are practically pure 
cholinomimetics. PrFMe 3 and BuFMe 3 are agonistic in lower and non-
*&concractur« 
100 -. 
Κ)0η 
8 0 -
60-
4 0 -
70-
H«KFM»J /Ó 
VI 
410'mmol/l 
10"* КГ7тп>оі/1 H F M e , IO"1 IO 7 mmol/1 BuN*Me, 
Fio. 8α, Ь 
a), b). Cumulative log concentration-response curves for an agonist in the presence 
of constant concentrations of HexFMe3 or Pr¡FMes Note the non-competitive anta-
gonistic actions of these drugs. 
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competitive antagonistic in higher concentration (auto-inhibition). The 
higher homologue HexFMe3 behaves as a non-competitive antagonist 
of cholinomimetics (See FIG. 8a). The slight contracturing property of 
HexFMe3 is evidently not due to a low intrinsic activity but to the 
fact that the agonistic affinity is smaller than the non-competitive affinity. 
Thus in the R'FMe3 series there is a gradual decrease in the agonistic 
affinity simultaneously with a gradual increase in the non-competitive 
affinity. From this series it also follows that the chain length is important 
for a good non-competitive affinity. It is evidently not merely the chain 
length as Pr2FMe3 is non-competitive (FIG. 8¿>), while PrFMe3 has 
still large agonistic properties. 
EXPERIMENTS WITH NERVE-MUSCLE PREPARATIONS 
There are good reasons for dividing peripheral muscle relaxants or 
curariform drugs into three classes (ARIENS et al. 1955). 
a) cholinomimetics or depolarizing drugs (high i.a.). 
b) cholinolytics or competitive antagonists (low i.a.). 
c) non-competitive antagonists of cholinomimetics. 
It is not possible to differentiate between these three types by esti-
mating the head drop dose. The features of the various curariform 
drugs can be demonstrated especially well with avian nerve-muscle 
preparations. The various types of curariform drugs could be distin-
The action of three types of neuro-muscular blocking agents on the sciatic-gastroc-
nemius preparation of the chick. The cholinomimetic suxamethonium (SuCh) induces 
a contracture (a). The cholinolytic D-tc induces a flaccid paralysis (b) which is completely 
reversed by neostigmine. The non-competitive relaxants C10Me iBu, Cn,Me2Pent and 
C,„\Ie2Hept also produce a flaccid paralysis (c. d. e.) which is slightly or not reversed 
by edrophonium (c). C10Me2Bu may still have some cholinolytic (competitive antagonistic) 
properties. See also table II. Doses were added in μτχ\ο\ to a chick of 2 kg. (2 5 of full size). 
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guished experimentally. T h i s is shown by a few of our experiments 
with nerve-muscle preparat ions of the chick and the cat as represented 
in figures 9 and io . 
Drugs of the type a) induce a contracture on chicken muscle and 
on cat muscle a flaccid paralysis, which is not reversible by e d r o p h o n i u m . 
Suxamethonium, C 1 0 M e 3 and the biscarbaminoylcholines belong to this 
group for instance. T h e contracture induced by S u C h on a chicken 
nerve-muscle preparat ion is represented in figure да. O n cat muscle 
this c o m p o u n d produced a flaccid paralysis which could not be reversed 
by e d r o p h o n i u m as shown in figures 10a and b. 
F I G . IO 
The action of three types of neuro-muscular blocking agents on the peroneus-tibialis 
anterior preparation of the cat. The cholinomimetic SuCh induces a flaccid paralysis 
(a) which is not reversed but enhanced by neostigmine (b). The cholinolytic D-tc induces 
a flaccid paralysis (c) which is completely reversed by neostigmine. The non-competitive 
relaxant C 1 0 Me 2 Hept also produces a flaccid paralysis (e) which is slightly or not reversed 
by neostigmine (ƒ). Dosis were added in fimol to a cat of 3 kg. ( 1 4 of full size). 
Drugs of the type b) produce a flaccid paralysis of both chicken and 
cat muscle, which is reversible by edrophonium. Examples are D-tc, 
gallamine, benzoquinonium and C 1 0 Me 2 pNO 2 Benz . See also THESLEFF 
and U N N A (1954). Figure gb represents the flaccid paralysis induced by 
D-tc on the chicken nerve-muscle preparat ion which is completely 
reversible by neostigmine. T h e flaccid paralysis induced by D-tc on 
the cat nerve-muscle preparation is also completely reversed by neo-
stigmine as shown in figures in 10c and d. 
Drugs of the type c) produce a flaccid paralysis both in chick and 
cat muscle, which is not or only to a small degree reversible by edro-
phonium. Examples are D e c N M e 3 (DALLAMAGNE and P H I L L I P O T 195I, 
ARIËNS et al. 1955), C1 0Bu3 (THESLEFF and U N N A 1954). T h e flaccid 
paralysis of the chicken muscle by C 1 0 Me 2 Bu is only slightly reversed 
by edrophonium (See F I G . gc). T h e higher homologues C 1 0 Me 2 Pent 
and C 1 0 Me 2 Hept also induce a flaccid paralysis on the chicken muscle 
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as shown in figures gd and e. The flaccid paralysis induced by 
C10Me2Hept on the cat muscle is also slightly or not reversed by neo-
stigmine (See F I G . IO« and / ) . C10Me2Hept which is thus a non-competi-
tive antagonist of cholinomimetics approximates the activity of D-tc. 
Many curariform drugs are of a mixed type. Drugs which belong to 
the type a) and b) are called drugs with a competitive dualism in action 
(intermediate i.a.). Examples are C4ChMea and C10Me2iPr. Drugs which 
belong to the type a) and c) are called drugs exhibiting an auto-inhibition, 
e.g. PrFMe3 and HexNMe3. Drugs which belong to the type b) and c) 
are drugs with a dualism in antagonism. An example is C10Me2Pr. 
Drugs even exist which belong to the types a), b) and c) as for instance 
decapyrrolidinium. As mentioned before the action of these mixed type 
curariform drugs could be clearly demonstrated on the frog rectus 
abdominis muscle. 
If curariform drugs have a multiple mode of action in reacting with 
different receptor systems, different affinities (dissociation constants) and 
different reaction-velocity constants are involved. According to these 
constants the various types of action may be manifested successively. 
It has been observed by ZAIMIS (1956) that the depolarizing block 
induced by decamethonium changes into another type. This can be 
explained on the basis of different reaction-velocity constants and disso-
ciation constants (this thesis chapter I). 
DISCUSSION 
The affinity and intrinsic activity are essential parameters in the study 
of structure-action relationships. In order to make a differentiation 
between these parameters possible, it is useful to perform experiments 
with simple biological objects. The isolated rectus abdominis muscle 
of the frog appeared to be suitable for this purpose. Isotonic and iso-
metric measurements revealed no fundamental differences. With the 
latter an equilibrium was reached sooner. The intrinsic activity and 
affinity vary with the chemical structure in relative independence of 
each other. With respect to the affinity of drugs towards ACh-receptors 
it was not possible to draw sound conclusions concerning the molecular 
properties required for optimal affinity. A good affinity can be achieved 
with quite different molecular configurations. 
As regards affinity towards non-competitive receptors, a positive cor-
relation is found between the affinity and the surface activity. Together 
with the surface activity, a certain degree of fat-solubility is of 
6 
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importance. With winterfrogs as a rule smaller affinity ratio's were 
found. 
For the intrinsic activity of cholinomimetics, especially the positive 
charge on the onium groups and distance to which this charge can 
approach the receptor field are of primary importance. The length and 
nature of the chain separating the onium groups in bis-onium compounds 
both have a part in determining the value of the intrinsic activity. A 
shortening of this chain is followed by a decrease of the intrinsic activity. 
Probably this is due to mutual interference of the onium in the shorter 
chains, which subsequently results in a decrease of the positive charge 
of the onium group and a lessened effectiveness wherewith the onium 
group can interfere with the receptor field. See the CnMe3 series (ARIËNS 
et al. 1956o), the CnChMe3 and the CnCarbChMe3 series. Introduction 
of electro-negative (ester) groupings into the chain separating the onium 
groups results in an increase of the intrinsic activity, presumably due 
to a larger positive charge on the onium group and greater effectiveness 
of this positive charge. For instance, from C10Me3 (i.a. = 0.75) to SuCh 
(i.a. = 1.0) or from C12Me3 (i.a. = 0.8) to C2CarbChMe3 (i.a. = 0.9) 
or Adipinylcholine (i.a. = 1) there is an increase of intrinsic activity. 
Introduction of electro-positive groupings (amides) causes a decrease of 
the intrinsic activity e.g. from C10Me3 (i.a. = 0.75) to D2AMe3 (i.a. = 
0.5) and from C12Me3 (i.a. = 0.8) to D4AMe3 (i.a. = 0.4). Substitution 
of heavier groups for the methyl groups on the quaternary nitrogen 
atom results in a decrease of the intrinsic activity. Consequently cholino-
mimetic actions gradually change into cholinolytic actions via competitive 
dualistic actions. In C10Me2R the intrinsic activity decreases gradually, 
for instance on elongation of the alkyl chain R. At the end of this series 
non-competitive antagonists are found, presumably because the higher 
members exert a " strong " surface activity. As could be predicted from 
theory and former experiments the C10Me2R series presents in succession 
agonists, competitive dualists, competitive antagonists, drugs with a 
dualism in antagonism and non-competitive antagonists. 
The reaction between drug and receptors is an interaction between 
their electrical fields. The affinity is related to the field interaction in 
its most general sense. The intrinsic activity is connected with some 
special part of the field interaction. The experiments give strong sup-
port to the hypothesis that the intrinsic activity is connected with the 
effectiveness of the positive charge of the onium group in changing 
some part of the electrical field of the receptor. 
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SUMMARY 
On basis of theories of drug-receptor interactions (ARIENS et al. 1950, 
1954, 1956a, b, 1957e, thesis chapter I) the molecular pharmacology of 
various homologous series of quaternary ammonium salts affecting 
skeletal muscle was studied. 
The essential parameters, affinity and intrinsic activity (i.a.), varied 
with the inherent molecular configuration or physical properties. 
It was found possible to classify the various types of curariform drugs 
as follows : 
a) cholinomimetics or depolarizing drugs (high i.a.) e.g. Suxametho­
nium. 
b) cholinolytics or competitive antagonists (low i.a.) e.g. D-tc. Both 
these types react with ACh-receptors. 
c) non-competitive antagonists ; these interfere with the action of ACh 
but they react with other than ACh-receptors, e.g. decamethylene-(bis-
tributylammonium salts). Affinity to the ACh-receptors can be achieved 
by different molecular configurations. The experiments support the 
hypothesis that the intrinsic activity of cholinomimetics and cholino­
lytics is connected with the effectiveness wherewith the positive charge 
of the onium group can interfere with the electrical field of the receptor. 
Affinity towards non-competitive receptors correlates with the surface 
activity of the drugs. 
As predicted, gradual changes from the one type of drug into the 
other via intermediate forms were found in various series of drugs. 
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CHAPTER III 
PHARMACODYNAMICS OF PARASYMPATHETIC 
DRUGS Í1) 
Structure-action relationships in homologous series of 
quaternary ammonium salts 
INTRODUCTION 
The parasympathetic nervous system plays an essential role in the 
maintenance of the tone of intestinal smooth muscle. A functional 
scheme is represented in figure i. Parasympathetic nervous activity 
results in a release of acetylcholine (ACh) at the parasympathetic end-
synapse (p.e.s.). The occupation of the parasympathetic receptors by 
ACh molecules brings about a " parasympathetic " stimulus. 
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Scheme for the regulation of intestinal smooth muscle tone. T h e parasympathetic 
pathway is presented in detail. Acetylcholine is the transmitter in both the parasympathetic 
ganglia and the parasympathetic end-synapse. T h e occupation of A C h receptors in the 
latter results in a stimulus (parasympathetic) which brings about the effect. T h e effects 
of non-parasympathetic drugs are induced on the " other " receptors. There is a feedback 
to the central nervous system and to the parasympathetic ganglia. 
(') Partly presented in a preliminary paper (VAN ROSSUM and A R I E N S 1957). 
»? 
The effect is a linear (CLARK 1937, ARIËNS 1954), an all-or-none 
(ARIËNS and VAN ROSSUM 1957ft) or a non-linear (STEPHENSON 1956, 
and this thesis chapter 1) function of the number of receptors 
occupied or of the stimulus. From the scheme it is evident that drugs 
affecting smooth muscle activity may have different points of attack. 
a) Drugs which cause a change in the ACh concentration in the 
immediate neighbourhood of the receptors. This may be due to a change 
in the production of ACh by e.g. hemicholiniums (MACINTOSH 1956), 
a change in the release of ACh by botulinum toxin (AMBACHE 1955), 
or a change in the breakdown of ACh by ACh-esterase inhibitors. 
b) Drugs reacting with parasympathetic receptors; these are called 
parasympathetic drugs. According to the value of the intrinsic activity 
(ARIËNS 1950) a further distinction is possible. 
c) Drugs which are inactive as such but which cause a change in the 
sequence of events leading from the parasympathetic receptors to the 
final effect. 
These drugs are non-competitive antagonists of parasympathomi-
metics. Papaverine is an example. 
d) Drugs which are active as such and which produce an effect after 
reacting with the " other " receptors of the scheme in figure 1. The 
occupation of the other receptors brings about an " other " stimulus, 
which sets the effector system in motion. BaCl2 and histamine are 
examples. A functional interaction may exist between these drugs and 
parasympathetic drugs (ARIËNS et al. 1956c). 
PARASYMPATHETIC DRUGS 
Drugs which show affinity to parasympathetic receptors can be divided 
into three groups on the basis of their intrinsic activity. Drugs with a 
high intrinsic activity are called parasympathomimetics or muscarinic, 
cholinomimetic compounds. Drugs with a very low intrinsic activity 
behave as competitive antagonists of the cholinomimetics. For this reason 
they are designated parasympatholytics or anti-muscarinic, cholinolytic 
or atropine-like compounds. Drugs with an intermediate intrinsic activity 
may show parasympathomimetic and parasympatholytic properties. They 
are therefore called drugs with a dualism in action (see this thesis 
chapter 1). STEPHENSON (1956) has called them partial agonists. 
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STRUCTURE-ACTION RELATIONSHIPS 
The affinity as well as the intrinsic activity of drugs may vary with 
the molecular structure or with physical and chemical properties in-
herent to their structure. The variation of both parameters with the 
molecular configuration may be relatively independent. 
Parasympathomimetics or drugs with a high intrinsic activity require 
an onium group with a pronounced positive charge. This can be ammo-
nium, sulphonium, phosphonium etc. (See TABLE I). 
A good affinity to the parasympathetic receptors is necessary for a 
high biological activity. An increase in the affinity of parasympatho-
mimetics can be achieved in various ways. In addition to the onium 
group a more or less lipoid character is of value (BARNES and BEUTNER 
1949). A chain length of 5 atoms is of advantage (ING et al. 1949, 1952). 
Our experiments have revealed that meprocholum is not an exception 
to Ing's 5-atom rule as cited by BARLOW (1955). As may be seen from 
table I meprocholum is at least ten times less active than acetylcholine. 
Negative (ester) groupings at a distance of about two carbon atoms 
from the onium group increase the affinity. The steric configuration 
is of importance, since optical isomers show different affinities. In this 
way it has been discovered that natural muscarine is about three times 
more potent than the mixture of synthetic racemates (KÖGL et al. 1957). 
A coïncidence of optima in the various factors is required for a maximal 
affinity. For this reason the most potent parasympathomimetics are 
closely related in their molecular configuration. (See TABLE II). 
The parasympatholytics have the affinity in common with the para-
sympathomimetics. In fact they differ from the parasympathomimetics 
in the molecular properties required for intrinsic activity. The onium 
group of the parasympatholytics has a less pronounced positive charge. 
As a rule they are molecules with a large spatial configuration. A good 
affinity is necessary for a high biological activity. The affinity can be 
increased by introduction of an electro-negative grouping at a distance 
of about 3 C-atoms from the onium group, while a planar ring on the 
negative side seems to be of value (ING et al. 1945, BOVET et al. 1948, 
BARLOW 1955, LANDS et al. 1951, 1956, LONG et al. 1956, 1957). The 
steric configuration is of importance for the parasympatholytics also. 
L-hyoscyamine is 100 times more potent than its D-isomcr (KRONEBERG 
1955, LONG et al. 1956). The (/>A2-/>A10) values do not allow the con-
clusion that L-hyoscyamine is a competitive and its D-isomer a non-com-
petitive antagonist of ACh as was tacidly believed by MARSHALL (1955). 
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T A B L E I 
Parasympathomimetics 
formula 
CH=C-CH2-N+(CHa)a 
CH
a
 = CH-CH2-N ι (CH3)3 
Br-CH2-CH2-N+(CH3)a 
Br-CH2-CH2-CH2-N+(CII3)3 
CH2 
II 
CH3-0-CH-CH2-N+(CH3)3 
(esmodyl) 
affinity 
ACh = ioo formula 
1
 affinity 
intr. act. ACh = ioo 
О 
Il ι 
o.os (*) C H 3 - C O C H 2 - C H 2 - N ' H ( C H 3 ) , high 2 ( b ) 
1 
О 
II ! 
0.05 (·) CH3-COCH2-CH2-S'(CH3)2 
о 
i l 
о 
II 
2 (») C H
a
- C S C H 2 - C H 2 - N + ( C H a ) 3 
о 
l i 
S (») CH^CNHCHj-CHj-N-tiCH,), 
·) Our experiments performed with the isolated rat jejunum. 
b ) Experiments on other objects as referred by Bovet et al. 1948. 
c) Ing et al. 1952. 
high io ( c) 
0.5 (») CH,-COCH2-CH2-P+(CH3)3 high 1 (b) 
high 1 (b) 
0.01 (•) 
As was stated earlier, a drug-receptor interaction is in fact an inter­
action of the electrical fields which are inherent to the molecular con-
TABLE II 
High potent parasympathomimetics 
Drug 
ACh 
1 
formula 
О 
1
 l i 
¡ С С 
/ \ / \ 
С О C-N+(CH3)3 
log 
íntr. I affinity 
act. !-
i PD* ; P,5 
I I 
ι 7-49 7-27-7-71 
\ 
probit. 
vs log cone. 
slope P,j 
2.24 I.79-2.69 
I 
num­
ber 
of 
exp(*) 
I I 
о 
CarbCh , С С 
/ \ / \ 
JH2N О C-N+(CH,), 
I О С 
II I 
MeCh 1 С С 
! / \ / \ 
¡С O C-N+(CH3)3 i 
ι 
О — С \ 
ι ι ! 
MeFMe3 1 С С | 
I / \ / \ 
¡С О C-N+(CH3), ¡ 
I 
7.ОО ' 6.87-7·Ι3 1 2.23 I I.88-2.58 , 12 
I ! 
1 I 6.91 6.61-7.21 2.19 1 9 1 - 2 . 4 7 13 
« 7-53 7.36-7-70 2-57 2.06-3.08 12 
I 
HO 
Musca­
rine (*) 
\ 
С С 
I ' 
с с 
/ \ / \ 
С O C-N+(CH3)3 
7-45 7.30-7.60 2.59 2.19-2.98 i o 
ι 5-41 5 · 3 ΐ - 5 · 5 · ι 2.39 2.IO-2.S8 34 
О С 
I I 
HFMe 3 Н г С С 
\ / \ ! ' ; 
| О C-N+(CH3)3 ¡ 
С
1) Usually 2-3 estimations with the same piece of jejunum. 
(2) Natural Muscarine chloride obtained by courtesy of Dr EUGSTER (Zurich). 
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figuration of drug molecule and of receptor (thesis chapter 2). The 
affinity is related to the interaction of the fields in the most general 
sense, while the intrinsic activity is connected with some special part 
of this field interaction. It is logical to surmise that the intrinsic activity 
is connected with the effectiveness wherewith the positively charged 
onium group can interfere with some part of the electrical field of the 
receptor. This implies that the value of the positive charge of the onium 
group, its spatial arrangement and its distance from the receptor field 
are important for the intrinsic activity. Alterations in the molecular 
structure which influence one of these factors are expected to cause 
a change in the intrinsic activity. 
METHODS AND MATERIALS 
For the study of parasympathetic drugs, experiments were performed 
with isolated rat jejunum. This object has advantages over guinea-pig 
intestine. Contrary that of the guinea-pig, the rat intestine gives only 
a feeble response to ganglionic drugs (nicotine). For this reason the 
guinea-pig jejunum was used only for experiments in which histamine 
was tested. The intestine, obtained from decapitated animals, was 
washed with Tyrode solution. Pieces of about 2 cm in length were 
suspended in a bath containing 10 ml Tyrode solution, through which 
air was bubbled while the temperature was kept at 37o С. Composition 
Tyrode : 1 L. H 2 0 ; 8.0 g NaCl; 0.2 g KCl; 0.2 g CaCl¡¡; ο.ι g MgCl,; 
ι.о g N a H C 0 3 ; 0.05 g NaHjPOj and 1 g glucose. The responses were 
recorded isotonically on a sooted drum. Cumulative concentration-
response curves were made by adding amounts of the drug in the following 
sequence : а; а; га; etc. A given concentration was left in contact with 
the intestine for one minute, which appeared sufficient to give a steady 
state, after which the concentration was doubled by adding the sub­
sequent dose. After each curve there was washed out for 5-10 minutes 
(See F I G . 2). From this figure it can also be seen that the shape of the 
cumulative concentration-response curve is identical with that obtained 
from the responses to successive individual concentrations. The variation 
in the sensitivity of the different pieces of intestine was mainly manifested 
by the place of the log concentration-response curves on the concen­
tration-axis (TABLE II). There was little variation in the slope. With 
a single piece of intestine many (10-40) cumulative concentration-
response curves could be obtained. The experiments were carried out 
in such a way that response curves for a drug under investigation were 
made alternately with those for the standard H F M e 3 (See FlG. 5 and 8). 
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The intrinsic activity is calculated from the maximal height of the 
concentration-response curves and expressed in terms of the maximal 
effect of HFMe 3 (i.a. = i) . This procedure is justified for the mo-
ment, since there is no actual proof of a receptor reserve for parasym-
pathetic drugs. For the guinea-pig intestine experimental evidence for 
spare receptors for histamine has been found (NICKERSON 1956). 
FIG. 2 
Cumulative dose-response curves as registered on the sooted drum. The doses were 
doubled every minute. All effects of H F M e , were performed with the same piece of 
rat jejunum (no. I 10). Note the good agreement of the effects in the cumulative curve 
and those of the individual concentrations. Doses added in io"5 mmol to a 10 ml bath. 
(1/3 of full size). 
On the grounds of the unlikely supposition that a linear relationship 
exists between logarithm of the affinity and length of the alkyl chain 
of alkyltrimethylammonium salts, STEPHENSON (1956) came to assume 
the existence of a large amount of spare receptors for some parasym-
pathomimetics. The experiments used by STEPHENSON to support this 
assumption were based on kinetics. It is, however, difficult to draw 
conclusions from kinetic experiments, as not only the drug-receptor 
interaction but also the drug concentration in the biophase is time-
dependent. In order to estimate the amount of possible spare receptors, 
essentially irreversible competitive antagonists are required, (thesis 
chapter 1). These drugs are not yet available with respect to parasym-
pathetic receptors. There is no reason to make things more complicated 
by assuming an arbitrary amount of spare receptors. 
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The affinity is expressed in terms of the average concentration which 
produces a standard effect. Thus pO2 values for parasympathomimetics 
(ARIËNS and VAN ROSSUM 1957a), and pA2 values for competitive anta-
gonists (SCHILD 1949) were used. 
Several homologous series of quaternary ammonium salts were in-
vestigated. For the greater part they were synthesized in this laboratory 
(thesis chapter V). Others were obtained from various sources (acknow-
ledgements). 
QUATERNARY DIOXOLANES 
" Dilvasène " (2249 F) is a parasympathomimetic drug (FOURNEAU 
1944). Homologues with substituents on the " positive " (onium) and 
on the " negative " (acetal) side could be synthesized in a fairly easy 
way. The dioxolanes are more advantageous than the choline esters, 
being rather stable in aquous solution. The series of quaternary dioxo-
lanes have been coded as follows : 
О—С 
"с с 
/ \ / \ 
ι 0 c-R'FR, 
R' О—С 
\ / \ 
С с 
-N+RS.X—, R' О С—N+R..X-; 
R'4FR, 
О—С 
^ / \ (СН,). с с 
• — \ / \ 
О С—N+Ra.X-
CnFRj 
a) Substitutions on the "positive" side. 
Introduction of heavier substituents on the onium group may cause 
a reduction of the effectiveness wherewith the positive charge of the 
onium group can interfere with the electrical field of the receptor. 
Therefore it may be expected that the successive replacement of methyl 
groups by ethyl groups on the quaternary nitrogen atom of MeFMe 3 
will be followed by a gradual decrease of the intrinsic activity. 
Thus parasympathomimetic actions will gradually turn into para­
sympatholytic actions via drugs with a competitive dualistic behaviour. 
The experiments performed with the isolated rat jejunum fully con­
firmed the expectations. MeFMe 3 and MeFMe 2 Et proved to be para­
sympathomimetics (high i.a.). Further ethylation results in MeFMeEt 2 
(intermediate i.a.), which is a drug with a dualism in action. This drug 
shows agonistic and competitive antagonistic properties, dependent on 
the effect already obtained with an agonist. The higher homologue 
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MeFEt 3 is devoid of contracturing properties (low i.a.). MeFEt 3 is a 
competitive antagonist of the parasympathomimetics. The gradual 
change from agonist to competitive antagonist is clearly demonstrated 
by figure 3. 
The relationship between the effectiveness of the onium group and 
the intrinsic activity—as predicted from the theory and confirmed by 
the experiments just described—is of general value. For all the members 
of the R'FMe 3 series it holds that ethylation results in a decrease of 
the intrinsic activity. Consequently in these series also parasympatho-
4feeontr«ctiir· 
l°° η rUFRj 
ВО 
60 
40 
20 
% contracture *-
100-
HT'minol/1 HFMrj 
FIG. 3a, Ь 
a. Cumulative log concentration-response curves for the MeFR
a
 series. Note with 
successive replacement of methyl groups by ethyl groups a progressive decrease of the 
intrinsic activity as a decline of the slope and a decrease of the maximal height. Con­
sequently parasympathomimetic actions change gradually into parasympatholytic actions. 
b. Cumulative log concentration-response curves for HFMe, in the presence of MeFEtj. 
Note a competitive antagonism as a shift of the curves for HFMe
a
. 
mimetic actions gradually change into parasympatholytic actions. For 
instance EtFMe 3 is a parasympathomimetic (high i.a.), EtFMe 2 Et is a 
drug with a dualism in action (intermediate i.a.), while EtFMeEt 2 and 
EtFEt
a
 are parasympatholytics (low i.a.). The intrinsic activities for the 
complete series are collected in table III . 
In analogy to the various series of drugs mentioned thus far it can 
be predicted for the R 2 FMe 3 series that ethylation will cause a gradual 
decrease of the intrinsic activity. Experiments showed this to be correct ; 
M e 2 F M e 3 is a parasympathomimetic (high i.a.), Me 2 FMe 2 Et and 
Me 2 FMeEt 2 are drugs with a competitive dualism in action (inter­
mediate i.a.), while Me 2 FEt 3 is a competitive antagonist of the para-
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sympathomimetics. The intrinsic activities of the other members of this 
series are included in table III . 
The affinity generally decreases with ethylation. In consequence, para­
sympatholytics obtained by ethylation of parasympathomimetics have 
too small an affinity to be useful as therapeutic atropine substitutes. 
The affinities of the complete series are collected in table III. 
b) Substitutions on the " negative " side. 
Large substituents on the negative side of H F M e 3 may prevent a 
good approach of the onium group to the receptor in such a way that 
the effectiveness wherewith the positive charge of the onium group 
can interfere with the receptor field can be reduced. Consequently the 
expectation arises that elongation of the alkyl chain in R'FMe 3 will 
result in a gradual decrease of the intrinsic activity. The parasympatho­
mimetic actions of H F M e 3 should then change gradually into competitive 
antagonistic actions. The experimental confirmation is demonstrated in 
figure 4. 
К Г
1
 ІСГ-* I O - 3 I0-2mmo]/l H e x IO"3 lO'VimoW HFMe3 
F I G . 4a, b 
a. Cumulative log concentration-response curves of the R'FMe3 series. Note with 
elongation of the alkyl chain R' a progressive decrease of the intrinsic activity and con­
sequently a gradual change from parasympathomimetic to parasympatholytic actions. 
b. Cumulative log concentration-response curves for HFMe, in the presence of 
constant concentrations of HexFMe9. Note competitive antagonism. 
Thus HFMe 3 , MeFMe 3 and EtFMe 3 are parasympathomimetics (high 
i.a.)and P r F M e 3 is a drug with a competitive dualistic action (intermediate 
i.a.). Its dualistic action is clearly demonstrated in figure 5 and 6. The 
higher members BuFMe 3 and HexFMe 3 are devoid of contracturing 
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properties (low i.a.). The competitive antagonistic properties of HexFMe3 
are presented in figure 4. 
As was to be expected, an analogous change in the mode of action 
is observed, in the R'FMe2Et series. Thus HFMe2Et and MeFMe2Et 
are parasympathomimetics (high i.a.), EtFMe2Et is a drug with a 
competitive dualism in action, while PrFMe2Et is already a competitive 
antagonist. See table III. 
FIG. 5 
Cumulative dose-response curves as registered on the sooted drum for HFMe : ) and 
PrFMe3 alone and for PrFMe3 in the presence of constant concentrations of HFMe 3 . 
Note that according to the effect already produced by HFMe3 , PrFMe 3 is agonistic 
(curve c, ƒ and h) slightly agonistic (j) inactive (g) and competitively antagonistic (d, 
e, i and k). Finally, with high doses of PrFMe3 the same effect is always obtained. Doses 
added in io 5 mmol to a io ml bath, (i 3 of full size). 
Corresponding to the prediction, in the R2FMe3 series also there is 
a gradual change from agonist to competitive antagonist with increasing 
chain length of R'. Thus Me2FMe3 is a parasympathomimetic. Et2FMe3 
is a drug with a dualistic mode of action and the higher members 
iPr2FMe3, Pr2FMe3 and Bu2FMe3 are parasympatholytics (low i.a.). See 
table III. 
In the R2FMe2Et series the intrinsic activity gradually decreases like-
7 
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wise with elongation of R'. In this way Me2FMe2Et is a drug with a 
dualism in action, while the higher members are competitive anta-
gonists. (See Table III). 
As was expected in the CnFMe3 series also a decrease in the intrinsic 
activity is found when the number of methylene groups in the poly-
methylene ring is increased. The lowest member C4FMe3 already has 
a rather low intrinsic activity. The low intrinsic activity of C4FMe3 in 
comparison with Et2FMe3 is presumably accounted for by the rigid 
structure of the former compound. The competitive antagonistic pro-
TABLE III 
Intrinsic activities and affinities of quaternary dioxolanes tested on the rat jejunum 
R'FR, 
R' 
H 
Me 
Et 
Pr 
Bu 
Hex 
Ph 
R',FR3 
R'2 
Me, 
Et, 
iPr, 
Prä 
Bu, 
Ph, 
CnFR, 
Cn 
c4 CS 
i.a. 
I 
I 
I 
°·5 
о 
о 
О 
1 
θ·5 
о 
о 
о 
° 
О.І 
о 
Me, 
log aff. О 
5-3 (ο.ι) 
7.23 (0.08) 
5.38 (ο.ιο) 
4-94 (0.05) 
4.89 (0.15) 
4.46 (0.18) 
4·ΐ (о.з) 
4-33 (ο.ιι) 
4.6 (0.2) 
4.4 (0.2) 
6.23 (0.10) 
6.94 (0.12) 
7.10 (0.07) 
4-1 (°·2) 
4-3 (o-2) 
i.a. 
I 
I 
0.4 
0 
— 
— 
0 
0.6 
0 
0 
0 
0 
— 
0 
° 
Me,Et 
log aff. 
4.87 (0.14) 
7.06 (0.12) 
5-J5 (°-25) 
4.95 (0.17) 
— 
— 
4-3 (ο·3) 
4.67 (0.22) 
4.89 (o.32) 
4.7 (0.2) 
6.77 (0.16) 
7.25 (0.13) 
— 
4.2 (0.2) 
4.4 (0.2) 
i.a. 
0.4 
0 3 
0 
— 
— 
— 
— 
0-3 
— 
— 
0 
— 
— 
— 
MeEt, 
log aff. 
3-9 (о-З) 
4.8 (0.2) 
4.6 (o.2s) 
— 
— 
— 
— 
i.a. 
0 . 1 
0 
0 
0 
— 
— 
— 
1 
4.19 (0.25) 
— 
— 
6.89 (0.10) 
— 
— 
— 
-
0 
— 
— 
0 
— 
— 
— 
Et, 
log aff. 
3-5 (o-S) 
3.6 (0.5) 
4.2 (0.5) 
4.77 (0.09) 
— 
— 
— 
4.18 (0.11) 
— 
— 
6.61 (0.09) 
— 
— 
— 
Atropine i.a. = o; log aff. 8.80 (o.n) . 
(') Log affinity is the pD 2 value for the parasympathomimetics and the pA, value for 
the parasympatholytics. The 95% confidence value of the mean affinity is obtained 
by adding and substracting from the affinity the value between the parenthesis. The 
affinities of the various drugs were obtained from 6-100 experiments. 
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perties of C4FMe3 and its homologue C5FMe3 are demonstrated in 
figure 7. 
With regard to the affinity in the R'FMe3 and R'FMe2Et series there 
is an optimum for MeFMe3 and MeFMe2Et. The R¿FMe3 series shows 
°/o contracture 
100 η 
8 0 -
60 
4 0 -
20 
~^> 
I 0 ' 3 10-2 
I 
ισ' mmol/lPrFMej 
Fie. 6 
Cumulative log concentration-response curves for the competitive dualist PrFMe
s
 in the 
presence of various constant concentrations of the agonist HFMe,. Note that, according 
to the initial effect induced by the agonist, PrFMe
s
 is agonistic, inactive or competitively 
antagonistic. Finally, with high concentrations of PrFMe
s
 the same effect is always 
obtained. 
^contracture 
100-ι 100 η 
60 -
60 -
че­
го-
CjFM.j θ/ U li/ ' ъгш4тт^лл 
I ' 
icr' I O ' m m o l / 1 ІОГ' H F H « j IO"1 m mol/I H FM « j 
FiC. Ja, Ь 
Cumulative log concentration-response curves for the agonist HFMe 3 in the presence 
of constant concentrations of C,FMe, and C,FMe,. Note the competitive antagonism 
as a parallel shift of the curves for the agonist. 
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a maximum of affinity for Et2FMe3. Concerning the higher homologues, 
which are parasympatholytics, the affinity increases with the chain 
length. Thus Bu2FMe3 is a potent parasympatholytic (See TABLE III). 
A further increase in the affinity is observed in Ph2FMe3. The diphenyl 
derivative approximates the affinity of atropine (BROWN and WERNER 
1949). A planar ring on the " negative " side seems to be of advantage, 
(see also LONG et al. 1957), although it is not proved that planar rings 
are essential to get an optimal affinity. 
A more pronounced decrease in the intrinsic activity of dioxolane 
compounds is achieved by introducing larger substituents on the positive 
and on the negative side simultaneously. In the several R'FR3 series 
the intrinsic activity fell to zero for MeFEt3, EtFMeEt2, PrFMe2Et and 
BuFMe3 and in the various R2FR3 series for Me2FEt3, Et2FMeEt2 and 
Pr2FMe3. (See TABLE III). 
If the groups on the negative side are of such a size that the intrinsic 
activity is zero, ethylation can only influence the affinity. It is found 
that, e.g. for the Pr2FR3 series, the affinity is maximal for Pr2FMeEt2. 
CHOLINE DERIVATIVES 
H O — C H J C H Î N + R J Code : ChR, 
Choline (ChMe3), which has a low affinity for parasympathetic re-
ceptors, is a parasympathomimetic with a high intrinsic activity. It was 
found that the triethyl analogue of choline (ChEt3) behaves as an anta-
gonist of choline (WELLS and MALLOV 1956). It is impossible to conclude 
from these experiments whether this antagonism is competitive or not. 
In the light of the experiments described thus far the expectation arises 
that successive ethylation of ChMe3 will result in a gradual decrease 
of the intrinsic activity. The experiments demonstrated that ChMe3 is 
a parasympathomimetic, ChMe2Et and ChMeEt2 are drugs with com-
petitive dualism in action (intermediate i.a.) and ChEt3 is a competitive 
antagonist of parasympathomimetics (F IG. 8). Data for the ChR3 series 
are included in table IV. 
ALKYLTRIMETHYLAMMONIUM SALTS 
С Н
а
( С Н 4 ) я — N + M e , Code : R"NMe 3 
Since alkyltrimethylammonium salts are the simplest acetylcholine 
analogues, these compounds have been the subject of many investigations 
1 0 0 
(CLARK 1937, RAVENTOS 1937, STEPHENSON 1956). Stephenson's experi-
ments performed on the guinea pig ileum showed that elongation of 
the alkyl chain in R'NMe3 results in a gradual decrease of the intrinsic 
activity (called " efficacy " by him). Our experiments with the jejunum 
of the rat also show a gradual decrease in the intrinsic activity. Contrary 
to Stephenson's findings, the decrease in the intrinsic activity was here 
FIG. 8 
Cumulative dose-response curves for choline derivatives ChR3. Note a progressive 
decrease of the intrinsic activity with successive replacement of methyl groups by ethyl 
groups. ChMe2Et and ChMeEt» are parasympathetic drugs with a dualism in action. 
The higher homologue ChEt3 shows only competitive antagonistic properties. (1/3 of 
full size). 
more pronounced. These differences may be accounted for by the fact 
that the guinea pig ileum is much more sensitive to ganglionic action. 
In this way also in the guinea pig ileum the intrinsic activity of HeptNMe3 
may be zero at the parasympathetic receptors but not yet at the ganglionic 
ACh-receptors. Thus the lower homologues up to PentNMe3 behave 
as parasympathomimetics. HexNMe3 and HeptNMe3 have an inter-
mediate intrinsic activity and therefore are drugs with a competitive 
dualism in action. The higher members are already competitive anta-
gonists of the parasympathomimetics. (See TABLE IV). 
It may be expected that with respect to the R'NMe3 series, successive 
1 0 1 
ethylation will result in a decrease of the intrinsic activity. The experi-
ments confirmed this. Thus BuNMe3 and PentNMe3 are parasympatho-
mimetics (high i.a.). BuNMe2Et and PentNMe¡,Et behave as drugs 
with a competitive dualism in action (intermediate i.a.). The R'NEt3 
derivatives have very low intrinsic activity and are competitive anta-
gonists of the parasympathomimetics (F IG. 9). 
Sbcontracturt 
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FIG. да, Ь 
Cumulative log concentration-response curves for HFMe, in the presence of the 
competitive antagonists OctNEt
a
 and NonNEt
s
. 
Regarding the affinity in the R 'NMe 3 series there is an optimum 
for the parasympathomimetic with a chain length of 5 С atoms 
(PentNMe 3). On ethylation of the parasympathomimetics the affinity 
decreases. For the parasympatholytics the affinity increases with the 
chain length, while the affinity is hardly influenced by ethylation (See 
TABLE IV). The shape of the concentration-response curves for the 
lower homologues MeNMe 3 to PrNMe 3 differs from those for BuNMe 3 
PentNMe 3 and the standard HFMe 3 . In contrast to the shape of 
curves of the latter drugs, those of the curves for e.g. P r N M e 3 are 
changed by hexamethonium in rather low concentrations (10_ 1 mmol/1). 
This is possibly due to ganglionic actions (See also STEPHENSON 1956). 
It may be remarked here that mono-onium compounds which are 
parasympatholytics or competitive antagonists of parasympathomimetics 
since they contain in their molecular configuration a chain of considerable 
length (surface activity) behave as non-competitive antagonists of cho­
linomimetics at the level of the ACh-receptors in skeletal muscle. For 
instance DecNMe 3 , HexFMe 3 and P r 2 F M e 3 are competitive antagonists 
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of cholinomimetics on the rat jejunum but non-competitive antagonists 
of cholinomimetics on the rectus abdominis muscle of the frog. 
TABLE IV 
Affinities and intrinsic activities of the R'NR3 and ChR3 series tested on the rat jejunum 
RTSIR, 
R' 
Me 
Et 
Pr 
Bu 
Pent 
Hex 
Hept 
Oct 
Non 
Dec 
Dodec 
ChR, 
Ch 
Me, 
i.a. 
0.9 
O.I 
0 
0 
0 
0 
I 
log aff. (») 
3.9· 
3 7 · 
3-6· 
5-a 
5-4 
5-0 
4.6 
5-0 
5 0 
5-9 
6.0 
3 * 
Б 
Me,Et 
i.a. 
o-S 
0 . 4 
0 
0 
— 
o-S 
log aff. 
S-i 
5-2 
4-7 
5·» 
— 
— 
— 
3-4 
·, 
i.a. 
0 
0 
— 
— 
— 
— 
— 
0 . 2 
MeEt, 
log aff. 
4.0 
4 1 
— 
— 
— 
3 1 
Et, 
i.a. 
0 
0 
0 
0 
0 
0 
0 
0 
log aff. 
4-3 
4.4 
S·«· 
5-5 
5-4 
5.6 
6.0· 
3-4 
(') Log affinities are pD 2 or pA, values. The upper and lower limits of the 95% confi­
dence range for the logarithm of the affinity are from 0.1-o.z below to 0.1-0.2 above 
the number given in the table. For the numbers marked with * the limits are wider since 
less than 5 estimations were made. 
NON-COMPETITIVE INTERACTION 
It is generally assumed that myotropic spasmolytics such as papaverine, 
are non-competitive antagonists of parasympathomimetics. The family 
of log concentration response curves for MeFMe 3 obtained on the rat 
jejunum in the presence of papaverine is found to give a clear-cut 
picture of non-competitive antagonism (See FIGURE 10a). This might 
suggest that the rat jejunum does not contain spare receptors for para­
sympathomimetics. This however is not a proof, as a possible receptor 
reserve will not be manifested if papaverine has its point of attack 
directly on the effector system (thesis chapter I). 
In experiments on the guinea-pig intestine, papaverine causes a small 
amount of shifting of the curves for histamine as well as a decline in 
the slope and a decrease of the maximal height ( F I G . 10b). This shift 
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may be due to a receptor reserve for histamine. With the aid of an 
irreversible competitive antagonist NICKERSON (1956) demonstrated a 
large amount of spare receptors for histamine in the guinea-pig intestine. 
The possible receptor reserve indicated by papaverine is, however, much 
smaller. This difference is compatible with the theory (thesis chapter I). 
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F I G . 10α, Ъ 
Cumulative log concentration-response curves for M e F M e 3 on the rat jejunum and 
for histamine on the guinea-pig jejunum in the presence of constant concentrations of 
papaverine. N o t e a non-competitive antagonism. For detailed explanation see text. 
According to the point of attack of papaverine somewhere in the 
sequence of events leading from the specific ACh-receptors to the final 
effect, a different amount of spare receptors will become manifest. 
Another possibility is that on the guinea-pig intestine papaverine exerts 
competitive antagonistic actions in low, and non-competitive anta­
gonistic actions in high concentrations. A distinction between these 
possibilities can be made if other histamine-like compounds are used 
as agonists (thesis chapter I). 
In the preceding pages it was shown that successive replacement of 
methyl groups by ethyl groups on the quaternary nitrogen atom of 
parasympathomimetics results in competitive antagonists. By substitu­
ting a 2-phenylethyl group (Phet) for one methyl group on the positive 
side of the parasympatholytic BuFMe 3, non-competitive properties were 
introduced. The combined action of BuFMe2Phet and an agonist such 
as e.g. H F M e 3 results in an interesting family of concentration-response 
curves. As shown by figure 11 BuFMe2Phet has competitive anta­
gonistic and incomplete non-competitive antagonistic properties. How­
ever, the incomplete non-competitive action becomes apparent to a 
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variable extent. The existence of a type of interaction as given in figure 11 
was predicted by the theory (ARIËNS et al. 1956e). 
% contractu« 
I0"s Ю - г IO"1 mmol/1 HFMej 
FIG. I I 
Cumulative log concentration-response curves for HFMe, in the presence of constant 
concentrations of BuFMe2Phet. Note an incomplete non-competitive antagonism as a 
decrease of the maximal height of the curves to about 60 %, on which a competitive 
antagonism is superimposed as a parallel shift. 
FUNCTIONAL INTERACTION 
Barium ions cause a contraction of intestinal smooth muscle, which 
is due to reaction with other than parasympathetic receptors ( F I G . 1). 
It may be expected that parasympathomimetics and Ba-1""1" ions behave 
as functional synergists. A functional interaction can be demonstrated 
in the most suitable way by preparing log concentration-response curves 
for a drug with a dualism in action, having affinity towards the one 
receptor system, in the presence of certain concentrations of an agonist 
interacting with another receptor system (this thesis chapter I). The 
expected functional interaction of BaCl2 and PrFMe 3 (a parasympatho­
mimetic with a dualism in action) is clearly demonstrated in figure 120. 
There is a striking difference between the family of curves obtained 
with PrFMe 3 in the presence of an agonist with the same point of attack, 
e.g. H F M e 3 ( F I G . 5 and 6) and in the presence of an agonist with a 
different point of attack, e.g. BaCl2 ( F I G . 12a). In the first case there 
is a competitive interaction and in the latter a functional interaction. 
For parasympathomimetics and histamine a functional interaction was 
likewise expected to exist. Experiments proved this to be true. The 
functional interaction of histamine and E t 2 F M e 3 (parasympathomimetic 
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with intermediate i.a.) is given in figure 12b. From this it can be seen 
that E t 2 F M e 3 in higher concentrations shows antihistaminic properties. 
The affinity of the parasympathomimetics Et 2 FMe 3 and PrFMe 3 towards 
histamine receptors was determined from the shift in the curves for 
histamine, produced by these drugs in the presence of atropine. 
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Cumulative log concentration-response curves for the parasympathetic competitive 
dualist PrFMe3 in the presence of constant concentrations of BaCl2 on rat jejunum and 
of the parasympathetic dualist EtjFMe
a
 in the presence of constant concentrations of 
histamine on the guinea-pig jejunum. Note a functional synergism. Compare with the 
competitive dualism (FIG. 5 and 6). 
TABLE V 
Affinities and intrinsic activities of R'FMe3 and R'^FMe^ compounds tested on the 
guinea-pig jejunum 
Drugs 
PrFMe, 
BuFMe
s 
HexFMes 
Et2FMea 
Pr2FMe s 
BujFMe, 
Ph 2FMe s 
atropine 
parasympathetic receptors 
int. act. log aff. (Ч 
0.6 
0 
0 
0.4 
0 
0 
0 
0 
4.8 
5-1 
5-2 
4-3 
6.1 
6.9 
7-3 
8.1 
histamine receptors 
int. act. log aff. (i) 
2.9 
З.4 
3.8 
3-7 
5 1 
5-7 
6.2 
6-5 
log 
(aff. ratio) 
(') Log affinities are pD 2 or рАг values. The 95% confidence range is the same as that 
in table IV. 
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The antihistaminic properties of a number of parasympatholytic 
dioxolane derivatives, R'FMe3 and R^FIV^, were also evaluated (TABLE 
V). The antihistaminic action of Ph2FMe3 had already been studied 
by BROWN and WERNER (1949). 
The affinity of the quaternary dioxolanes for the parasympathetic 
receptors is considerably greater than for the histaminic receptors (See 
TABLE V). There is a positive correlation between the parasympatholytic 
and antihistaminic properties of the R'FMe3 and RgFMeg compounds. 
Although the parasympathetic and histamine receptors are essentially 
different, this might be an indication that they have a physicochemical 
resemblance. 
T H E SLOPE OF THE CURVES 
The slope of the log concentration-response curves for the para-
sympathomimetics is considerably steeper than that of those calculated 
from the Menten-Michaelis or Clark formula (CLARK 1937). This may 
be accounted for in several ways. 
a) The drug concentration in the biophase may be a non-linear 
function of the dose applied. This explanation is unlikely (NICKERSON 
!957)· 
b) The drug-receptor interaction may be a higher-order reaction. 
Higher-order reactions as such are improbable, but they can be simu-
lated by a sequence of bimolecular reactions. 
c) The relationship between the effect and the fraction of receptors 
occupied may be given by an all-or-none response with a biological 
variation (ARIËNS and VAN ROSSUM 1957e) or a non-linear continuous 
function (STEPHENSON 1956, thesis chapter I). 
For the moment the experiments do not allow a decision as to which 
explanation is preferable. 
NON-REVERSIBILITY AND HYSTERESIS 
The term irreversible is mostly used for non-equilibrium drugs 
(NICKERSON 1957), meaning drug molecules which cannot be removed 
from the receptors. This may be due to the fact that the drug combines 
with the receptors in an irreversible way. It is, however, also possible 
that the penetration of the drug into the biophase is " irreversible ". 
The nitrogen mustard derivatives as described by NICKERSON (1952) 
probably combine in an " irreversible " way with the receptors. 
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The term non-reversibility is used here to indicate different pathways 
for the upward and backward reaction (e.g. contraction and relaxation), 
while according to NICKERSON (1957) the term non-equilibrium is limited 
to the " irreversible binding ". 
Also in these cases a stimulus may be postulated which is linearly 
related to the number of receptors occupied. It is conceivable that the 
non-reversibility is limited to the relationship between the stimulus and 
the effect. This means that in spite of the non-reversibility, drug action 
can be studied in the equilibrium state. Since in addition to mechanical 
IO''mmol/l HFM«j lO 7mmol/] 10* Jtropcnt 
F I G . 13 
Cumulative concentration-response curves for HFMe 3 made in the presence of constant 
concentrations of atropine (antagonist added preventively) in the left part of the figure 
and in the right part a cumulative response curve for atropine on a piece of rat jejunum 
which was already in contact with a constant concentration of HFMe 3 (antagonist added 
curatively). Atropine is 10-40 times more potent when added curativelv than preventively, 
which stresses the necessity for using identical methods in estimating the potency of 
parasympatholytics and histaminolytics on the animal intestine. 
differences there are also differences in the chemical events in muscle 
contraction and relaxation, it is conceivable that the effectivity of the 
stimulus in producing an effect may depend not only on the value of 
the stimulus but also on whether the stimulus is built up or broken 
down. Thus a kind of hysteresis may be involved in muscle contraction 
and relaxation. This implies that the same percentage contraction can 
be produced with different values for the stimulus, according to whether 
a contraction or a relaxation is induced. In our experiments the aim 
was to follow a constant way and thus if possible, as a result of addition 
of the drug, to bring about an increase of the stimulus. Therefore 
practically all our experiments are concerned with muscular contraction. 
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Also for this reason antagonists were added before the agonists. In 
studying the combined action of an agonist such as HFMe 3 and a com-
petitive dualist as PrFMe a it was not always possible to measure the con-
traction only. It appeared that PrFMe3 showed a better " affinity " when 
added to a contracted muscle than to a relaxed one (see FIG. 5). This 
suggests that a relaxation is easier to produce than a contraction. Further 
investigation revealed that parasympatholytics need a considerably lower 
concentration to induce a reduction of contraction (curative) than a 
prevention of contraction (preventive). (The terms curative and preven-
tive are used according to SCHILD 1949; see FIG. 13). When added 
before a parasympathomimetic, atropine, for instance, is a less effective 
spasmolytic than when added afterwards. The same phenomenon was 
observed for antihistaminics and histamine. 
This type of hysteresis must presumably be explained by the existence 
of non-reversible steps in the sequence of events leading from the receptor 
occupation to the final effect. The hysteresis does not plead against the 
validity of the theories on competitive interaction. It may partly account 
for the large differences in activity found by several authors for para-
sympatholytics and antihistaminics when using different experimental 
techniques. 
DISCUSSION 
The intrinsic activity and affinity are essential parameters for the 
study of the mode of drug action. The experiments reported support 
the supposition that the intrinsic activity of parasympathetic drugs is 
connected with the effectiveness wherewith a positively charged onium 
group can interfere with the receptor field. Introduction of heavier 
substituents on the " positive " as well as on the " negative " side 
always results in a gradual change from parasympathomimetics into 
parasympatholytics via drugs with a dualism in action. This is accounted 
for by a decrease in the intrinsic activity, independent of the relationship 
between the effect and the fraction of receptors occupied (thesis chap-
ter I). The intrinsic activities included in the tables were calculated 
from the maximal height of the concentration-response curves. Cor-
rections may possibly have to be made if the existence of spare receptors 
for parasympathetic drugs can be demonstrated and their amount 
evaluated. 
A coincidence of optima in several physical properties is required 
for a maximal affinity. This coincidence seems to differ for the para-
sympathomimetics and parasympatholytics. There are indications that 
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the parasympatholytics make use of a receptor system of greater di­
mensions than the parasympathomimetics. Theoretically it is even 
possible that the parasympathomimetics and their competitive anta­
gonists may react with different, although strongly interdependent 
receptors or double receptors (this thesis chapter I). 
The experiments underline once more the fact that the receptors 
have to be considered functionally and not morphologically. It can be 
stated that each drug actually uses a somewhat different receptor. In 
the various homologous series of parasympathomimetics an optimum 
in the affinity was found for such compounds as could be predicted 
from the 5 atom rule of ING (1952), e.g. PentNMe 3, MeFMe 3 and 
MeFMe 2 Et. The optimum of biological activity in the R'NMe 3 series 
for PentNMe 3 has been attributed by STEPHENSON to an optimum of 
intrinsic activity (his " efficacy " ) , while the affinity was supposed to 
be proportional to the length of the alkyl chain. It is however more 
likely that the intrinsic activity is proportional to the length of the alkyl 
chain, so that there is an optimum in affinity. The final decision can 
only be given when irreversible competitive antagonists of parasym­
pathomimetics become available. 
In addition to parasympathetic receptors, the animal intestine also 
contains ganglionic ACh-receptors. The effect of nicotine is supposed 
to be the effect of reaction with ganglionic receptors. By reason of the 
fact that the rat jejunum responds feebly to nicotine, this object is of 
use for investigating parasympathetic drugs. The guinea-pig intestine 
has a better response to ganglionic drugs and therefore is less suitable 
for this purpose. Contrary to the experiments of STEPHENSON (1956) 
with R'NMe 3 compounds on the guinea-pig ileum, our experiments 
with the R'FR 3, R 2FR 3, CnFR 3 and R'NR 3 series on the rat jejunum 
were performed in absence of hexamethonium. Hexamethonium in lower 
concentrations ( < 0.4 mmol/1) did not influence the log concentration-
response curves of the parasympathetic drugs. The shape of the curves 
for parasympathomimetics with very low affinity, for instance EtNMe 3 , 
P r N M e 3 and AllNMe3, were altered slightly by hexamethonium (ο.ί­
ο. 4 mmol/1). It might therefore be that these drugs, in addition to the ;r 
parasympathomimetic actions, have strong ganglionic stimulating pro­
perties. For EtNMe 3 , AUNMe3 and PrNMe 3 the S-shaped concentration-
response curve is complicated by some extra effect at lower concen­
trations. This extra effect could be eliminated for a good deal by previous 
addition of hexamethonium (0.1-0.4 mmol/1). It is therefore presumably 
due to a ganglionic stimulating effect. In higher concentrations ( > 0.4 
mmol/1) hexamethonium acts as a parasympatholytic, since hexametho-
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nium causes the same amount of shifting of parasympathomimetics with 
different affinities, for example MeFMe 3 and HFMe 3 . 
It was substantiated that the quaternary ammonium compounds de­
signated parasympathomimetics actually react with the same receptor 
system. For this purpose log concentration-response curves were re­
gistered for the parasympathomimetics in the presence of a constant 
concentration of atropine ( ю Б mmol/1). These experiments revealed, in 
accordance with the theory, the same amount of shifting for the various 
parasympathomimetics. It was also demonstrated that the parasympatho­
lytics made use of the same " receptor system " . The various para­
sympatholytics cause a shift of the curves for the same agonist. 
For the combined action of an agonist and a competitive antagonist 
it can be derived theoretically (this thesis chapter I) that for equal 
effects the ratio cone, agonist/cone, antagonist is constant. Experi­
mentally this happened to hold for the combined action of an agonist 
(HFMe 3 ) and almost all the parasympatholytics, except for the para­
sympatholytics with extreme low affinity, e.g. the lower members of 
the R'FEt 3 series e.g. HFEt 3 and MeFEt 3 . For the latter compounds 
the concentration ratio was found to be too small (See F I G . 36). A satis­
factory explanation cannot be given. 
When the structural features required for intrinsic activity and affinity 
are borne in mind, with the theories of drug-receptor interactions in 
the background, it is possible to predict the mode of parasympathetic 
action of quaternary ammonium salts. It is predicted here that when 
homologous substitutions (ethylation on the " positive " side, or intro­
duction of heavier groups on the " negative " side) are carried out in 
muscarine, gradual changes will be found from parasympathomimetic 
to parasympatholytic actions. 
SUMMARY 
On the basis of theories concerning drug-receptor interactions (ARIËNS 
et al. 1950, 1954, 1956 а, Ь, с, i957^> thesis chapter I), the molecular 
pharmacology of various homologous series of quaternary parasympa­
thetic drugs has been studied. 
The essential parameters, affinity and intrinsic activity (i.a.) vary 
with the molecular configuration. 
The experiments give a large amount of support to the hypothesis 
that the intrinsic activity of parasympathetic drugs is connected with 
the effectiveness wherewith the positive charge of the onium group 
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can interfere with some part of the electrical field of the receptor. 
Heavier substituents on the positive as well as on the negative side of 
parasympathomimetics result in a gradual decrease of the intrinsic 
activity. 
As predicted, in various series of drugs gradual changes were found 
from the parasympathomimetic to parasympatholytic actions via drugs 
with a competitive dualism in action. 
Parasympathomimetics (high l.a.) and parasympatholytics require a 
partial different molecular configuration for a good affinity. These 
findings and the results of LANDS (1951) and LONG et al. (1956-1957) 
indicate that the parasympatholytics make use of a more extensive 
receptor system than the parasympathomimetics. 
On parasympathetic receptors, successive replacement of methyl 
groups by ethyl groups on the " positive " side and elongation of alkyl 
chains on the " negative " side of the drug molecule (introduction of 
surface activity) effect a gradual change from parasympathomimetic to 
competitive antagonist (parasympatholytic). On the ACh-receptors of 
skeletal muscle (end- plate) elongation of an alkyl chain in mono-onium 
compounds results in non-competitive antagonists, (see this thesis chap­
ter II). Therefore ACh-receptors differ to some extent in the motor 
end-plate and the parasympathetic end-synapse. 
A functional interaction was shown to exist between parasympatho­
mimetics and histamine or BaCl2. 
The potency of parasympatholytics and antihistamines was found to 
differ depending on the mode of investigation. 
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CHAPTER IV 
PHARMACODYNAMICS OF DRUGS AFFECTING THE 
BLOOD PRESSURE 
Structure-action relationships of quaternary ganglionic and 
parasympathetic drugs 
INTRODUCTION 
The blood pressure is regulated in order to obtain an adequate blood 
supply in all parts of the organism and thus ensure an optimal action 
of metabolic processes. In the light of cybernetics (WIENER, 1950 and 
WAGNER, 1954) the value of the blood pressure at any moment may be 
assumed to be maintained at a setpoint. Any deviation from the setpoint 
is counteracted. In this respect the sympathetic pathway especially 
plays a major role but the parasympathetic pathway is also involved. 
Fig. 1 gives a schematic representation of some factors involved in the 
regulation of blood pressure. The scheme is based on data from the 
littérature (HEYMANS, 1950), GOODMAN and GILMAN, 1955 and others). 
Our attention is mainly limited to drugs reacting with the acetyl-
choline (ACh) receptors of the ganglionic synapses in the sympathetic 
and parasympathetic nervous system and the parasympathetic end-
synapses. As such are considered all autonomic cholinergic end-synapses 
irrespective of whether they are the end-synapses of the " parasym-
pathetic " nerves or those erroneously called the " sympathetic " vaso-
dilatator nerves. It is possible to influence the blood pressure in different 
ways by both cholinomimetic and cholinolytic drugs (FIG. I ) . 
1) Parasympathomimetics or parasympathetic drugs with high in-
trinsic activity (i.a.) produce an abrupt fall in the blood pressure. This 
blood pressure lowering is transient, owing to a rapid counteraction 
which is possible since the arterenergic pathway is unaffected by para-
sympathetic drugs. 
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That this is not due to a rapid breakdown is substantiated by the 
findings that unstable (ACh) and stable (e.g. 2249 F) parasympatho­
mimetics produce a blood pressure fall of the same duration. Simul­
taneous measurements of the heart rate, the blood pressure and central 
venous pressure revealed that a blood pressure lowering induced by 
parasympathomimetics is followed immediately by a slight increase of 
the heart rate which lasts about twice as long as the blood pressure 
decrease. The venous pressure was not affected. The rapid correction 
of the blood pressure fall cannot be accounted for solely by the increase 
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Some factors concerned in the regulation of blood pressure. Attention is drawn mainly 
to the ACh-receptors in the ganglionic synapses (s.g.s. and p.s.g.s.) and in the parasym­
pathetic end synapses (p.s.e.s.). 
Parasympathetic and ganglionic drugs (cholinomimetics and cholinolytics) which inter­
fere at the ACh-receptors may influence the blood pressure by influencing the cardiac 
output (c.o.) and the peripheral resistance (p.г.). T h e arterial blood pressure at any 
moment is picked up by the pressoreceptors and fed back to the central nervous system, 
after which a deviation of the setpoint is counteracted in several ways. 
of the heart rate. Since especially the small vessels of skeletal muscle 
contain parasympathetic end-synapses (UVNÄS, 1954, FOLKOW, 1956) 
it is conceivable that parasympathomimetics may produce a blood 
pressure fall which is due to a vasodilatation chiefly in skeletal muscle 
while arterenergic vasoconstriction in other parts of the body (e.g. 
splanchic area) contributes to the rapid correction of the blood pressure 
fall. 
2) Parasympatholytics (low i.a.) have hardly any influence upon the 
blood pressure since under normal physiological conditions the para-
sympathetic pathway plays a minor role in blood pressure regulation. 
3) Cholinomimetics (high i.a.) acting on the receptors of ganglionic 
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synapses produce a blood pressure rise since the action on sympathetic 
ganglia predominates over the action on parasympathetic ganglia. In 
higher concentrations these drugs (e.g. nicotine) produce a " ganglionic 
block " of the depolarizing type and consequently a fall in blood 
pressure. 
4) Cholinolytics (low i.a.) acting on the receptors of ganglionic syn-
apses cause a fall in blood pressure, mainly as result of a " sympathetic " 
ganglionic blockade. These ganglionic blocking agents (e.g. hexametho-
nium) are competitive antagonists of the cholinomimetics. 
5) Drugs which react with non-ACh-receptors may also influence 
the events in the ganglionic and parasympathetic synapses. These drugs 
are called non-competitive with respect to ACh. 
The ganglionic drugs give a response of longer duration than the 
parasympathetic drugs. This is reasonable since ganglionic drugs act 
on the " sympathetic " pathway by which, normally for the greater 
part, the blood pressure changes are counteracted. 
The parasympathetic and ganglionic ACh-receptors must have a 
certain resemblance. Hence cholinomimetics and cholinolytics must exist 
which show affinity towards the parasympathetic end-synapse as well 
as towards the ganglionic synapse. The experience shows that this 
will be the case especially for drugs with low affinity. From a theoretical 
point of view this is conceivable also, since the molecular configurations 
of drugs with low affinity do not satisfy the requirements for high 
specificity. 
Experiments on blood pressure have necessarily to be performed with 
total animals or large animal preparations. One therefore cannot get 
rid of various disturbing factors. In order to achieve a more thorough 
analysis of the action, the different drugs were also investigated on 
isolated organs. 
METHODS AND MATERIALS 
a) The isotonic contractions of the isolated frog heart were recorded 
on a sooted drum (FIG. 2). The various drugs were applied by replacing 
the 1 ml of Ringer fluid in the cannula by a solution which contained 
the desired concentration. The intrinsic activity is assumed to be pro-
portional to the maximal decrease in heart amplitude. The affinity of 
parasympathomimetics is expressed in terms of the negative logarithm 
of the concentration (/>D2) which produce a decrease of the heart ampli-
tude to 50 % of the maximal decrease. For the parasympatholytics the 
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affinity is expressed as the pA2 values (SCHILD, 1949, ARIËNS and VAN 
ROSSUM, 1957). 
b) The mean carotid blood pressure of the anaesthezised cat (pento-
barbitone-Na, B.P. 30 mg/Kg i.p.) was recorded with an Hg manometer. 
The drugs were administered by rapid injection into the femoral vein. 
The intrinsic activity can only be roughly determined and is therefore 
indicated as high for the parasympathomimetics, low for the para-
sympatholytics and intermediate for dualists. The affinity of parasym-
pathomimetics was expressed as the negative logarithm of doses which 
produce the same blood pressure lowering as 3 . ιο 4 μπιο1 ACh. The 
affinities of ganglionic stimulants were expressed as the negative loga­
rithm of doses which produce the same blood pressure rise as 0.3 ¿¿mol 
nicotine. The drugs were assumed to be ganglionic stimulants when 
this effect could be prevented or reduced by previous addition of hexa-
methonium (2-5 /xmoI/Kg). The affinities of ganglionic blocking agents 
were expressed as the negative logarithm of doses which produce the 
same blood pressure fall as 5 цхтоі EtN + Et 3 . As a criterion for ganglionic 
blockade the ability of the drugs to antagonize ganglionic stimulants 
was used. Another criterion was found in the fact that constant doses 
of nor-epinephrine if administered before and after a ganglionic blocking 
agent produce a blood pressure rise of practically the same absolute 
height, which implies that nor-epinephrine induces a greater effect in 
the presence than in the absence of a ganglionic blocking agent. This 
in contrast to the case of a sympatholytic (e.g. tolazoline) or an anti­
spasmodic (e.g. papaverine). 
Experiments with the frog rectus abdominis muscle (See this thesis 
CHAPTER II, ARIËNS et al. 1954) and with the rat intestine (See this 
thesis CHAPTER III) were performed in order to investigate ganglionic 
drugs in-vitro. 
Most of the drugs investigated were synthesized in this laboratory 
(thesis CHAPTER V). Others were obtained from different sources (see 
acknowledgements). 
PARASYMPATHETIC DRUGS ON THE ISOLATED FROG HEART 
The intrinsic activity of parasympathomimetics is assumed to be 
connected with the effectiveness wherewith the positive charge of the 
onium group can interfere with the electrical field of the receptor 
(Compare thesis CHAPTER III). 
Thus in tests on the rat jejunum a gradual change from parasympatho-
119 
mimetic to parasympatholytic activity was observed as result of homo­
logous substitutions in H F M e 3 (2249 F) and other 1 : 3-dioxolanes. 
о—с 
/ \ 
С с 
/ \ / \ 
R' О С — N + R 3 
(R'FRa) 
О—С 
/ \ 
and R — С С 
/ \ / \ 
R' О С — N + R 3 
(R' 2 FR 3 ) 
Ach Ach 
4.I0"5 4.I0"5 
+ 
Ach Ach 
4.10 i 2.10' 
F I G . га, Ь 
Effect of the R'FMe, series on the contractions of the isolated frog heart. There is 
a gradual change from parasympathomimetics (high i.a. as for H F M e 3 and MeFMe 3 ) 
via a drug with a dualism in action (intermediate i.a. as for EtFMe 3 ) to parasympatholytics 
(low i.a. as for PrFMe 3 etc.). P r F M e 3 and the higher homologues as such have no influence 
on the heart amplitude. In doses of o.i /¿mol/ml they abolish the action of ACh, as may 
be seen from the lower part of this figure. Doses are expressed in μηιοΐ/ml. Note a 
maximum in affinity for MeFMe 3 . 
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The isolated frog heart is a suitable test-object for parasympathetic 
drugs. Both elongation of R' and ethylation on N + are expected here 
also to result in a decrease of the intrinsic activity. 
As predicted, elongation of the alkyl chain, R', in the R'FMe 3 series 
results in a gradual decrease of the intrinsic activity also on the frog 
heart ( F I G . za) Consequently H F M e 3 and MeFMe 3 are parasympatho­
mimetics (high i.a.). EtFMe 3 exerts a competitive dualism in action 
(intermediate i.a.). The higher homologues, PrFMe 3 , BuFMe 3 and 
HexFMe 3, are parasympatholytics. The decrease in heart amplitude 
caused by a parasympathomimetic is abolished by addition of these 
parasympatholytics ( F I G . 26) which also prevent the effect of para­
sympathomimetics. 
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Log concentration-response curves on the isolated frog heart for ACh in the presence 
of constant concentrations of the antagonists HexFMe3 ) MeFEt3 or Bu2FMea. These 
drugs cause a parallel shift of the curves for the agonist, which implies a competitive 
antagonism. There is a maximum in affinity for Bu,FMe3. 
The log concentration-response curve for, e.g., ACh is shifted in a 
parallel manner to higher values by a certain concentration of, e.g., 
HexFMe 3 (see F I G . 3a). This pleads, therefore, that HexFMe 3 is a 
competitive antagonist of the parasympathomimetics. 
As expected, an analogous change from parasympathomimetic to com­
petitive antagonistic actions was found in the RáFMe3 series. Thus 
Me2FMe3 is a parasympathomimetic with rather low affinity. Et2FMe3 
and its higher homologues are parasympatholytics or competitive anta-
gonists of the parasympathomimetics. As may be seen from fig. 3c, 
Bu2FMe3 also causes a parallel shift of the log concentration-response 
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curve for ACh. For the parasympathomimetics of the R'FMe3 and 
R2FMe3 series there is a maximum in affinity for the Me-derivative. 
This confirms the findings with other biological objects. For the 
parasympatholytics the affinity increases with elongation of the alkyl 
chain R'. Thus Bu.;FMe3 approximates the affinity of atropine. 
In accordance with the expectation, successive replacement of methyl 
groups by ethyl groups on the quaternary N-atom of MeFMe3 also 
results in a gradual change from parasympathomimetic to parasym-
patholytic activity. Thus MeFMe3 and MeFMe2Et are parasympatho-
mimetics (high i.a.), MeFMeEt2 and MeFEt3 are parasympatholytics 
or competitive antagonists (See FIG. 3ft). Data on the complete R'FMe3, 
R2FMe3, and MeFR3 series are included in table I and II. 
The sensitivity of the frog heart varies widely. This is manifested 
in a variation of the pO2 value for the agonists and in a variation of 
the pA2 value for competitive antagonists. Also the slope of the log 
concentration-response curve, which as a rule is very steep (F IG. 3), 
is rather variable. Since the intrinsic activity also varies, drugs with 
intermediate intrinsic activity (e.g. EtFMe3) act as agonists on one heart 
(high i.a.) and as competitive antagonists (low i.a.) on another heart. 
The drugs with high i.a. (TABLE I and II e.g. HFMe3) always behave 
as agonists while drugs with low i.a. (e.g. BuFMe3) are always anta-
gonists. 
These experiments are in agreement with the findings obtained with 
the rat jejunum (See this thesis CHAPTER III). In the case of the frog 
heart the change from parasympathomimetic into parasympatholytic is 
more abrupt than in the case of the intestine, and it generally takes 
place with lower homologues. 
EXPERIMENTS ON THE CAT'S BLOOD PRESSURE 
It has been found that the intrinsic activity is decreased by the intro-
duction of heavier substituents on the quaternary nitrogen atom of 
cholinomimetic drugs which have affinity to the ACh-receptors of the 
myoneural junction and the parasympathetic end-synapse (this thesis 
CHAPTER II and III). 
Consequently, as a result of ethylation of quaternary trimethylammo-
nium salts, a gradual change from cholinomimetic activity to cholinolytic 
activity via competitive dualistic actions takes place. Since ganglionic 
synapses also contain ACh-receptors, analogous changes in the mode 
of action of quaternary ganglionic drugs are expected to occur. Both 
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parasympathetic and ganglionic ACh-receptors are involved in blood 
pressure regulation ( F I G . I ) , therefore the ratio of the affinities of a 
drug for the parasympathetic and ganglionic receptors determines what 
type of effect will become visible first. When the logarithm of this 
affinity ratio is positive the parasympathetic actions become visible first, 
and vice versa. 
Successive replacement of methyl groups by ethyl groups in MeFMe 3 
is expected to result in a gradual decrease of the intrinsic activity both 
at the level of the parasympathetic and ganglionic ACh-receptors. Con­
sequently there may be a gradual change from parasympathetic and 
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Parasympathetic and ganglionic effects of the MeFR 3 series on the carotid blood 
pressure of the anaesthesized cat (30 mg/kg pentobarbitone-Na, B.P.). In figure 4a, the 
sharp peaks induced by the lower homologues of the MeFR 3 series are parasympatho­
mimetic effects while the prolonged blood pressure lowering induced by MeFEt 3 is a 
ganglionic blocking effect. In figure 4b, the parasympathomimetic effects are prevented 
by atropine (5 /¿mmol/kg). MeFMeEt2 in higher concentrations than under (a) produces 
a ganglionic blocking action, while MeFEt3 behaves as a ganglionic blocking agent 
before and after atropine. Note a gradual change from parasympathomimetic to ganglionic 
blocking activity. Doses expressed in ¿¿mol 2 kg. 
ganglionic cholinomimetic activities to parasympathetic and ganglionic 
cholinolytic activities. These expectations were confirmed experi-
mentally. As may be seen from fig. 4a, MeFMe3, MeFMe2Et and 
MeFMeEt2 behave as parasympathomimetics and MeFEt-, behaves as 
a ganglionic blocking agent. The parasympathomimetic actions can be 
prevented by atropine (5 /u.mol kg) (See FIG. 4e). In extreme high doses 
MeFMe3 and MeFMe2Et may produce a ganglionic stimulation. These 
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drugs have a large positive log affinity ratio and hence are specific para-
sympathomimetics. After atropinization, the parasympathomimetic ac-
tions of MeFMeEt2 turn into ganglionic blocking actions, the log affinity 
ratio is positive. MeFEt3 behaves as a ganglionic blocking agent in the 
same dose before and after atropine. Since this drug does not exhibit 
parasympatholytic actions in the dose used, the log affinity ratio is 
negative. Thus as a consequence of ethylation in the MeFR3 series the 
parasympathetic affinity decreases in a large measure while the ganglionic 
affinity hardly alters (TABLE II). Hence there is a gradual change from 
parasympathetic into ganglionic drugs. In the meantime the intrinsic 
activity decreases gradually for both the parasympathetic and the 
ganglionic receptors, but more for the latter than for the former. As a 
result of ethylation, specific parasympathomimetic activities gradually 
change into ganglionic blocking activity. MeFEt3, with a negative log 
affinity ratio, might exert parasympatholytic actions in high concen-
trations. Compare its actions on the frog heart (TABLE II). 
A similar change in the mode of action is observed in the Me2FR3 
series (TABLE II). In this series the ganglionic actions are more pro-
nounced owing to a low parasympathomimetic affinity of these drugs. 
Thus Me2FMe3 is a parasympathomimetic (high i.a.) and in higher 
concentrations a ganglionic stimulant (cholinomimetic). Me2FMe2Et is 
a parasympathomimetic and ganglionic stimulant in the same dose range. 
Me2FMeEt2 and Me2FEt3 are ganglionic blocking agents (cholinolytics-). 
Thus in the Me2FR3 series, also ethylation gradually changes para-
sympathomimetic activities into ganglionic blocking activities, owing to 
a decrease of the affinity ratio and to a decrease of the intrinsic activity 
at the parasympathetic and ganglionic ACh-receptors. 
Investigation of the R'FMe3 series on parasympathetic receptors of, 
for instance, the intestinal smooth muscle (See this thesis CHAPTER III) 
showed that elongation of the alkyl chain R' results in a gradual decrease 
of the intrinsic activity with the consequence that parasympathomimetic 
actions gradually change into parasympatholytic competitive antagonistic 
actions. When the drugs were investigated on the ACh-receptors of 
skeletal muscle, however, elongation of R' gave rise to a gradual change 
from cholinomimetics into non-competitive antagonists. It is therefore 
expected that when the R'FMe3 series is studied on the blood pressure 
a gradual change from parasympathomimetic to parasympatholytic 
actions and simultaneously a gradual change from ganglionic stimulants 
to competitive or possibly non-competitive ganglionic blocking agents 
will be found. In analogy with drugs which influence neuro-muscular 
transmission there may exist three types of ganglionic drugs : a) chohno-
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mimetics (ganglionic stimulants); b) cholinolytics (competitive anta­
gonists) c) non-competitive antagonists. 
The expectations were confirmed experimentally. Thus HFMe 3 , 
MeFMe 3 , EtFMe 3 and PrFMe 3 are parasympathomimetics (high i.a.). 
The affinity shows an optimum at MeFMe 3 and gradually decreases 
with further elongation of R'. 
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Parasympathetic and ganglionic effects of the R'FMe 3 series on the carotid blood 
pressure of the anaesthesized cat (30 mg kg pentobarbitone-Na, B.P.). The lower homo­
logues ( H F M e 3 to PrFMe 3 ) behave as parasympathomimetics, while HexFMe 3 is 
ganglionic blocking agent. As a result of the biological variation of the affinity ratio and 
the values of the intrinsic activties at the parasympathetic and ganglionic ACh-receptors, 
BuFMe 3 > which has an intermediate affinity ratio and intrinsic activity, exerts ganglionic 
stimulating (in 56) or parasympathomimetic (50) actions. When the parasympathomimetic 
actions are prevented by atropine the lower homologues e.g. PrFMe 3 , in higher con­
centrations than under (b) produce ganglionic stimulating actions which are manifested 
as long-lasting blood pressure rise. Note also in this series a gradual change from para­
sympathomimetic to ganglionic blocking activity. Doses expressed in μπιοΙ/2 kg. 
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These drugs are devoid of ganglionic activities and therefore have a 
positive affinity ratio (F IG. 5a, ¿>). BuFMe3 is an intermediate compound 
and exerts parasympathetic and ganglionic activities at the same dose 
range. Owing to the biological variation with respect to the affinity 
ratio, BuFMe3 is a parasympathomimetic in one animal (FIG. 5a) and 
a ganglionic stimulant (FIG. 5e) in another. BuFMe3 has an intermediate 
i.a. at both the ganglionic and parasympathetic receptors which is 
variable with the various animal preparations. BuFMe3 may therefore 
behave as a cholinomimetic or as a cholinolytic at both parasympathetic 
and ganglionic ACh-receptors. With the higher homologue HexFMe3 
the intrinsic activity and the parasympathetic affinity are further lowered. 
Thus HexFMe3 behaves as a ganglionic blocking agent (F IG. 5a). 
Possibly the appearance of gangliolytic action of BuFMe3 and higher 
homologues has to be attributed to the introduction of non-competitive 
ganglionic blocking activities instead of a decrease of the intrinsic 
activity. From these experiments it is not possible to decide whether 
HexFMe3 is a competitive or a non-competitive ganglionic blocking 
agent. Thus with elongation of the alkyl chain R' in the R'FMe3 series 
there is a gradual decrease of the affinity ratio accompanied by a gradual 
decrease of the intrinsic activity at the parasympathetic ACh-receptors 
and possibly also at the ganglionic ACh-receptors. From table II it may 
be seen that MeFMe3 has the largest affinity ratio and hence is the most 
specific parasympathomimetic. 
As expected, an analogous change from parasympathomimetic activity 
to ganglionic blocking activity is obtained in the R2FMe3 series with 
elongation of R'. 
Thus Me2FMe3 and Et2FMe3 are parasympathomimetics, high i.a. 
and positive affinity ratio. In iPr2FMe3 the affinity ratio is decreased 
but still positive. The higher homologues are already ganglionic blocking 
agents. Bu2FMe3 is also a parasympatholytic in larger doses. Consistent 
with the findings on isolated organs (e.g. frog heart), the parasympatho-
lytic activity increases with elongation of R' in the R2FMe3 series. 
Pr2FMe3 is therefore the most specific ganglionic blocking agent (lowest 
affinity ratio) in this series. 
It has been observed by SCHUELER et al. (1952) that the dibromide 
of 2-(trimethylammonium)ethyl 3-(trimethylammonium)propionate is a 
ganglionic stimulant. It may be expected that successive replacement of 
methyl groups by ethyl groups in the latter drug will result in a gradual 
change from ganglionic stimulant to ganglionic blocking agent. For 
this purpose the following " Racet " analogues were used : 
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R 3 N+—(CH 2 ) t —С—O—(CH.) 2 —N+R, Code : RacetR, 
Experimentally it was found that RacetMe3 and RacetMe2Et have 
parasympathomimetic activities, while in higher concentrations RacetMe3 
behaves as a ganglionic stimulant. RacetMe2Et sometimes acts as a 
ganglionic stimulant, but in the most cases as a ganglionic blocking 
agent, which may be due to the fact that RacetMe2Et at the ganglionic 
receptors has a lower intrinsic activity than RacetMe3. The higher 
homologues, RacetMeEt2 and RacetEt3, are evidently ganglionic blocking 
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the numbers marked with * the confidence range is wider since only a few estimations 
were made. 
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TABLE II 
frog heart arterial blood pressure of the cat 
Drug 
parasympathetic 
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ganglionic 
activity 
intr, I 
I 
I intr. 
I act. I log aff. (l) | act. 
MeFMe3 
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RacetMe, 
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(aff. ratio) 
> 3 
> 3 
1.6 
< о 
2.0 
I.I 
< о 
< о 
I . I 
> o 
< o 
< о 
С). ("). С) Compare table I. 
agents (TABLE II). The Racet compound of SCHUELER et al. (1952) 
which they found to be a ganglionic blocking agent probably is not 
2-(triethylammonium)ethyl 3-(triethylammonium)propionate but in view 
of the synthesis used by them, rather triethylammonium bromide. 
It has been suggested that ganglionic ACh-receptors have a greater 
resemblance to ACh-receptors in skeletal muscle than to parasympathetic 
receptors (GOODMAN and GILMAN 1955). If this is true HexFMe 3 and 
Pr 2 FMe 3 may be non-competitive ganglionic blocking agents. Actually, 
on the frog rectus abdominis muscle they are non-competitive anta­
gonists of cholinomimetics (See this thesis CHAPTER II). On the basis 
of structure-action relationships it may be expected that ganglionic 
blocking agents with a structural formula such as those of chlorisonda-
mine and compound 139C55 (ADAMSON et al. 1956) will be non-com­
petitive antagonists of ACh at least on the skeletal muscle. 
With experiments on the blood pressure it is not possible to estimate 
whether a ganglionic blocking agent is a competitive or a non-competitive 
antagonist of ACh. A number of ganglionic agents were studied as 
antagonists of cholinomimetics on the frog rectus abdominis muscle. 
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EXPERIMENTS WITH FROG RECTUS MUSCLE 
The rectus abdominis muscle of the frog is a suitable object for in­
vestigating ganglionic drugs since ganglionic stimulants produce a con­
tracture and ganglionic blocking agents can be studied as antagonists. 
In the RacetR3 series the gradual decrease of the intrinsic activity 
as result of successive ethylation of RacetMe3 could be demonstrated 
on the frog rectus more quantitatively than on the blood pressure. 
(See F I G . 6). From this figure it follows that RacetMe3 is an agonist 
with high intrinsic activity. This is remarkable from a chemical point 
Fie. 6a, ft, с 
Cumulative concentration response curves on the frog rectus abdominis muscle for 
the RacetRg series. 
In fig. 6a, successive ethylation results in a gradual decrease in the intrinsic activity 
from unity for RacetMe3 to zero for RacetMeEt2 and RacetEt3. 
In fig. 6ft, e, the cumulative log concentration-response curves for a cholinomimetic 
(octamethylenebis(carbamylcholine), ВС,) are shifted in a parallel manner by constant 
concentrations of RacetMeEt2 and RacetEt3 (competitive antagonism). 
of view, since hexamethonium, in which the chain length separating 
the onium groups is the same as in RacetMe3, has a low intrinsic activity. 
Probably this is accounted for by the electro-negativity of the ester 
group in RacetMe3. Compare, analogously suxamethonium and deca-
methonium (ARIENS et al. 1956α, and this thesis CHAPTER II). In 
RacetMe2Et the intrinsic activity is lowered while the higher homologues 
are devoid of contracturing properties. From figs, bb and с it may be 
seen that RacetMeEt2 and RacetEt3 are competitive antagonists of 
cholinomimetics. 
Hexamethonium is a competitive antagonist of cholinomimetics on 
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the rectus abdominis muscle also (ARIËNS et al. 1956α). Ganglionic 
blocking agents with small substituents on the quaternary nitrogen 
atoms, as for instance pentapyrrolidinium and pentapiperidinium, behave 
as competitive antagonists of cholinomimetics (See also F I G . 7). These 
drugs produce a shift of the log concentration-response curves for an 
agonist. 
°/ocontracture ι 1 1 
FIG. ja, b, с 
Cumulative log concentration-response curves on the frog rectus abdominis muscle 
for a cholinomimetic (BuN+Me
a
) in the presence of constant concentrations of some 
ganglionic blocking agents. These ganglionic blocking-agents, which contain small sub­
stituents on the quaternary nitrogen atoms, cause a parallel shift of the curves for the 
agonist. They are therefore competitive antagonists of cholinomimetics. 
Chlorisondamine and Cxg2i3 (GOLDBERG et al. 1957) contain a large 
substituent on one N +—atom. They are therefore expected to be non­
competitive antagonists. This was confirmed experimentally (see F I G . 8a, 
b). The non-competitive antagonistic properties have been found to be 
correlated with the surface activity of the compounds. From a com­
parison of the molecular configurations of hexamethonium, azametho-
nium (" pendiomide ") with chlorisondamine and Cxg2i3 it is evident 
that the latter drugs have a stronger surface activity than the former. 
Also mecamylamine which contains only one onium group will have 
a higher surface activity than hexamethonium, and mecamylamine has 
been found to behave as a drug with a dualism in antagonism. In fig. 8r 
the non-competitive antagonistic action of mecamylamine is seen as a 
decline in the slope and a decrease of the maximal height while the 
shift in the curves for the agonist indicates some competitive antagonistic 
actions. Extensive studies have revealed that the ganglionic action of 
mecamylamine is different from that of, for instance, hexamethonium 
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(BENNET et al. 1957), which is possibly accounted for by the non­
competitive antagonistic properties of this drug. 
Ganglionic blocking agents (e.g. hexamethonium) have a very low 
affinity when studied as antagonists of acetylcholine on intestinal smooth 
muscle. They are therefore practically devoid of atropine-like properties. 
This was substantiated by experiments on the rat jejunum for the 
ganglionic blocking agents mentioned. 
They were as little active as hexamethonium in this respect, except 
Cxg2i3 which was about ten times more potent. 
KT'mmol/l Ю1 Ю"4 lO^mmol/l IGT* IO-»mmol/l 10'* 
Fie. 8a, ¿>, с 
Cumulative log concentration-response curves on the frog rectus abdominis muscle 
for a cholinomimetic (BCg) in the presence of constant concentrations of some ganglionic 
blocking agents. Contrary to the shift in the curves produced by the ganglionic blocking 
agents of fig. 7, these drugs, which contain a large substituent on one quaternary nitrogen 
atom, cause a decline in the slope of the curves and a decrease of the maximal height. 
Therefore the ganglionic blocking agents chlonsondamine (FIG. 8a) and Cxgzi3 (Fie. 6b) 
are non-competitive antagonists of cholinomimetics while mecamylamine (FIG. 8C) in 
addition to its non-competitive action shows slight competitive antagonistic properties. 
DISCUSSION 
The affinity and the intrinsic activity are essential parameters in the 
study of structure-action relationships. The affinity in a strict sense 
is inversely proportional to the dissociation constant of the drug-receptor 
complex. In the experiments the relationship between the dose of the 
drug applied and the concentration of the drug in the immediate vicinity 
of the receptors has an influence on the affinity. This holds especially 
in the case of in-vivo experiments. Therefore experiments with isolated 
organs are preferable to those with intact animals in order to find the 
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essential molecular configurations for the affinity and intrinsic activity. 
In the investigation of parasympathomimetic drugs of the R'FMe3 series, 
the correlation between the molecular structure and the affinity was 
found to be similar for the in-vitro (frog heart) and the in-vivo test 
(cat's blood pressure). This implies that in this case the affinity is 
mainly determined by the dissociation constant of the drug-receptor 
complex. The intrinsic activity is in no way dependent on the relationship 
between the dose of a drug added and the amount of receptors occupied. 
At the level of both the motor end-synapse and the parasympathetic 
end-synapse as well as the ganglionic synapse, the effect of cholino-
mimetics (high i.a.) is preceded by a depolarization of the cell mem-
brane. The cholinolytics which do not induce a depolarization have low 
intrinsic activity. It is logical to assume that the onium groups in the 
cholinomimetics are responsible for this electro-physiological event. The 
introduction of heavier groups in cholinomimetics is followed by a 
decrease of the intrinsic activity. It is therefore justifiable to put forward 
the hypothesis that irrespective of the localisation of the ACh receptors, 
the intrinsic activity of cholinomimetics is connected with the effectivity 
wherewith the positive charge of the onium group can interfere with 
the electric field of the receptor. 
The specificity of cholinomimetic and cholinolytic drugs depends on 
the ratios of the affinities to the various ACh-receptors. Drugs with a 
high affinity ratio are specific, as for instance the parasympathomimetic 
MeFMe3 (see TABLE II). 
In the regulation of the blood pressure, both parasympathetic and 
ganglionic ACh-receptors are involved. 
Alterations of the molecular structure of the quaternary onium group 
which cause a change in the intrinsic activity may also change the ratio 
of the affinity for parasympathetic and ganglionic receptors. Thus it is 
found that when in the parasympathomimetic, MeFMe3, methyl groups 
are successively replaced by ethyl groups, the intrinsic activity decreases 
progressively at both receptor systems. Since for the higher homologues 
the affinity ratio decreases simultaneously, ganglionic properties become 
manifest before parasympatholytic actions are obtained. In such a homo-
logous series, the drugs with intermediate intrinsic activity and inter-
mediate affinity ratio are of special interest. Owing to the biological 
variation, drugs with intermediate intrinsic activity or affinity ratio may 
produce a different mode of action on different animals of the same 
species. So, for instance, BuFMe3 behaves as a parasympathomimetic, 
as a ganglionic stimulant, or as a ganglionic blocking agent. Drugs 
with a high intrinsic activity always are cholinomimetics, those with a 
J 3 2 
low intrinsic activity are cholinolytics. Drugs with high affinity ratio 
behave as parasympathetic drugs and those with low affinity ratio behave 
as ganglionic drugs. 
It is useful to stress here that a gradual decrease from mimetics to 
lytics (competitive antagonists) is always accounted for by a decrease 
in the intrinsic activity irrespective of whether or not the receptor 
occupation is describable with the Michaelis and Menten equation and 
irrespective of whether the effect is a linear or non-linear function of 
the number of receptors occupied (thesis CHAPTER I). 
SUMMARY 
On the basis of theories concerning drug-receptor interactions (ARIËNS 
et al. 1956a, b, 1957α, thesis CHAPTER I) the molecular pharmacology 
of some series of quaternary parasympathetic and ganglionic drugs 
was studied on the cat's blood pressure, on the isolated frog heart and 
on the isolated rectus abdominis of the frog. 
The essential parameters, intrinsic activity (i.a.) and parasympathetic 
and ganglionic affinity, vary with the molecular configuration of the 
drugs. 
The experimental findings give good support for the hypothesis that 
at the ganglionic ACh-receptors also the intrinsic activity is connected 
with the effectiveness wherewith the positive charge of the onium group 
can interfere with some part of the electric field of the receptor. This 
hypothesis holds as a general principle for all ACh-receptors of the 
peripheral autonomic and motor nervous systems. 
Both at the ACh receptors of the myoneural junction, the parasym­
pathetic synapse and the ganglionic synapse, cholinomimetic drugs (high 
i.a.) gradually change into cholinolytic drugs (low i.a.) as a consequence 
of introduction of heavier groups on the quaternary nitrogen atom. 
Thus it always holds that successive replacement of methyl groups by 
ethyl groups in cholinomimetics results in a progressive decrease of 
the intrinsic activity. 
When with a certain effect, as for instance the blood pressure, different 
ACh-receptors are involved, changes in the molecular structure (e.g. 
ethylation) may alter not only the intrinsic activity but also the affinity 
ratio for parasympathetic and ganglionic receptors. Thus ethylation of 
quaternary 1 : 3-dioxolanes (e.g. MeFMe 3) results in a gradual change 
from parasympathomimetic to ganglionic blocking activity. 
Drugs which influence neuro-muscular transmission can be divided 
13З 
into three groups : Cholinomimetics (e.g. suxamethonium); cholino-
lytics or competitive antagonists of the mimetics (e.g. D-tubocurarine) 
and non-competitive antagonists (e.g. decamethylenebis (dimethylhepty-
Iammonium bromide) (See this thesis CHAPTER II). In an analogous 
way a distinction can be made for drugs which influence ganglionic 
transmission : cholinomimetics (e.g. nicotine, RacetMe3), competitive 
antagonists of the cholinomimetics (e.g. hexamethonium and other bis-
onium compounds with small substituents on the onium groups); or 
non-competitive antagonists (probably chlorisondamine and other onium 
compounds which contain a large substituent on an onium group). 
On the rectus abdominis of the frog, which is a suitable object for 
studying ganglionic and neuromuscular drugs, it was found that the 
ganglionic blocking agents of the cholinomimetic type are contracturing 
agents. Those of the cholinolytic type are competitive antagonists of 
cholinomimetics while chlorisondamine Cxg2i3 and mecamylamine be­
have as non-competitive antagonists. 
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CHAPTER V 
SYNTHESIS OF QUATERNARY AMMONIUM SALTS 
INTRODUCTION 
Since the discovery that bis-quaternary ammonium compounds are 
neuromuscular and ganglionic blocking agents, the number of quaternary 
ammonium compounds synthesized has increased enormously (BARLOW 
and ING 1948, PATON and ZAIMIS 1949, PHILLIPS 1949-1951, FAKSTORP 
et al. 1953-1954, Fusco et al. 1949, DELABY et al. 1955, ARCHER et al. 
1956). 
In general, quaternary ammonium salts are prepared from a tertiary 
amine and an alkyl halide. According to the reactivity of both the amine 
and the halide, more or less polar solvents have to be used. Often 
methanol will be polar enough. If the ability of the amine or the halo-
genide to react is small, the polar solvent dimethylformamide is useful 
(ING 1957). If for any reason a polar solvent cannot be used, it is necessary 
to heat the mixture for several hours. 
The principles of the preparation of various kinds of quaternary 
ammonium salts and possible intermediaries are described below. 
DECAMETHONIUM DERIVATIVES 
It was discovered by PATON and ZAIMIS in 1949 that decamethylenebis-
quaternary ammonium compounds exert a neuromuscular blocking 
action. From theoretical considerations, a series of new and already 
known decamethonium homologues was prepared. 
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a) Halides of ι : io-bis (dìmethylalkylammonium) decane. 
For the preparation of the lower alkyl homologues the following 
reaction scheme was used. 
i) Br-(CH2)10-Br + 2 N H M e , - • Me2N-(CH2)10-NMe2 .2 HBr 
2) Me2N-(CH2),0-NMe2 + 2 RI - * Me2RN+-(CH2)10-N+RMe2.2 I" 
1 ) 1 : io-bis (dimethylamino) decane was prepared by heating a mix-
ture of 0.1 mol 1 : 10-dibromodecane, 0.35 mol dimethylamine and 
50 ml methanol for 20 hours in a sealed tube on a water bath. When 
instead of methanol, dimethylfcrmamide was used, heating over half 
an hour was sufficient. After cooling the reaction mixture was evaporated 
under reduced pressure. The residue was acidified with 4 N HCl and 
the solution was shaken twice with ether to remove any unreacted di-
bromide. After alkalizing with 4 N NaOH the amine formed, was 
extracted with ether. The combined ether layers were dried over K 2 C 0 3 
and Na2S04 , the ether removed and the final product distilled under 
reduced pressure. B.P. 162-164o С at 20 mm. Yield : 62 %. 
2) The iodide of 1 : io-bis (dimethylalkylammonium) decane was 
prepared by heating a mixture of 0.01-0.02 mol of 1 : io-bis(dimethyl-
amino) decane, 0.03-0.06 mol alkyl iodide and 20-40 ml methanol for 
5-15 hours in a sealed tube on a water bath. The reaction product was 
crystallized from ethanol-acetone-ether mixtures. The yields were good 
70-90 %. Acetone was especially useful in removing the brown colour 
of oxidized iodide. Data on the compounds are given in table I. For 
the homologue in which R is pentyl the following scheme was used. 
3) RBr + N H M e , -»- RNMe 2 .HBr 
4) 2 RNMej + Вг-(СН2)10-Вг->- Me 2 RN+-(CH 2 ) 1 0 -N+Me 2 R.2 Br" 
3) The RNMe 2 amines were prepared as described under 1), except 
that benzene was used as a solvent instead of methanol. 
4) The quaternary ammonium salts were prepared by heating a mix­
ture of 0.01 mol of 1:10-dibromodecane and 0.03 mol of the tertiary 
amine in methanol for 30-40 hours in a sealed tube on a water bath. 
Crystallization from acetone-ethanol-ether mixtures. The data are given 
in table I. 
b) Halides of 1 : io-bis (N-methylcyclinium) decane. 
The decamethonium compounds in which cyclinium is pyrrolidinium, 
piperidinium or morpholinium were prepared according to the reaction 
scheme given for the pyrrolidinium compound. (LIBMAN et al. 1952, 
TAYLOR 195 I ) . 
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і) A mixture of 0.05 mol ι : io-dibromodecane and 0.15 mol cycline 
(pyrrolidine, piperidine or morpholine) in 20 ml methanol, was heated 
for 20-30 hours in a sealed tube on a water bath. The reaction mixture 
was evaporated to dryness. The residue was acidified with 4 N HCl 
and shaken twice with ether. After alkalinization with 4 N NaOH it 
was extracted with ether. The ether layers were dried over K 2 C 0 3 and 
N a 2 S 0 4 . The tertiary amine was used without further purification. 
2) Approximately 0.02 mol of the crude tertiary amine 1) was refluxed 
with 0.06 mol CH3I in methanol solution for one or two hours. The 
final product was crystallized from ethanol-acetone-ether mixtures. Data 
are presented in table I. The yields were good 80-90 %. 
c) Halid.es of 1 : io-bis (trialkylammonium) decane. 
The reaction scheme for the preparation of these compounds is : 
Вг-(СН2)10-Вг + Î R , N - > R3N+-(CH2)10-N+R3 . 2 Br 
A mixture of 0.01-0.02 mol of 1 : io-dibromodecane, 0.03-0.06 mol 
of R3N and 40 ml dimethylformamide was heated on a water bath for 
2 hours in a sealed glass tube. The final product was crystallized from 
ethanol-acetone-ether mixtures. Data are given in table I. 
DlCARBOXYLIC ACID B I S - 2 - ( T R I A L K Y L A M M O N I U M ) E T H Y L A M I D E S 
The quaternary ammonium ethylamides of aliphatic dicarboxylic acids 
have a weak neuromuscular blocking action (PHILLIPS 1950, 1951). These 
drugs, which will be designated as D„AR3I, were prepared with good 
IS» 
TABLE I 
Decamethonium derivatives 
Compound 
C10NMe2iPrI 
C,0NMe2nPrI 
С 1 (^Ме гпВи1 
C1(,NMe2nPentBr 
CioNMejnHexI 
C1 0NMe2nHeptI 
C1 0NMe2nDecBr 
C10PipMeI 
C10MorfMeI 
C10PyrrolidMeI 
C10NEt3Br 
C,„NPr
s
Br 
C10NBu3Br 
m.p. °C 
htt. 
— 
— 
— 
— 
— 
— 
— 
248») 
217-218») 
246-247 ») 
235 b ) 
_ 
m.p. °C 
uncorr. 
240 
198 
164 
.67 
145 
134 
_ 
263-264 
216-218 
249-250 
222-223 
182-183 
H С 
cale. I found cale. 1 found 
8.11 7.88 42.25 
8.11 , 8.26 42.25 
8.40 8.25 
10.28 10.48 
8.95 
9.14 
8.54 
8.57 
44-3 
54.2 
47-9 
49-4 
11.13 11.16 60.85 
41-58 
42.35 
44.2 
54-0 
46.9 
48.7 
59-52 
7.83 7.78 . 44.58 ' 44.19 
7.10 7.II 
7-5° 
— 
7-49 
— 
1 
— 
40.26 
42.54 
— 
40.05 
42.64 
— — 
— 
Rj-value 
68») 
74 
77 
82 
85 
86 
86 
73 c) 
46 
64 
46") 
68 
81 
a ) Taylor 1951. 
b) Barlow and Ing 1948. 
c) eluent Butanol : Acetic Acid : water : dimethylformamide = 16 : 2 : 1 : 1. 
d ) eluent Butanol : ethanol : water = 5 : 3 : 1 . 
yields according to the procedure of PHILLIPS (1951) as represented in 
the following scheme : 
1) EtOC-(CH2)„-COEt -J- 2 NH2-(CH2)2-NMe2 -» 
II II 
о о 
Me2N-(CHt)1-NH-C-(CH2)„-C-NH-(CH2)J-NMe2 + 2 EtOH 
II II 
о о 
2) Me2N-(CH2)2-NH-C-(CH2)„-C-NH-(CH2)2-NMe2 + 2 RI - * 
Il II 
о о 
Me2RN+-(CH2VNH-C-(CH2)n-C-NH-(CH2)2-N+RMe2 . a l ­
lí II 
о о 
i) A mixture of o.i mol of a diethyl dicarboxylate and 0.35 mol 
dimethylethylenediamine was refluxed for 5-10 hours at a temperature 
of 150o С on a sand bath. After the ethanol formed had been removed 
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under reduced pressure, the viscous liquid became solid. Crystallization 
from ethyl acetate gave white crystals, which were used as such for 
the next step of the reaction. Yield 60-80 % of the theory. 
2) A mixture of 0.01-0.02 mol of the tertiary amine as prepared 
under 1), 0.05-0.1 mol of an alkyl iodide and 10-40 ml anhydrous 
methanol was heated for one or two hours on a water bath. The final 
product was crystallized from ethanol-acetone-ether. Data on these com­
pounds are presented in table II. Yield 80-90 %. 
R A C E T D R U G S 
Racet or the dibromide of the 2-(triethylammonium)ethyl ester of 
3-(triethylammonium) propionic acid was introduced by SCHUELER et 
al. (1951) as a new ganglionic blocking agent. Racet analogues were 
prepared according to a procedure as represented in the next scheme, 
which differs from the method of SCHUELER et al. (1954). 
ι) ВГ-(СН2)2-С-0-(СН2)2-ВГ + 2NHR2 -• RjN-CCHjVC-CMCH^-NRj . г НВг 
II II 
о о 
г) R2N-(CH2)2-C-0-(CH2)2-NR2 + 2 R I -»· 
il 
О 
R'R2N+-(CH2)2-C-0-(CH2)2-N+R2R' . 2 I" 
л 
о 
ι) 2-(dialkylamino)ethyl 3-dialkylaminopropionates. Only the Racet 
R2 compounds were prepared in which R2 is Me 2 or Et 2. Slightly different 
procedures were followed for RacetMe2 and RacetEt2. 
RacetMe2; to 0.2 mol dry dimethylamine in a thick-walled glass tube 
under ice-salt cooling, a sealed thin-walled glass tube, containing 0.05 mol 
2-bromoethyl 3-bromopropionate was added. 
After sealing, the tube was vigorously shaken in order to smash the 
thin-walled glass tube. The reaction took place immediately. To com­
plete the reaction, the mixture was heated for half an hour. After cooling 
a saturated potassium carbonate solution was added, the tertiary amine 
was extracted twice with ether and the combined ether layers were 
dried over N a 2 S 0 4 . The ether was removed under reduced pressure. 
The residue was dissolved in 40 ml acetone and the acetone solution 
was used for the next step of the reaction. 
RacetEt2; a mixture of 0.05 mol 2-bromoethyl 3-bromopropionate and 
0.20 mol diethylamine dried over sodium, was heated on a water bath 
140 
for 5 hours in a sealed tube. After completion of the reaction, the same 
procedure as for RacetMe2 was used. 
2) The diiodide of the 2-(trialkylammonium)ethyl ester of 3-(trial-
kylammonium) propionic acid (RacetR3I). A mixture of 20 ml of the 
RacetRjj solution (prepared as described under 1) was refluxed with 
excess R'l (R' = Me or Et) for one hour. The final product was crystal­
lized from methanol or ethanol-acetone, and ether, or mixtures of these 
solvents. The RacetMe3I had a very salt-like character and was there­
fore only slightly soluble in hot ethanol. RacetEt3I was not crystallized 
TABLE II 
Quaternary amides and Racet derivatives 
S i 1 r»ct"iir>r*p 
k.J LILJolallt*^ 
D„AMe3I 
D,,AMe2EtI 
ОгАМезІ 
D2AMe2EtI 
D2AMe2nPrI 
D2AMe2PentI 
D,AMe,I 
D4AMe2EtI 
RacetMe
s
I 
RacetMe2EtI 
RacetMeEtjI 
RacetEtjI 
m.p. °C 
litt. a) 
288-290 
256-260 
251-252 
189-190 
— 
203-304 
— 
— 
— 
— 
' — 
m.p.uC 
uncorr. 
283-285 
247-248 
241-243 
I 8 I - I 8 3 
I70-I7I 
! 119-121 
196-198 
114-117 
182 
165 
•Si 
181 
cale. 
, — ! 
— 1 
— , 
— 
i 6.7 1 
! 7 ' 4 
6.7 
5-52 
6.00 
6-45 
6.96 
! found 
1
 -
— ! 
— 
1 
6.5 
7-4 
— 
6.5 
5-59 
6.27 
1 ¿ 6.43 
6.86 
cale. 
1 
— 
36.2 
40.1 
— 
36.2 
27.96 
3I-I5 
34.05 
3 9 6 9 
found ' 
i — 1 
! - 1 
t — 1 1 
1 
' 35-4 
39-7 
— , 
36.0 | 
I 
1 
28.26 
30.70 1 
34-01 ] 
35-72 , 
Rr-
value b) 
57 
65 
62 
67 
76 
84 
69 
72 
32 
44 
53 
62 
m) Phillips 1955. 
·>) Eluent ІРЮН : AcOH : H 2 0 : Dimethylformamide = 4 : 1 : 2 : 1 for the D nAR3I 
series and 
BuOH : EtOH : H 2 0 = 5 : 5 : 2 for the RacetR3I series. 
from alkohol mixtures since it easily hydrolizes. Data on these compounds 
are given in table II. 
In order to prepare also the dibromide of RacetEt3 a mixture of 0.05 
mol 2-bromoethyl 3-bromopropionate, 0.2 mol NEt 3 dried over sodium 
and 20 ml dimethylformamide was heated over half an hour. A good 
yield of white crystals was obtained which appeared to be identical with 
Schuelers RacetEt3Br (m.p. 245o С). The microanalysis, the estimation 
of the RF value and the pharmacological test, however, revealed that 
this compound evidently is not a RacetEt3 salt but HNEt 3 Br. 
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QUATERNARY DIOXOLANES 
Some quaternary ι : 3-dioxolanes were investigated by FOURNEAU et 
al. 1944, a n d B R O W N and W E R N E R 1949. H e r e the preparat ion is pre­
sented of a large n u m b e r of mainly new 1 : 3-dioxolanes. 
Iodides of 2-a.lh.yl-4- (trialhylammonium) methyl-1 : 3-dioxolanes. 
FOURNEAU et al. (1945) prepared a series of amino-acetals, some of 
which show acetylcholine-like propert ies . T h e iodide of 2-methyl~4-
( t r imethy lammonium) methyl-1 : 3-dioxolane is as active as m u s ­
carine ( F O U R N E A U et al. 1944). I n h o n o u r of FOURNEAU t h e 2-alkyl-4-
(tr ia lkylammonium) methyl-1 : 3-dioxolanes are designated as R ' F R 3 I . 
T h e preparat ion is represented in t h e following scheme. 
1) О—С О—С 
W / \ 
С + С • С С (R'FCl) 
/ Ч \ / \ / \ 
R' О С-С1 R' О С-С1 
2) О—С О—С 
/ \ / \ 
С С + HNRj • С С (R'FRa) 
R' О С-С1 R' О C-NR, 
3) О—С О—С 
/ \ / \ 
С С + RI > С С (R'FR.I) 
R' О C-NRj R' О C-N+R, . Г 
2-alkyl-4-chloromethyl-i : 3-dioxolane. 
T h e procedure of Willfang was used for t h e preparat ion of all R ' F C l 
c o m p o u n d s , except for H F C l ( B E R S I N and W I L L F A N G 1937, W I L L F A N G 
1941). T o 25-30 ml C C 1 4 in a i-l itre three-necked flask equipped with 
a mechanical st irrer was added a solution of 0.5-1.0 mol of an aldehyde 
and 0.55-1.1 mol epichlorohydrin in 50-100 ml C C 1 4 s imultaneously 
with a solution of 5-10 ml S n C l 4 in 25-50 ml CC1 4 . T h e t e m p e r a t u r e 
was held between 20 and 2 5 o С by cooling. If t h e tempera ture rises 
too m u c h , large a m o u n t s especially of the shorter chain aldehydes are 
polymerized. Often the reaction mixture acquires a slight yellow to 
brown colour. After the solutions have been added, the reaction was 
complete. T h e n the catalyst S n C l 4 was destroyed with 4 N N a O H , 
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added at such a rate that the temperature was kept below 30o С. The 
aqueous layer was extracted twice with CC14 and the combined CC14 
layers were dried over N a 2 S 0 4 , the carbon tetrachloride was removed 
by evaporation and the final product distilled under reduced pressure. 
The HFCI compound was prepared according to the procedure given 
by FOURNEAU et al. (1945). Equimolar amounts of a-monochlorohydrin 
and an aqueous solution of formaldehyde (40 % v /
v
) were heated in 
a sealed tube on a water bath for 60 hours. The mixture was steam-
distilled at atmospheric pressure. HFCI was separated from the water 
layer, dried over N a 2 S 0 4 and distilled under reduced pressure. Data 
are given in table III . 
TABLE III 
4-chlorometkyl-i : 3-dioxolanes 
Substance 
HFCI 
MeFCl 
EtFCl 
PrFCl 
BuFCl 
HexFCl 
PhFCl 
PhMeCFCl 
Me.FCl 
Et
s
FCl 
iPr 2FCl 
Pr 2 FCl 
Bu 2FCl 
PhjFBr 
C4FCI 
C5FCI 
literature 
b.p. 
•C/mm H g 
54/20 
56/16 
65-70/18 
79-85/14 
— 
123/14 
164/40 
— 
64/2S 
82-85/20 
— 
— 
— 
159-167/2-3 
— 
— 
m 
С) 
С) 
С) 
С) 
С) 
С) 
(с) 
(с) 
found 
b.p. 
•C/mm Hg 
45-48/15 
61-64/34 
5З-65/11 
74/13 
89-91/15 
120-122/12 
158-163/40 
155/іг 
50/I7 
91-21 
94-96/13 
i io/ i8 
137-140/18 
155-160/2 
97-98/16 
122-125/30 
yield 
i n % 
42 
4 0 
62 
56 
57 
52 
56 
30 
55 
58 
35 
66 
49 
60 
7г 
7S 
(a) Fourneau et al. 1945 (b) Bersin et al. 1937 (c) Willfang 1941 
2 : 2-Dialkyl-4-chloromethyl-i : 3-dioxolanes (R^FCl) and 2 : 2-
poIymethyIene-4-chloromethyl-i : 3-dioxolanes (CnFCl), were prepared 
in essentially the same way as the R'FCl compounds from equimolar 
amounts of a ketone and epichlorohydrin. Data on R£FC1 and CnFCl 
compounds are given in table III. 
4 3 
2-Alkyl-4-(dialkylamino)methyl-i : 3-dioxolanes (R'FR2). 
For the preparation of all R'FR 2 compounds the procedure described 
by FOURNEAU et al. (1945) was used in a slightly modified form. To 
0.05-0.2 mol of a dioxolane chloride, R'FCl, under ice-salt cooling, 
0.15-0.5 mol of anhydrous HNR 2 and 10-30 ml benzene were added. 
The mixture was heated in a sealed tube on a water bath for 15-80 hours. 
The course of the reaction was followed by noting the amount of 
HNMe 2 .HCl that precipitated. As a rule the reaction with H N E t 2 was 
much slower than that with HNMe 2 . The preparation of RFEt 2 there­
fore required heating for a longer period. The precipitate formed was 
removed by suction and discarded. Unreacted H N R 2 was removed 
from the filtrate under reduced pressure, the residue was acidified with 
4 N acetic acid, while the temperature was carefully kept below 25 o С, 
since the dioxolanes are unstable especially in acid solution. The acid 
solution was extracted twice with ether to remove R'FCl. 
The solution was then alkalinized with 4 N NaOH and the R'FR 2 
compound extracted with ether. The combined ether layers were dried 
over K 2 CO a . The ether was removed and the final product was frac­
tionated under reduced pressure. If the tertiary amine is not carefully 
dried, the boiling point may be too low or a large fraction with a low 
boiling point may precede the required product, since the lower homo-
TABLE IV 
z-alkyl-\-(dialkylamino)methyl-i : 3-dioxolanes 
Substance 
H F M e , 
H F E t
s 
M e F M e
a 
MeFEt 2 
EtFMcj 
EtFEtj 
P r F M e 2 
PrFEtj 
BuFMe 2 
HexFMcj 
P h F M e 2 
PhMeCFMe 2 
literature · ) 
b.p. 
°C/mm Hg 
68/21 
106/60 
65/17 
— 
8 7 ' 2 5 
— 
— 
— 
— 
, 145 '40 
! 147/1З 
1 — 
found 
b.p. 
°C/mm Hg 
67-70/34 
75/13 
59-61/16 
75-82/15 
70/12 
85.Ί3 
89-91/16 
99-105/10 
94-99/13 
124Í28 
147/18 
155/14 
reaction 
time in hrs. ' 
60 
70 
50 
70 
50 
60 
45 
80 
45 
! 50 
40 
50 
yield 
in °„ 
63 
41 
47 
26 
70 
32 
72 
ЗІ 
73 
59 
38 
40 
') Fourneau et al. 1945. 
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TABLE V 
2 : z-dialkyl- and 2 : 2-polymethylene-4-(dialkylamino)methyl-i : j-dioxolanes 
Substance 
Me2FMe2 
Me2FEt2 
EtjFMe, 
iPrtFMe2 
PraFMej 
Bu,FMe, 
C4FMe2 
CsFMe, 
| 
j literature · ) 
b.p. 
°C/mm Hg 
1 64/25 
1 106/60 
1 — 
— 
— 
— 
! — 
1 — 
found 
b.p. 
°C/mm Hg 
74-75/54 
82 /12 
92 /14 
108/14 
118/20 
147-148/24 
100-101/14 
114-116/12 
reaction 
time 
in hrs. 
5 0 
7 0 
4 0 
45 
45 
45 
45 
3° 
yield 
in % 
68 
2 1 
63 
5* 
59 
5^ 
69 
62 
· ) Fourneau et al. 1945· 
TABLE VI 
Jodides of 2-alkyl-4-(írialkylammonium)methyl-\ : 3-dioxolanes 
Substance 
HFMe,I 
HFMe,EtI 
HFMeEtjI 
HFEt3I 
MeFMe3I 
MeFMe2EtI 
MeFMeEtJ 
MeFEt3I 
EtFMe,I 
EtFMe2EtI 
EtFMeEtjI 
EtFEtjI 
PrFMejI 
PrFMe2EtI 
PrFEtal 
BuFMejI 
HexFMe,I 
PhFMe,I 
PhFMejEtl 
m.p. °C 
litt. (») 
1 6 0 
— 
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1 4 1 
— 
— 
— 
1 2 8 
— 
— 
— 
— 
— 
— 
1 2 0 
155 
— 
m.p. °C 
uncorr. 
159 
I 2 I - I 2 3 
58-60 
137-139 
1 4 0 
— 
— 
75-79 
1 2 4 
— 
— 
76 
1 0 6 
— 
78 
94 
1 1 8 
I5S 
1 2 8 
Η 
cale. 
5·9ΐ 
6.32 
— 
7.04 
6.32 
6.69 
— 
7-35 
6.69 
— 
7.64 
7.04 
— 
7.З5 
— 
— 
— 
found 
6.00 
6.12 
— 
6.85 
6.19 
6-55 
— 
7.24 
6.57 
— 
— 
7 5 8 
6.86 
— 
— 
7.19 
— 
— 
— 
С 
_ 
cale. 
30.78 
ЗЗ.46 
— 
38.10 
ЗЗ46 
3589 
40.13 
3589 
— 
— 
4 1 9 9 
I 38.10 
— 
— 
4 0 1 3 
— 
' — 
ι 
found 
30.71 
33-17 
— 
37-94 
3 3 » 
35-72 
— 
39-44 
35-44 
— 
— 
41-73 
38.02 
— 
— 
3976 
— 
— 
-
Rf-
value (b) 
37 
4 1 
46 
48 
45 
53 
55 
57 
53 
58 
61 
63 
59 
65 
68 
63 
67 
57 
59 
(a) Foumeau (1945). 
(b) Eluent butanol : ethanol : water 5 : 5 : 2 . 
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logues especially pass over with water as azeotropic mixtures. Data on 
R'FR 2 compounds are given in table IV. 
2 : 2-Dialkyl(dialkylamino)methyl-i : 3-dioxolanes and 2 : 2-poly-
methyIene-4-(dialkylamino)methyl-i : 3-dioxolanes (R 2 FR 2 and CnFR 2 ) 
were prepared in essentially the same way as the R'FR 2 compounds. 
Data on these amines are collected in table V. 
Iodides of 2-alkyl-4-(trialkylammonium)methyl-i : 3-dioxolanes 
The R'FR 2 compounds were quaternized with an alkyl iodide in 
acetone solution. A mixture of 0.01-0.03 mol R'FR 2 and 0.03-0.1 mol 
RI in 20-50 ml dry acetone was refluxed for 10-60 minutes. Mel reacted 
almost immediately, while higher homologous alkyl iodides required 
TABLE VII 
Iodides of 2 : z-dialkyl- and 2 : z-polymethylene-^-(trialkylammomum) methyl-1 : 3 
dioxolanes 
Substance 
Me3FMe sI 
Me2FMe2EtI 
Me2FMeEt2I 
Me2FEt3I 
Et2FMe3I 
Et2FMe2EtI 
iPr
a
FMe3I 
iPr
a
FMe2EtI 
Pr2FMe3I 
PrjFMejEtl 
Pr2FMeEt2I 
Pr2FEt3I 
Bu 2FMe s 
Bu2FMe2EtI 
PhjFMe3Br 
C4FMe3I 
C4FMe2EtI 
CsFMe3I 
CsFMe2EtI 
m.p. °C 
litt, a) 
208 О 
— 
— 
ИЗ О 
— 
— 
— 
— 
— 
— 
— 
— 
210-12 ( ' ) 
— 
— 
— 
— 
m.p. °C 
uncorr. 
202-204 
1 2 7 
1 2 4 
1 4 5 
i S i 
74 
1 8 2 
1 9 9 
1 4 З 
84 
— 
164-165 
108-110 
65-68 
2 1 5 
151-152 
129-130 
131-132 
75-76 
H 
cale. 
— 
7.04 
— 
— 
7-35 
7.64 
7.90 
8.14 
7.90 
— 
— 
— 
8.37 
— 
— 
6.73 
7.09 
7.09 
7.38 
found 
— 
6.83 
— 
— 
7.25 
7-49 
7.66 
8.03 
7-52 
— 
— 
8.29 
— 
— 
6.65 
6.90 
6.89 
715 
С 
cale. 
— 
38.10 
— 
— 
40· 13 
41.99 
43-70 
45-28 
43-70 
— 
— 
4Ö-75 
— 
— 
40.03 
42.23 
42-23 
43-95 
found 
— 
37-28 
— 
— 
39-75 
41.84 
43-48 
44.96 
43.29 
— 
— 
— 
46.53 
— 
— 
39.87 
4 2 0 5 
41.30 
43.28 
Rf-value 
(8) 
4 2 
5 1 
55 
57 
55 
63 
66 
74 
67 
76 
82 
84 
78 
8 2 
75 
54 
57 
61 
64 
( l) Fourneau et al. 1945. 
(!) Blicke et al. 1952. 
(*) Eluent Butanol : ethanol : water = 5 : 3 : 1 . 
146 
refluxing for a longer time. The reaction product was crystallized from 
ethanol-acetone-ether. The trimethyl and triethyl derivatives could 
easily be obtained in a crystalline state, while the dimethylethyl and 
methyldiethyl compounds gave difficulties. The yields were good (80-
90 % ) . RF values and CH analysis were used as criteria for purity (') of 
the compounds. Paper chromatograms were made on Whatman No. 1 
paper, using various alcohol-water mixtures as eluents and a modi-
fied Draggendorffs reagent (THIES et al. 1954) as an indicator. Data 
about these compounds are collected in table VI. 
Iodides of 2 : 2-dialkyl-4-(trialkylammonium)methyl-i : 3-dioxolanes 
(R2FR3I) and 2 : 2-polymethylene-4-(triaIkylarnmonium)methyl-i : 3-
dioxolanes (CnFR3I) were prepared in essentially the same way as the 
RTR3I compounds. The Ph2FMe3Br compound was prepared according 
to a method of BLICKE et al. (1952). A sealed glass tube containing 
0.02 mol Ph2FBr and excess NMe3 in benzene was heated on a water 
bath for 60 hours. The Ph2FMe3Br compound precipitated as fine 
colourless needles. Data on R2FR3 and CnFR3 compounds are given 
in table VII. 
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SUMMARY 
Drugs are chemical agents, which applied in relatively small amounts 
interfere with the physiological and pathophysiological events of a bio-
logical object. Drug molecules therefore necessarily have to interact 
with specific molecules (receptors) in the biological object. The action 
of a drug can be studied by measuring and analysing dose-effects curves 
and time-effects curves. In view of the complexity of the biological 
object it is reasonable to distinguish three phases in drug action in 
order to get a good insight into the mechanism of action. 
i) The first phase represents the relationship between the amount 
of a drug applied and the concentration in the immediate vicinity of 
the specific receptors, i.e. the concentration in the biophase. This con-
centration is in part determined by resorption, biotransformation, break-
down etc. The concentration in the biophase is therefore strongly de-
pendent on the mode of application. In intact animals the concentration 
in the biophase is often time dependent. Using isolated organs makes 
it possible to reduce the influence of the resorption etc. to a large extent. 
In that case the concentration in the biophase often will be a linear 
function of the dose of the drug. 
2) The second phase concerns the reaction of the drug molecules 
with the specific receptors. The magnitude which determines the number 
of receptors occupied when equilibrium is reached after addition of 
a certain concentration is called the affinity. In addition to the number 
of receptors occupied the effectivity of the drug-receptor complex to 
induce the effect is of importance. This effectivity is presented by the 
intrinsic activity (ARIËNS 1950) which is the contribution to the effect 
per unit of drug-receptor complex. Both the affinity and intrinsic activity 
are of importance for the biological activity of a drug. According to 
the value of their intrinsic activity drugs can be divided into agonists 
(high i.a.) competitive antagonists (very low i.a.) and competitive dualists 
(intermediate i.a.). The affinity as well as the intrinsic activity are sub-
stance constants. They therefore vary with the molecular configuration 
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ôf the drugs. The intrinsic activity covers the chain of events from the 
occupation of the specific receptors to the final effect. As a matter of 
fact the effect is not always a linear function of the number of receptors 
occupied. It is however always possible to indicate a magnitude which 
is linearly related to the number of receptors occupied. Being previous 
to the final effect this magnitude has the nature of a stimulus. With 
respect to the stimulus the intrinsic activity is defined as the contri-
bution to the stimulus per unit of drug-receptor complex. 
3) The third phase concerns the relationship between the stimulus 
and the effect. The nature of this relationship is mainly determined 
by the biological object and the effect concerned and may be independent 
of the molecular properties of the drug under study. It is useful to 
consider the following possibilities. 
The relationship between the stimulus and the effect may be linear. 
In that case it is not necessary to consider the stimulus apart. 
The relationship between the stimulus and the effect may also be a 
discontinuous function. This is fcr instance the case for the all-or-none 
response. A biological unit for which this relationship holds responds 
maximally when the stimulus reaches a critical value. Generally a bio-
logical object is composed of several units. For the different units the 
critical value may vary according to some frequency distribution. In 
that case the relationship between stimulus and effect is given by the 
frequency distribution. 
The relationship between stimulus and effect may also be based upon 
a non-linear-monotonic increasing function. In this case as well as in 
the case of an all-or-none response a maximal effect can be obtained 
before all receptors are occupied. Then there is a reserve in receptors 
for the drug in question. On this basis several aspects of the interaction 
of a single drug or combinations of drugs with one or more receptor 
systems have been considered. Special attention was called to the 
following types of interaction. 
The interaction of a single drug and a specific receptor | R 
system, the effect of which is achieved by means of the ^ 
effector system ER. A useful measure for the affinity is I 
the pDx value (ARIËNS and VAN ROSSUM 1957). A 
The competitive interaction. The interaction of two drugs E_ 
with the same receptor system. According to the values λ 
of the intrinsic activity of the drugs, there is a competitive / \ 
synergism (both drugs have equal i.a.), a competitive A В 
dualism (one drug a high, the other an intermediate i.a.) 
or a competitive antagonism (one drug a high, the other a very low i.a.). 
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A useful measure for affinity of competitive antagonists is the pA
x 
value (SCHILD 1949). 
The " irreversible " competitive interaction. The receptors b n 
which once are occupied by the irreversible drug (B) arc R 
excluded from reaction with the reversible drug (А). У \ 
Irreversible competitive antagonists are especially useful A B 
in determining the amount of possible spare receptors. 
Non-competitive interaction. If a drug B, which is inactive ^R 
as such, changes the effect of an active drug A after re- R O R ' 
action with other receptors than those for A, a non- î î 
competitive interaction exists. The receptor systems R and д ¿ 
R' are interdependent. The change in the effect of the 
active drug may result from a change in the affinity, in the intrinsic 
activity, as well as from a change in the relationship between stimulus 
and effect. 
According to the value of the intrinsic activity of the non-competitive 
drug we are dealing with a sensitization or inhibition. A useful measure 
for the affinity of a non-competitive drug is the pO 'z value (ARIËNS and 
VAN Rosst'M 1957). 
Auto-interaction. A drug A which has affinity towards two RR 
interdependent receptor systems, R and R', shows an R - ^ R-
auto-interaction. The effect of A which would become \ / 
apparent after reaction of A with R is changed by the д 
interaction of A on R'. This change may be a change in 
the affinity, the intrinsic activity or the relationship between stimulus 
and effect. According to the value of the intrinsic activity of A at R' 
there is an auto-sensitization or auto-inhibition. A measure for the 
affinities of these drugs towards R and R' are the ρΏ
 x
 and pD', values 
respectively. The auto-inhibition is observed frequently and is analogous 
to the substrate-inhibition in enzymological reactions. 
Dualism in antagonism. A drug В which is both a competi- ^в 
tive and non-competitive antagonist of an active drug A R O R ' 
exhibits a dualism in antagonism. A useful measure for У \ ^ у 
the affinities towards R and R' of a drug with a dualism A D 
in antagonism are the pA
x
 and ρΏ'
χ
 values respectively. E R 
Functional interaction. Two drugs which react with dif- R R 
ferent independent receptor systems and produce an effect t t 
by means of the common effector system are functional I 1 
synergists. A measure for the affinities are the pD
x
 values. 
The several forms of drug interaction which were derived theoretically 
really exist as could be demonstrated in experiments with various bio-
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logical objects. The drugs used chiefly were quaternary ammonium salts. 
They may interfere with the physiological role of ACh anywhere in 
the peripheral autonomic and motor nervous system. If these drugs have 
affinity towards the ACh-receptors they are designated according to the 
value of their intrinsic activity cholinomimetics (high i.a.) or cholinolytics 
(very low i.a.). Some of the drugs interfere with the ACh-action in 
reacting with other than ACh-receptors. They are non-competitive anta-
gonists of cholinomimetics. According to the point of attack the drugs 
were divided into the following groups. 
a) Drugs which interact at the level of the myoneural junction. These 
include cholinomimetics (e.g. decamethonium), cholinolytics (e.g. D-
tubocurarinc) and non-competitive drugs (e.g. decamethonium derivative 
C10Me2Hept). This means that there exist three types of curariform 
drugs. As biological objects were used the frog rectus abdominis muscle 
and the muscle-nerve preparations of the cat and the chick. As was 
expected from the theory and from data of former experiments, in 
various series of drugs gradual changes were found from agonists to 
competitive antagonists via drugs with a competitive dualism in action, 
from agonists to non-competitive antagonists via drugs exhibiting an 
auto-inhibition and from competitive antagonists to non-competitive 
antagonists via drugs with a dualism in antagonism. 
b) Drugs which interact at the level of the parasympathetic end-
synapse. These include cholinomimetics (e.g. muscarine), cholinolytics 
(e.g. the dioxolane compound Bu2FMe3, atropine) and non-competitive 
antagonists (e.g. papaverine). As effects were measured the contraction 
of the isolated intestine of the rat and guinea-pig, the contraction of the 
isolated frog heart and the mean arterial blood pressure of the cat. 
As could be predicted from the theory and from data of former experi-
ments, here also in various series of drugs gradual changes were found 
from agonists to competitive antagonists via drugs with a competitive 
dualism in action. As expected, parasympathomimetics and BaCl2 or 
histamine behave as functional synergists. 
c) Drugs which interact at the level of the ganglionic synapse. These 
include cholinomimetics (e.g. nicotine, RacetMe3), cholinolytics (e.g. 
hexamethonium) and non-competitive drugs (e.g. presumably chlorison-
damine and HexFMe3). This means that there may exist three types 
of ganglionic blocking agents. As effects were measured the mean arterial 
blood pressure of the cat and contracture of the frog rectus abdominis 
muscle. As predicted in various series of drugs gradual changes from 
agonist into antagonist were found. Since the transmission of impulsus 
in the myoneural junction and in the ganglionic synapse are analogous 
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to a certain extent, the experiments with the isolated rectus abdominis of 
the frog can give information on drugs which produce ganglionic actions. 
At the level of the motor end-plate, of the parasympathetic end-
synapse as well as of the ganglionic synapse the action of ACh is preceded 
by a depolarization of the cell membrane. It is logical to assume that 
the onium group in cholinomimetic drugs is responsible for this electro-
physiological event. Without exception it was found in our experiments 
that introduction of heavier substituents on the onium group of cholino-
mimetics results in a gradual decrease of the intrinsic activity at the 
level of the different ACh-receptors. The interaction of drug molecules 
and the specific receptors may be considered as an interaction of the 
(electrical) fields which underly the molecular configuration of both the 
drug and receptor molecule. The affinity will be connected with the 
field interaction in its broadest sense while the intrinsic activitv will 
be concerned with more special parts of the field interaction. This means 
that the molecular configuration in its entirety concerns the affinity, while 
the intrinsic activity may be connected with some special part or group. 
Our experiments strongly substantiate the hypothesis that the intrinsic 
activity of all types of cholinomimetics is connected with the effectiveness 
wherewith the positively charged onium group can interfere with the 
electrical field of the ACh-receptors. The effectiveness of the positively 
charged onium is mainly determined by the value of the positive charge 
and the distance how closely this charge can approach to some part of 
the receptor. On the basis of this hypothesis it was possible to predict 
the result of alteration in the configuration of cholinomimetic drugs. 
The affinity and intrinsic activity may alter relatively independently of 
each other with alterations in the molecular configuration of a drug. 
The drugs used in the experimental part of this investigation were 
for the greater part synthesized in our laboratory and are described in 
a separate chapter. 
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SAMENVATTING 
Farmaca zijn chemische verbindingen die, in betrekkelijk kleine 
hoeveelheden toegediend, ingrijpen in het fysiologisch en pathofysio-
logisch gebeuren van een biologisch object. Moleculen van het farmacon 
moeten daarvoor over het algemeen in interactie treden met specifieke 
moleculen, de zogenaamde receptoren, in het biologisch object. De 
werking van een geneesmiddel kan aan dosis-effects curven en tijd-effects 
curven worden bestudeerd. Gezien de samengesteldheid van het bio-
logisch object is voor het verkrijgen van inzicht een analyse van het 
werkingsmechanisme van het farmacon nodig. Hiertoe kunnen drie fasen 
worden onderscheiden : 
i) De eerste fase geeft het verband weer tussen de hoeveelheid van 
een farmacon dat wordt toegediend en de concentratie in de onmiddellijke 
nabijheid van de specifieke receptoren (concentratie in de biofase). Deze 
concentratie wordt mede bepaald door de snelheid en de mate van 
resorptie, biochemische omzettingen zoals afbraak en de uitscheiding. 
De concentratie in de biofase is daarom sterk afhankelijk van de wijze 
van toedienen. In intakte dieren is de concentratie in de biofase vaak 
tijdsafhankelijk. Door gebruik te maken van geïsoleerde organen is het 
mogelijk de genoemde invloeden grotendeels uit te schakelen. In dat 
geval zal de concentratie in de biofase vaak een lineaire functie zijn van 
de dosis van het farmacon. 
2) De tweede fase betreft de reactie van de farmacon-moleculen met 
de specifieke receptoren. De grootheid die de bindingsneiging aangeeft 
wordt de affiniteit genoemd. Als zich in de biofase verschillende farmaca 
bevinden, die elk op zich een affiniteit hebben tot dezelfde receptoren, 
dan zal er een onderlinge wedijver zijn om receptoren te bezetten. We 
spreken dan van competitie. Naast de affiniteit is de intrinsieke activiteit 
(ARIËNS 1950) van belang voor de werkzaamheid van een geneesmiddel. 
De intrinsieke activiteit is een evenredigheidsconstante die de bijdrage 
tot het effect per eenheid van farmacon-receptor complex aangeeft. 
Naar de waarde van de intrinsieke activiteit (i.a.) kunnen geneesmiddelen 
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worden ingedeeld in agonisten (hoge i.a.), competitieve antagonisten (zeer 
lage i.a.) en competitieve dualisten (middelmatige i.a.). De affiniteit en 
de intrinsieke activiteit zijn beide stof-afhankelijk. Zij zullen dus veran-
deren met de moleculaire configuratie van de geneesmiddelen. De in-
trinsieke activiteit dekt de keten van gebeurtenissen welke na het bezetten 
van de specifieke receptoren aanleiding geven tot het effect. Vanzelf-
sprekend zal het effect niet altijd een lineaire functie zijn van het aantal 
bezette receptoren. 
Er is echter altijd een grootheid aan te wijzen die dat wel is. Deze 
grootheid heeft het karakter van een stimulus, omdat deze aan het uit-
eindelijke effect voorafgaat. Natuurlijk zijn er vele stimuli aan te wijzen. 
Die stimulus die nog direct stof-afhankelijk is heeft echter een bijzondere 
betekenis. In geval van een stimulus kan de intrinsieke activiteit worden 
gedefinieerd als de bijdrage tot de stimulus per eenheid van farmacon-
receptor complex. 
3) De derde fase geeft het verband aan tussen de stimulus, die even-
redig is met het aantal bezette receptoren en het uiteindelijk effect. 
Het is zinvol, voor dit verband, dat niet stof-afhankelijk is, de volgende 
mogelijkheden onder ogen te zien. 
Het verband tussen stimulus en effect kan lineair zijn. Het is dan 
niet nodig om de stimulus apart te beschouwen. 
Het verband tussen stimulus en effect kan ook worden weergegeven 
door een discontinue functie. We spreken dan van een alles of niets 
effect. De biologische eenheid geeft zijn maximaal effect als de stimulus 
een critieke waarde bereikt. Een biologisch object is over het algemeen 
samengesteld uit meerdere eenheden. De critieke waarden van de ver-
schillende eenheden zullen volgens een of andere frequentieverdeling 
zijn verdeeld, zodat het verband tussen de stimulus en het effect van 
het biologisch object in feite door een frequentieverdeling wordt gegeven. 
Hel verband tussen de stimulus en het effect kan ook berusten op 
een niet-lineaire continue monotoon stijgende functie. In dit laatste 
geval zowel als in het geval van de alles of niets wet kan een maximaal 
effect optreden terwijl nog niet alle receptoren zijn bezet. Er is dan een 
reserve aan receptoren voor het betrokken geneesmiddel. 
Op deze basis zijn verschillende facetten van de interactie van een 
enkelvoudig farmacon en combinaties van meerdere farmaca met een 
of meer receptorsystemen ontwikkeld, waarbij de affiniteit en de intrin-
sieke activiteit steeds als essentiële parameters zijn gebruikt. Op deze 
wijze is voor verschillende vormen van interactie een zinvolle analyse 
en synthese mogelijk. Aan de volgende vormen werd speciale aandacht 
besteed. 
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De interactie van een enkelvoudig farmacon en het receptor- ^R 
systeem, waarvan het effect via een effectorsysteem, ER, tot R 
stand komt. Een bruikbare maat voor de affiniteit is de/>D
 T Î 
waarde (ARIËNS en VAN ROSSUM 1957). A 
De competitieve interactie ofwel de interactie van twee 
farmaca met hetzelfde receptorsysteem. Afhankelijk van | R 
de waarden van de intrinsieke activiteit van de farmaca J\. 
spreken we van een competitief synergisme (beide stoffen ¿ ^ 
een gelijke i.a.), van een competitief dualisme (de ene stof 
een hoge, de andere een middelmatige i.a.) of van een competitief anta-
gonisme (de ene stof een hoge, de andere een lage i.a.). Een bruikbare 
maat voor de affiniteit van een competitieve antagonist is depAx waarde 
(SCHILD 1949). 
De ,, irreversibele " competitieve interactie. De receptoren ER 
die eenmaal bezet zijn met het ,, irreversibele " farmacon
 R 
(B) zijn van reactie met het andere farmacon (A) uitge- / \ 
sloten. Irreversibele competitieve antagonisten zijn bij uit- А В 
stek geschikt om de reserve aan receptoren voor een farma­
con te bepalen. Er zijn echter nog te weinig werkelijk specifieke irrever­
sibele competitieve antagonisten bekend. 
Non-competitieve interactie. Farmaca (B) die op zich on- ^R 
werkzaam zijn, maar het effect van een ander farmacon R Q R ' 
(A) beïnvloeden door met andere (R') dan met de recep- Τ Τ 
toren (R) van het werkzame farmacon te reageren, worden А В 
non-competitieve stoffen genoemd. De receptorsystemen 
R en R' zijn afhankelijk. Deze verandering in het effect van het werkzame 
farmacon kan het resultaat zijn van een verandering in de affiniteit, de 
intrinsieke activiteit alsmede een verandering in de functie die het ver­
band tussen de stimulus en het effect aangeeft. Afhankelijk van de 
intrinsieke activiteit van het non-competitieve farmacon spreken we van 
sensibilisatie of inhibitie. Een bruikbare maat voor de affiniteit van de 
non-competitieve stof is de pO'
x
 waarde (ARIËNS en VAN ROSSUM 1957)· 
De auto-interactie. Een agonist A die affiniteit heeft tot 
twee afhankelijke receptorsystemen vertoont een auto- |P 
interactie. Het effect van dit farmacon dat door interactie 
met R tot stand zou komen wordt veranderd door de "* ¿ 
interactie van dezelfde stof met het non-competitieve re-
ceptorsysteem R'. Deze verandering kan weer zijn een verandering in 
de affiniteit, in de intrinsieke activiteit alsmede een verandering in de 
relatie tussen stimulus en effect. Afhankelijk van de intrinsieke activiteit 
van het farmacon op het niveau van R' is er een auto-inhibitie of auto-
R O R' 
*57 
sensibilisatie. Een maat voor de affiniteiten van dit soort farm аса is de 
ρΌ
χ
 en de pD
x
 waarde. De auto-inhibitie, die analoog is aan de sub­
straat-inhibitie in de enzymologie, komt het meest voor. 
Het dualisme in antagonisme. Het farmacon B, dat zowel '¡-R 
een competitieve antagonist als een non-competitieve anta- R o R' 
gonist is van een agonist A, vertoont een dualisme in У* \ y* 
antagonisme. Een maat voor de affiniteit van В is de pA
x
 А В 
en de ρΌ'
χ
 waarde.
 E 
De functionele interactie. Twee farmaca die eenzelfde / \ 
R R 
effect opleveren via eenzelfde effectorsysteem, maar door A' * U 
interactie met verschillende onafhankelijke receptorsyste- \ \ 
men worden genoemd functionele Synergisten. 
Experimenteel konden deze vormen van interactie aan verschillende 
biologische objecten worden gedemonstreerd. In hoofdzaak werden far­
maca onderzocht die de fysiologische rol van acetylcholine (ACh) op 
enigerlei plaats in het motorische en autonome perifere zenuwstelsel 
kunnen beïnvloeden. Deze stoffen kunnen in interactie treden met de 
ACh-receptoren en worden dan afhankelijk van hun intrinsieke activiteit 
cholinomimetica (hoge i.a.) of cholinolytica (zeer lage i.a.) genoemd, of 
zij reageren met non-competitieve receptoren en zijn dan vooral non-
competitieve antagonisten van cholinomimetica. De stoffen die invloed 
hebben op de werkzaamheid van ACh worden al naar de plaats van de 
ACh-receptoren in het organisme verdeeld in de volgende groepen. 
a) Cholinomimetica (decamethonium), cholinolytica (DTC) en non-
competitieve stoffen (C10Me2Hept) die op het niveau van de motorische 
eindplaat werken. Deze stoffen werden onderzocht op de geïsoleerde 
M. rectus abdominis van de kikker en aan spierzenuwpreparaten van de 
kat en de kip. Zoals op grond van de theorie en vroegere experimenten 
mocht worden verwacht werden aan de M. rectus abdominis van de 
kikker geleidelijke overgangen gevonden van agonisten naar competitieve 
antagonisten via competitieve dualisten, van agonisten naar non-competi-
tieve antagonisten via farmaca met auto-inhibitie en van competitieve 
naar non-competitieve antagonisten via stoffen met een dualisme in 
antagonisme. 
b) Cholinomimetica (MeFMe3, muscarine), cholinolytica (Bu2FMe3, 
atropine) en non-competitieve antagonisten (papaverine) op het niveau 
van de parasympathische eindsynaps. Deze stoffen werden onderzocht 
op de geïsoleerde darm van de rat en de cavia, aan het geïsoleerde 
kikkerhart en aan de gemiddelde bloeddruk van de kat. Zoals voorspeld 
op grond van de theorie en vroegere experimenten werden ook hier 
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geleidelijke overgangen gevonden van agonisten naar competitieve anta-
gonisten via competitieve dualisten. Bovendien werd aangetoond dat 
parasympathicomimetica en histamine of BaCl2 functionele Synergisten 
zijn. 
c) Cholinomimetica (nicotine, RacetMe3), cholinolytica (hexametho-
nium) en non-competitieve antagonisten (mogelijk chlorisondamine, 
HexFMe3) op het niveau van de ganglionaire synaps. Deze stoffen 
werden onderzocht aan de bloeddruk van de kat. Ook hier werden zoals 
voorspeld, geleidelijke overgangen gevonden van agonisten naar anta-
gonisten. De geïsoleerde M. rectus abdominus van de kikker bleek een 
bruikbaar object om de werking van stoffen met affiniteit tot de ganglio-
naire synaps te onderzoeken. 
Op het niveau van de motorische eindsynaps, van de parasympathische 
eindsynaps zowel als van de ganglionaire synaps wordt het effect van 
ACh en cholinomimetica door een electrofysiologisch verschijnsel (de-
polarisatie van de celmembraan) voorafgegaan. Het is logisch om de 
oniumgroep in de moleculaire configuratie van de cholinomimetica hier-
voor aansprakelijk te stellen. 
In feite wordt dan ook steeds gevonden dat het vergroten vans ubstitu-
enten aan het quaternaire stikstofatoom tot gevolg heeft dat de intrinsieke 
activiteit afneemt. 
De interactie van moleculen van een farmacon en specifieke receptoren 
kan beschouwd worden als de interactie tussen de (electrische) velden 
die aan de moleculaire configuratie van beide moleculen ten grondslag 
liggen. De affiniteit nu zal samenhangen met de veld-interactie in zijn 
geheel, terwijl de intrinsieke activiteit samen zal hangen met een bepaald 
gedeelte van de veld-interactie. 
Zonder een enkele uitzondering ondersteunen de experimenten de 
hypothese dat de intrinsieke activiteit van cholinomimetica op het niveau 
van alle ACh-receptoren is gekoppeld aan de effectiviteit waarmee de 
positieve lading van de oniumgroep het electrische veld van de receptor 
kan storen. De effectiviteit van de oniumgroep in dit opzicht wordt 
voornamelijk bepaald door de grootte van de positieve lading en door 
de afstand waartoe de oniumgroep de receptor kan naderen. Met deze 
hypothese was het mogelijk het resultaat van structuurwijzigingen in 
cholinomimetica verregaand te voorspellen. De intrinsieke activiteit en 
de affiniteit kunnen relatief onafhankelijk veranderen met wijzigingen 
in de moleculaire configuratie van het farmacon, afhankelijk van de mate 
waarin de moleculaire eigenschappen welke voor beiden worden vereist, 
met elkaar overeenkomen. 
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Het grootste gedeelte van de farmaca, die in het experimentele gedeelte 
van dit onderzoek werden gebruikt, werd door ons gesynthetiseerd en 
in een apart hoofdstuk beschreven. 
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beter worden begrepen, dan met de oudere theorieën. 
SZENT-GYOHGYI, Α., Science, 1957, 124, 873-876. 
VIII 
De juistheid van de argumenten, welke Borst aanvoert tegen de 
opvatting, dat de bijnierschors invloed heeft op de regulering van het 
circulerend volume, is aan bedenkingen onderhevig. 
BORST, J. G. G., Ned. T. Geneesk., 1957, 101, 1300. 
IX 
Een reserve aan receptoren voor biologisch werkzame stoffen kan 
slechts met zekerheid volledig worden aangetoond met behulp van 
irreversibele, competitieve antagonisten. 
D i t proefschrift, hoofdstuk I. 
X 
Aan de hand van de hypothese, dat de intrinsieke activiteit van 
cholinomimetica vooral is gekoppeld aan de effectiviteit, waarmee de 
positieve lading van de onium groep in het molecule het electrische 
veld van de receptor kan beïnvloeden, blijkt het mogelijk om de wer-
kingswijze van farmaca met affiniteit tot acetyl-choline receptoren van 
het perifere zenuwstelsel, te voorspellen. 
Dit proefschrift, hoofdstuk II, III en IV. 
XI 
De argumenten die Waser aanvoert, als zou muscarine in het orga-
nisme omgezet worden in een meer actieve acetylester, zijn niet steek-
houdend. Het is in tegendeel waarschijnlijk, dat de acetylester minder 
actief is dan muscarine. 
WASEH, P. G., Experienlia, 1955, 11, 452-453. 
XII 
De receptuur van de arts is over het algemeen nog te weinig weten-
schappelijk gefundeerd. 



